<SEC-DOCUMENT>0001193125-20-274059.txt : 20201022
<SEC-HEADER>0001193125-20-274059.hdr.sgml : 20201022
<ACCEPTANCE-DATETIME>20201022081958
ACCESSION NUMBER:		0001193125-20-274059
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20201022
DATE AS OF CHANGE:		20201022

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Iterum Therapeutics plc
		CENTRAL INDEX KEY:			0001659323
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-249432
		FILM NUMBER:		201251720

	BUSINESS ADDRESS:	
		STREET 1:		BLOCK 2 FLOOR 3, HARCOURT CENTRE
		STREET 2:		HARCOURT STREET
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			2
		BUSINESS PHONE:		(872) 225-6077

	MAIL ADDRESS:	
		STREET 1:		BLOCK 2 FLOOR 3, HARCOURT CENTRE
		STREET 2:		HARCOURT STREET
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			2

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Iterum Therapeutics Ltd
		DATE OF NAME CHANGE:	20151124
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d80934ds1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML><HEAD>
<TITLE>S-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on October&nbsp;22, 2020 </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-249432</FONT> </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>Amendment
No. 2 to </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF&nbsp;1933 </I></B></P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:19pt; font-family:Times New Roman" ALIGN="center"><B>ITERUM THERAPEUTICS PLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Ireland</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">98-1283148</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(State or other Jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Incorporation or Organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Primary Standard Industrial<BR>Classification Code Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification No.)</B></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Block 2 Floor 3, Harcourt Centre, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Harcourt Street, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Dublin 2, </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Ireland
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>+353 1 9038920 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Corey N. Fishman </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>President
and Chief Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>200 South Wacker Drive, Suite 2550 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chicago, Illinois 60606 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">(312)&nbsp;778-6070</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code,
of agent for service) </B></P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Brian A. Johnson</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Wilmer Cutler Pickering Hale and Dorr LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>7 World Trade Center</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>250
Greenwich Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10007</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Telephone: <FONT STYLE="white-space:nowrap">(212)&nbsp;230-8800</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Robert F. Charron, Esq.<BR>Ellenoff Grossman&nbsp;&amp; Schole&nbsp;LLP<BR>1345 Avenue of the Americas<BR>New York, New York 10105<BR><FONT STYLE="white-space:nowrap">(212)&nbsp;370-1300</FONT></B></TD></TR>
</TABLE> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:1pt; margin-bottom:0pt; text-indent:3%; font-size:7.5pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public: </B>As soon as practicable after this registration statement is declared
effective.<B> </B> </P> <P STYLE="margin-top:1pt; margin-bottom:0pt; text-indent:3%; font-size:7.5pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to
Rule&nbsp;415 under the Securities Act of 1933 check the following box:&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:1pt; margin-bottom:0pt; text-indent:3%; font-size:7.5pt; font-family:Times New Roman">If this Form is filed to register additional
securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:1pt; margin-bottom:0pt; text-indent:3%; font-size:7.5pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act,
check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:1pt; margin-bottom:0pt; text-indent:3%; font-size:7.5pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:1pt; margin-bottom:0pt; text-indent:3%; font-size:7.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company&#148; and &#147;emerging growth company&#148; in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Large&nbsp;accelerated&nbsp;filer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:1pt; margin-bottom:0pt; text-indent:3%; font-size:7.5pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Securities to be Registered<BR></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed<BR>Maximum<BR>Aggregate<BR>Offering&nbsp;Price(1)(2)(3)<BR></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>Registration Fee(1)(7)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Ordinary Shares, nominal value $0.01 per share(3)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$15,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$1,636.50</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants to
purchase Ordinary Shares(3)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Ordinary Shares issuable upon exercise of <FONT
STYLE="white-space:nowrap">Pre-funded</FONT> Warrants(3)(4)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Warrants to purchase Ordinary Shares(3)(4)(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Ordinary Shares issuable upon exercise of
Warrants(3)(4)(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$11,250,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$1,227.38</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Placement agent warrants to purchase Ordinary Shares and
Ordinary Shares issuable upon exercise thereof(6)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$1,312,500</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$143.19</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$27,562,500</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$3,007.07</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee pursuant to Rule&nbsp;457(o) under the
Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule&nbsp;416(a) under the Securities Act of 1933, as amended, this registration statement shall
also cover an indeterminate number of additional securities that may from time to time be offered or issued to prevent dilution as a result of share splits, share dividends, dividends or other distributions, reclassifications, or similar
transactions. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman; " ALIGN="left">The proposed maximum aggregate offering price of the Ordinary Shares and Warrants will be reduced on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">dollar-for-dollar</FONT></FONT> basis based on the offering price of any <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants and Warrants issued in the offering, and the proposed
maximum aggregate offering price of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants and Warrants to be issued in the offering will be reduced on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">dollar-for-dollar</FONT></FONT> basis based on the offering price of any Ordinary Shares and Warrants issued in the offering. Accordingly, the proposed maximum aggregate offering
price of the Ordinary Shares or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants, as applicable, and Warrants is $15,000,000. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman; " ALIGN="left">Filing fee included with the Ordinary Shares or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants,
as applicable. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Staff Compliance and Disclosure Interpretation 240.06, equals the aggregate exercise price of the
Warrants. Each Warrant offered with an Ordinary Share or Pre-funded Warrant, as applicable, is a Warrant to purchase 0.75 of an Ordinary Share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman; " ALIGN="left">Represents warrants issuable to H.C. Wainwright&nbsp;&amp;&nbsp;Co.,&nbsp;LLC, or its designees, to purchase a
number of Ordinary Shares equal to 7.0% of the aggregate number of Ordinary Shares and <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants being offered at an exercise price equal to 125% of the combined public offering price per Ordinary
Share and Warrant. See &#147;Plan of Distribution&#148; on page&nbsp;57 of this Registration Statement for additional information regarding placement agent compensation. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman; " ALIGN="left">The Registrant previously paid $2,078.36 of this amount in connection with the prior filing of this
registration statement and the additional amount of $928.71 is being paid herewith. </P></TD></TR></TABLE>  <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:1pt; margin-bottom:0pt; text-indent:3%; font-size:7.5pt; font-family:Times New Roman"><B>The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file&nbsp;a further amendment which specifically states that this registration statement shall
thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until this registration statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine.
</B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-right:2%; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this preliminary prospectus is not complete and
may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting offers
to buy these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>Subject to Completion, dated October&nbsp;22, 2020 </B></FONT></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preliminary Prospectus </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80934g49n79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Iterum Therapeutics plc </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>13,043,478 Ordinary Shares and </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Warrants to Purchase 9,782,608 Ordinary Shares </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants to Purchase 13,043,478 Ordinary Shares and </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Warrants to Purchase 9,782,608 Ordinary Shares </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">We are offering 13,043,478 of our&nbsp;ordinary shares, together with warrants, or the Warrants, to purchase 9,782,608 ordinary shares (and the
ordinary shares issuable from time to time upon exercise of the Warrants) pursuant to this prospectus based on an assumed combined public offering price of $1.15 per ordinary share and Warrant, which is equal to the last reported sale price of our
ordinary shares on the Nasdaq Global Market on October&nbsp;20, 2020. Each ordinary share will be offered and sold together with a Warrant to purchase 0.75 of an ordinary share. The ordinary shares, together with the Warrants, will be sold at a
fixed combined public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share and Warrant until the completion of this offering. The ordinary shares and the Warrants are immediately separable and will be issued
separately in this offering. Each Warrant will have an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share, will be exercisable upon issuance and will expire&nbsp;five years from the date of issuance. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">We are also offering 13,043,478 <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, or the
<FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants (and the ordinary shares issuable from time to time upon exercise of the Pre-funded Warrants), to those purchasers whose purchase of ordinary shares in this offering would result in the
purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding ordinary shares following the consummation of this offering in lieu of the
ordinary shares that would result in such excess ownership. The assumed combined public offering price per Pre-funded Warrant and Warrant is $1.14, which is equal to the last reported sale price of our ordinary shares on the Nasdaq Global Market on
October&nbsp;20, 2020, less $0.01. Each <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant will be exercisable for one ordinary share at an exercise price of $0.01 per ordinary share. The <FONT STYLE="white-space:nowrap">Pre-funded</FONT>
Warrants will be sold together with the same Warrants that will be offered and sold with the ordinary shares as described above. Each Pre-funded Warrant will be offered and sold together with a Warrant to purchase 0.75 of an ordinary share. The <FONT
STYLE="white-space:nowrap">Pre-funded</FONT> Warrants, together with the Warrants, will be sold at a fixed combined public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per <FONT STYLE="white-space:nowrap">Pre-funded</FONT>
Warrant and Warrant until the completion of this offering. Each <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant will be exercisable upon issuance and will expire when exercised in full. The
<FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants and the Warrants are immediately separable and will be issued separately in this offering. The aggregate number of ordinary shares, or Pre-funded Warrants, and Warrants we are offering is
based on an aggregate purchase price of $15.0&nbsp;million. </P>  <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">There is no established public trading market for the Warrants or the <FONT
STYLE="white-space:nowrap">Pre-funded</FONT> Warrants, and we do not expect a market to develop. We do not intend to apply for listing of the Warrants or the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants on any securities exchange or
nationally recognized trading system. Without an active trading market, the liquidity of the Warrants and the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants will be extremely limited. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">We have engaged H.C. Wainwright&nbsp;&amp;&nbsp;Co.,&nbsp;LLC, or the placement agent, to act as our exclusive placement agent in connection
with this offering. The placement agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered by this prospectus. The placement agent is not purchasing or selling any of the securities we are offering and
the placement agent is not required to arrange the purchase or sale of any specific number of securities or dollar amount. We have agreed to pay to the placement agent the placement agent fees set forth in the table below, which assumes that we sell
all of the securities offered by this prospectus. There is no arrangement for funds to be received in escrow, trust or similar arrangement. There is no minimum offering requirement. We will bear all costs associated with the offering. See &#147;Plan
of Distribution&#148; on page&nbsp;57 of this prospectus for more information regarding these arrangements. </P>  <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Our ordinary shares are
traded on the Nasdaq Global Market under the symbol &#147;ITRM.&#148; On October&nbsp;20, 2020, the last reported sale price of our ordinary shares on the Nasdaq Global Market was $1.15 per share. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">The combined public offering price per ordinary share and Warrant and the combined public offering price per
<FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant and Warrant will be determined between us and investors based on market conditions at the time of pricing, and may be at a discount to the current market price of our ordinary shares.
Therefore, the assumed combined public offering prices used throughout this prospectus may not be indicative of the actual public offering prices. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>Investing in the offered securities involves a high degree of risk. See &#147;<A HREF="#toc80934_4">Risk Factors</A>&#148; beginning on
page&nbsp;9 of this prospectus and the section entitled &#147;Risk Factors&#148; included in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and most recent Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q,</FONT> </B>which are incorporated by reference herein, for a discussion of information that you should consider before investing in our securities.<B> </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Ordinary</B><br><B>Share and</B><br><B>Warrant<BR></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Per&nbsp;Pre-Funded</FONT><BR>Warrant and<BR>Warrant<BR></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Placement Agent&#146;s fees(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents cash fee. We have agreed to issue warrants to the placement agent, or the Placement Agent Warrants,
to purchase a number of ordinary shares equal to 7.0% of the aggregate number of ordinary shares and <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants being offered at an exercise price equal to 125% of the combined public offering price
per ordinary share and Warrant, and to reimburse the placement agent for certain offering-related expenses. See &#147;Plan of Distribution&#148; on page&nbsp;57 of this prospectus for additional information regarding placement agent compensation.
</P></TD></TR></TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">The placement agent expects to deliver the ordinary shares, the Warrants and the
<FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants to purchasers in the offering on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, subject to satisfaction of certain
conditions. </P>  <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Pursuant to the terms of the investor rights agreement, or the Investor Rights Agreement, that we entered into in
connection with the January 2020 private placement, or the January 2020 Private Placement, of 6.500% exchangeable senior subordinated notes due 2025, or the Private Placement Exchangeable Notes, and limited recourse royalty-linked subordinated
notes, in each case which were issued by Iterum Therapeutics Bermuda Limited, or Iterum Bermuda, we are required to provide Sarissa Capital Offshore Master Fund LP and certain of its affiliates, collectively Sarissa, the opportunity to purchase a
number of ordinary shares and Warrants, or Pre-funded Warrants and Warrants, based on Sarissa&#146;s ownership percentage of our ordinary shares on a fully diluted basis as set forth in the Investor Rights Agreement on the terms and the prices
provided for in the offering being made hereby. Based on the assumed aggregate purchase price of $15.0&nbsp;million in this offering, Sarissa would have the right to purchase an aggregate of up to 3,063,216 ordinary shares and 2,297,412 Warrants or
up to 3,063,216 <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants and 2,297,412 Warrants. We refer to such rights of Sarissa to purchase our ordinary shares and Warrants or our <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants
and Warrants, collectively, as the Sarissa Right to Purchase. To the extent Sarissa elects to exercise the Sarissa Right to Purchase, any sale to Sarissa will be carried out in a separate transaction. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>H.C. Wainwright&nbsp;&amp;&nbsp;Co. </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80934_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80934_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80934_3">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80934_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80934_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80934_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80934_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80934_7a">CAPITALIZATION </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80934_8">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80934_9">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80934_10">DESCRIPTION OF SECURITIES WE ARE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80934_11">MATERIAL TAX CONSEQUENCES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80934_12">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80934_13">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80934_14">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80934_15">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc80934_16">INCORPORATION OF DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80934_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration statement we filed with the Securities and Exchange Commission, or SEC, of which this prospectus forms a part includes
exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus, the related exhibits filed with the SEC, and the documents incorporated by reference herein before making your investment decision. You
should rely only on the information provided in this prospectus and the documents incorporated by reference herein or any amendment thereto. In addition, this prospectus contains summaries of certain provisions contained in some of the documents
described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. It is important for you to read and consider all information contained in the
registration statement of which this prospectus forms a part, including the documents incorporated by reference herein and therein, in making your investment decision. You should also read and consider the information in the documents to which we
have referred you in the sections entitled &#147;Where You Can Find Additional Information&#148; and &#147;Incorporation of Documents by Reference&#148; in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not, and the placement agent has not, authorized anyone to provide any information or to make any representations other than those
contained in this prospectus, the documents incorporated by reference herein or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the
reliability of, any other information that others may give you. The information contained in this prospectus, the documents incorporated by reference herein or in any applicable free writing prospectus is current only as of its date, regardless of
its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document
that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a
representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately
representing the current state of our affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This prospectus does not constitute an offer to sell, or a solicitation of an offer to
purchase, the securities offered by this prospectus in any jurisdiction to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than in the United States, no action has been taken by us or the placement agent that would permit a public offering of the securities
offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or
advertisements in connection with the offer, issue and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that
jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer
to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus does not constitute a prospectus for the purposes of the Prospectus Regulation (Regulation (EU) 2017/1129), or the Prospectus
Regulation, the EU (Prospectus) Regulations 2019 (SI No 380/2019), or the Irish Companies Act, and this prospectus has not been approved by the Central Bank of Ireland, as competent authority under the Prospectus Regulation, or any equivalent
authority in an European Economic Area member </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
state. No offer of securities to the public is made, or will be made, that requires the publication of a prospectus pursuant to Irish or European prospectus law within the meaning of the above
legislation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All other trademarks, trade names and service marks appearing in this prospectus or the documents incorporated by reference
herein are the property of their respective owners. Use or display by us of other parties&#146; trademarks, trade dress or products is not intended to and does not imply a relationship with, or endorsements or sponsorship of, us by the trademark or
trade dress owner. Solely for convenience, trademarks, tradenames and service marks referred to in this prospectus appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and
<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not
assert its rights, to these trademarks and trade names. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80934_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary provides an overview of selected information contained elsewhere or incorporated by reference into this prospectus and does
not contain all of the information you should consider before investing in our securities. You should carefully read the prospectus, the information incorporated by reference and the registration statement of which this prospectus forms a part in
their entirety before investing in our securities, including the information discussed under &#147;Risk Factors&#148; in this prospectus and the documents incorporated by reference and our financial statements and notes thereto that are incorporated
by reference into this prospectus. Some of the statements in this prospectus and the documents incorporated by reference herein constitute forward-looking statements that involve risks and uncertainties. See information set forth under the section
&#147;Special Note Regarding Forward-Looking Statements.&#148; Except where the context otherwise requires, the terms &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;Iterum&#148; or &#147;the Company&#148; refer to the business of Iterum
Therapeutics plc, a public limited company in Ireland, and its consolidated subsidiaries. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview of Iterum Therapeutics plc </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a pharmaceutical company dedicated to developing and commercializing sulopenem to be potentially the first and only oral and intravenous
(IV)&nbsp;branded penem available globally. Penems, including thiopenems and carbapenems, belong to a class of antibiotics more broadly defined as &szlig;-lactam antibiotics, the original example of which was penicillin, but which now also includes
cephalosporins. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. We have also
successfully developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid, which we refer to herein as oral sulopenem. We believe that sulopenem and oral sulopenem have the potential to be important new treatment alternatives
to address growing concerns related to antibacterial resistance without the known toxicities of some of the most widely used antibiotics, specifically fluoroquinolones. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the second quarter of 2020, we announced the results of our Phase 3 clinical trials of sulopenem for the treatment of complicated urinary
tract infections, or cUTI, and uncomplicated urinary tract infections, or uUTI. In the cUTI trial, sulopenem did not meet the primary endpoint of statistical <FONT STYLE="white-space:nowrap">non-inferiority</FONT> compared to the control therapies,
with the difference in response rates driven almost entirely by higher rates of asymptomatic bacteriuria on the sulopenem IV to oral sulopenem arm relative to the ertapenem IV to oral ciprofloxacin arm, only evident at the test of cure visit. The
rates of patients receiving additional antibiotics or with residual cUTI symptoms were similar between therapies. Similarly, in the uUTI trial, sulopenem did not meet the primary endpoint of statistical
<FONT STYLE="white-space:nowrap">non-inferiority</FONT> compared to ciprofloxacin in the population of patients with baseline pathogens susceptible to ciprofloxacin, driven to a large degree by a greater amount of asymptomatic bacteriuria in the
sulopenem treated patients at the test of cure visit relative to those receiving ciprofloxacin. However, in the uUTI trial, in the population of patients with baseline pathogens resistant to quinolones, sulopenem achieved the related primary
endpoint by demonstrating superiority to ciprofloxacin, providing evidence of a treatment effect in patients with uUTI. On September&nbsp;30, 2020, we announced that based on discussions with the U.S. Food and Drug Administration, or FDA, at a <FONT
STYLE="white-space:nowrap">pre-New</FONT> Drug Application, or NDA, meeting and previous correspondence with the FDA, we plan to proceed with an NDA submission for oral sulopenem for the treatment of uUTI in patients with a quinolone-resistant
pathogen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information regarding our business, see the section entitled &#147;Business&#148; included in our most recent
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as well as the sections entitled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and the related
notes thereto included in our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> and the other filings we make with the SEC from time to time, which are incorporated by reference into this prospectus. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sarissa Right to Purchase </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Investor Rights Agreement we entered into connection with the January 2020 Private Placement, we are required to
provide Sarissa the opportunity to purchase a number of ordinary shares and Warrants, or Pre-funded Warrants and Warrants, based on Sarissa&#146;s ownership percentage of our ordinary shares on a fully diluted basis as set forth in the Investor
Rights Agreement on the terms and the prices provided for in the offering being made hereby. Based on the assumed aggregate purchase price of $15.0&nbsp;million in this offering, Sarissa would have the right to purchase an aggregate of up to
3,063,216 ordinary shares and 2,297,412 Warrants or up to 3,063,216 <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants and 2,297,412 Warrants, or the Sarissa Right to Purchase. To the extent Sarissa elects to purchase these securities, any
sale to Sarissa will be carried out in a separate transaction at the combined public offering price per ordinary share or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant, as applicable, and Warrant in this offering. The actual number of
ordinary shares, Pre-funded Warrants and Warrants Sarissa will have the right to purchase will depend on the number of securities that are issued in this offering and Sarissa&#146;s percentage ownership of our ordinary shares on a fully diluted
basis, as set forth in the Investor Rights Agreement, immediately prior to the closing of this offering. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of Ireland in June 2015 as a limited liability company and
<FONT STYLE="white-space:nowrap">re-registered</FONT> as a public limited company in March 2018. Our principal executive offices are located at Block 2 Floor 3, Harcourt Centre, Harcourt Street, Dublin 2, Ireland and our telephone number is +353 1
9038920. Our U.S. headquarters are located at 200 South Wacker Drive, Suite 2550, Chicago, Illinois 60606, and our telephone number is (312) <FONT STYLE="white-space:nowrap">778-6070.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our website address is www.iterumtx.com. Information contained on, or accessible through, our website is not a part of, and is not
incorporated by reference into, this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An
emerging growth company may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the auditor attestation requirement of Section&nbsp;404 of the Sarbanes-Oxley
Act of 2002 on the design and effectiveness of our internal control over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with any requirement that the Public Company Accounting Oversight Board may adopt
regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about the company&#146;s executive compensation arrangements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements to obtain
<FONT STYLE="white-space:nowrap">a&nbsp;non-binding&nbsp;advisory</FONT> vote on executive compensation or a shareholder approval of any golden parachute arrangements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions until December&nbsp;31, 2023 or such earlier time that we are no longer an emerging growth company.
We would cease to be an emerging growth company upon the earlier to occur of: the last day of the fiscal year in which we have more than $1.07&nbsp;billion in annual revenues; the date we qualify as a &#147;large accelerated filer,&#148; with <FONT
STYLE="white-space:nowrap">a&nbsp;non-affiliate&nbsp;public</FONT> float in excess of $700&nbsp;million; or the issuance by us of more than $1&nbsp;billion <FONT STYLE="white-space:nowrap">of&nbsp;non-convertible&nbsp;debt</FONT> over a three-year
period. We may choose to take advantage of some, but not all, of the available benefits under the JOBS Act. We have taken advantage of some reduced </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reporting burdens in this prospectus. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new
or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves
of delayed adoption of new or revised accounting standards and, therefore, we will adopt new or revised generally accepted accounting principles in the United States on the relevant dates on which adoption of such standards is required for other
public companies that are not emerging growth companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company&#148; as defined in <FONT
STYLE="white-space:nowrap">Rule&nbsp;12b-2&nbsp;promulgated</FONT> under the Securities Exchange Act of 1934, as amended, or the Exchange Act. We may remain a smaller reporting company until we have
<FONT STYLE="white-space:nowrap">a&nbsp;non-affiliate&nbsp;public</FONT> float in excess of $250&nbsp;million and annual revenues in excess of $100&nbsp;million, or <FONT STYLE="white-space:nowrap">a&nbsp;non-affiliate&nbsp;public</FONT> float in
excess of $700&nbsp;million, each as determined on an annual basis. Even after we no longer qualify as an emerging growth company, we may still qualify as a smaller reporting company, which would allow us to take advantage of many of the same
exemptions from disclosure requirements. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80934_3"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><I>Securities offered by us in this offering: </I></P></TD>
<TD>13,043,478 ordinary shares and Warrants to purchase 9,782,608 ordinary shares, assuming a combined public offering price of $1.15 per ordinary share and Warrant, which is equal to the last reported sale price of our ordinary shares on the Nasdaq
Global Market on October&nbsp;20, 2020, and <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants to purchase 13,043,478 ordinary shares and Warrants to purchase 9,782,608 ordinary shares. The assumed combined public offering price per <FONT
STYLE="white-space:nowrap">Pre-funded</FONT> Warrant and Warrant is $1.14, which is equal to the last reported sale price of our ordinary shares on the Nasdaq Global Market on October&nbsp;20, 2020 less $0.01. The aggregate number of ordinary
shares, or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants, and Warrants we are offering is based on an aggregate purchase price of $15.0&nbsp;million. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><I>Description of Warrants: </I></P></TD>
<TD>The ordinary shares or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants, as applicable, and Warrants will be separately transferable immediately upon issuance. Each ordinary share or Pre-funded Warrant, as applicable, will be offered
and sold together with a Warrant to purchase 0.75 of an ordinary share. Each Warrant will have an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, will be exercisable upon issuance and will
expire&nbsp;five&nbsp;years from the date of issuance. This prospectus also relates to the offering of ordinary shares issuable upon exercise of these Warrants. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><I>Description of <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants: </I></P></TD>
<TD>If the issuance of ordinary shares to a purchaser in this offering would result in such purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our
outstanding ordinary shares following the consummation of this offering, then such purchaser may purchase, if they so choose, in lieu of the ordinary shares that would result in such excess ownership, a
<FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant to purchase ordinary shares for a purchase price per ordinary share subject to such <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant equal to the per share public offering price
for the ordinary shares in this offering less $0.01. Each <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant will have an exercise price of $0.01 per ordinary share, will be exercisable upon issuance and will expire when exercised in full.
Purchasers of <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants will also receive Warrants as if such purchasers were buying ordinary shares in this offering. Each Pre-funded Warrant will be offered and sold together with a Warrant to
purchase 0.75 of an ordinary share. This prospectus also relates to the offering of ordinary shares issuable upon exercise of these <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><I>Ordinary shares outstanding after this offering </I></P></TD>
<TD>34,282,571 ordinary shares, assuming no sale of <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants in this offering and no exercise of the Warrants being issued in this offering or the Placement Agent Warrants. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><I>Use of proceeds </I></P></TD>
<TD>We estimate that our net proceeds from this offering will be approximately $13.1&nbsp;million, based on an assumed combined public offering price of $1.15 per ordinary share and Warrant (the last reported sale price of our ordinary shares on the
Nasdaq Global Market on October&nbsp;20, 2020) and assuming the sale of all of the ordinary shares and Warrants, no sale of any <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants in this offering and no exercise of any Warrants issued in
this offering, after deducting the placement agent&#146;s fees and estimated offering expenses payable by us. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds from this offering to support our planned NDA submission for oral sulopenem for the treatment of uUTI in patients with quinolone-resistant pathogens, the continued clinical development
of sulopenem and for working capital and general corporate purposes. See &#147;Use of Proceeds&#148; on page&nbsp;19 of this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><I>Dividend policy </I></P></TD>
<TD>We have never declared or paid cash dividends on our ordinary shares and do not anticipate declaring or paying any cash dividends for the foreseeable future. We currently intend to retain all available funds and future earnings to support
operations and to finance the growth and development of our business. See &#147;Dividend Policy&#148; on page&nbsp;20 of this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><I>Risk factors </I></P></TD>
<TD>See &#147;Risk Factors&#148; beginning on page&nbsp;9 of this prospectus and the section entitled &#147;Risk Factors&#148; included in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and most recent Quarterly
Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> which are incorporated by reference herein, and the other information included or incorporated by reference elsewhere in this prospectus for a discussion of factors you should carefully
consider before deciding to invest in our securities. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><I>Nasdaq Global Market symbol </I></P></TD>
<TD>Our ordinary shares are traded on the Nasdaq Global Market under the symbol &#147;ITRM.&#148; There is no established trading market for the Warrants or the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants, and we do not expect a
trading market to develop. We do not intend to list the Warrants or the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants on any securities exchange or nationally recognized trading system. Without a trading market, the liquidity of the
Warrants and the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants will be extremely limited. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of
ordinary shares to be issued and outstanding after this offering is based on 21,239,093 ordinary shares issued and outstanding as of October&nbsp;2, 2020. The number of ordinary shares to be issued and outstanding after this offering excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,146,157 ordinary shares issuable upon the exercise of share options to purchase ordinary shares as of
October&nbsp;2, 2020, at a weighted average exercise price of $7.56 per ordinary share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,042,000 ordinary shares issuable upon the vesting of outstanding performance restricted stock units as of
October&nbsp;2, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,387,966 additional ordinary shares available for future issuance as of October&nbsp;2, 2020 under our 2018
Equity Incentive Plan; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,636,229 ordinary shares issuable upon exercise of outstanding warrants as of October&nbsp;2, 2020, at a
weighted average exercise price of $1.66 per ordinary share; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary shares, or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants, as applicable, and Warrants that
may be sold to Sarissa pursuant to the Sarissa Right to Purchase. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all information contained
in this prospectus assumes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the outstanding options or warrants described in the bullets above; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no sale of <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants in this offering and no exercise of the
Warrants being issued in this offering or the Placement Agent Warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exchange of the Private Placement Exchangeable Notes or the 6.500% exchangeable senior subordinated notes due
2025 issued in our rights offering in September 2020, or the Rights Offering Exchangeable Notes and, together with the Private Placement Exchangeable Notes, the Exchangeable Notes, for our ordinary shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no sale of securities to Sarissa pursuant to the Sarissa Right to Purchase.<B> </B> </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80934_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>An investment in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider
carefully the risks and uncertainties described below and in the section entitled &#147;Risk Factors&#148; included in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and most recent Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q,</FONT> which are incorporated by reference herein, and other filings we make with the SEC from time to time, which are incorporated by reference herein in their entirety, together with the other information in this
prospectus and the information incorporated by reference herein and in any free writing prospectus that we may authorize for use in connection with this offering. If any of these risks actually occurs, our business, financial condition, results of
operations or cash flow could suffer materially. In such event, the trading price of our ordinary shares could decline and you might lose all or part of your investment. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are heavily dependent on the success of our sulopenem program, and our ability to develop, obtain marketing approval for and successfully
commercialize oral sulopenem and sulopenem. If we are unable to obtain marketing approvals for oral sulopenem or sulopenem, or if thereafter we fail to commercialize oral sulopenem or sulopenem or experience significant delays in doing so, our
business will be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no products approved for sale and have invested substantially all of our
efforts and financial resources in the development of our sulopenem program. Our near-term prospects are substantially dependent on our ability to develop, apply for and obtain marketing approval for and successfully commercialize oral sulopenem and
sulopenem. Because we have limited financial resources, we initially focused our sulopenem development program on the specific indications of uUTI, cUTI and complicated intra-abdominal infection, or cIAI. In December 2019, we announced that
sulopenem did not meet the primary endpoint of statistical <FONT STYLE="white-space:nowrap">non-inferiority</FONT> compared to the control therapy in a Phase 3 clinical trial for the treatment of cIAI. In the second quarter of 2020, we announced the
results of our Phase 3 clinical trials of sulopenem for the treatment of cUTI and uUTI. In the cUTI trial, sulopenem did not meet the primary endpoint of statistical <FONT STYLE="white-space:nowrap">non-inferiority</FONT> compared to the control
therapies, with the difference in response rates driven almost entirely by higher rates of asymptomatic bacteriuria on the sulopenem IV to oral sulopenem arm relative to the ertapenem IV to oral ciprofloxacin arm, only evident at the test of cure
visit. The rates of patients receiving additional antibiotics or with residual cUTI symptoms were similar between therapies. Similarly, in the uUTI trial, sulopenem did not meet the primary endpoint of statistical
<FONT STYLE="white-space:nowrap">non-inferiority</FONT> compared to ciprofloxacin in the population of patients with baseline pathogens susceptible to ciprofloxacin, driven to a large degree by a greater amount of asymptomatic bacteriuria in the
sulopenem treated patients at the test of cure visit relative to those receiving ciprofloxacin. However, in the uUTI trial, in the population of patients with baseline pathogens resistant to quinolones, sulopenem achieved the related primary
endpoint by demonstrating superiority to ciprofloxacin, providing evidence of a treatment effect in patients with uUTI. On September&nbsp;30, 2020, we announced that, based on discussions with the FDA at a
<FONT STYLE="white-space:nowrap">pre-NDA</FONT> meeting and previous correspondence with the FDA, we plan to proceed with an NDA submission for oral sulopenem for the treatment of uUTI in patients with a quinolone-resistant pathogen. However, due to
a variety of factors, including those described in this &#147;Risk Factors&#148; section and included in the documents incorporated by reference herein, we may nonetheless be delayed in obtaining or ultimately be unable to obtain FDA approval for
sulopenem for this or any other indication or for any other product or to successfully commercialize sulopenem. <B></B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in
the use of the net proceeds from this offering and may not use them effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will have broad discretion in the application
of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our ordinary shares. Our failure to apply these funds effectively could result in financial losses that
could have a material adverse effect on our business, cause the price of our ordinary shares to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in a manner that does
not produce income or that loses value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our ordinary shares has been volatile and could be subject to volatility related or
unrelated to our operations and our shareholders&#146; investment in us could suffer a decline in value. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our share price has been
and may continue to be volatile. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a
result of this volatility, investors may not be able to sell their ordinary shares at or above the price paid for the shares. The trading price of our ordinary shares could be subject to wide fluctuations in response to various factors, some of
which are beyond our control. The market price for our ordinary shares may be influenced by many factors, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results from, and any delays in, our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of regulatory approval or disapproval of oral sulopenem, sulopenem or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements with respect to the outcome, impact, effects or results of our evaluation of corporate,
organizational, strategic, financial and financing alternatives, including the terms, timing, structure, value, benefits and costs of any corporate, organizational, strategic, financial or financing alternative and our ability to complete one at
all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in the commercialization of oral sulopenem, sulopenem or any future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing and supply issues related to our development programs and commercialization of oral sulopenem,
sulopenem or any of our future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">quarterly variations in our results of operations or those of our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in our earnings estimates or recommendations by securities analysts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us or our competitors of new product candidates, significant contracts, commercial
relationships, acquisitions or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements relating to future development or license agreements including termination of such agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse developments with respect to our intellectual property rights or those of our principal collaborators;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commencement of litigation involving us or our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in our board of directors or management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new legislation in the United States relating to the prescription, sale, distribution or pricing of drugs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product liability claims, other litigation or public concern about the safety of oral sulopenem or sulopenem or
future products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to comply or regain compliance with the Nasdaq Global Market continued listing requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the healthcare market in general, or in the antibiotics segment in particular, including
performance of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic conditions in the United States and abroad, including resulting
<FONT STYLE="white-space:nowrap">from&nbsp;geo-political&nbsp;actions,</FONT> including war and terrorism, natural disasters, including earthquakes, hurricanes, typhoons, floods and fires, public health crises, or pandemics, <FONT
STYLE="white-space:nowrap">like&nbsp;COVID-19;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other factors described in this &#147;Risk Factors&#148; section and the &#147;Risk Factors&#148; sections of
our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and most recent Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q,</FONT> which are incorporated by reference herein. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock market in general, or the market for equity securities in our industry or industries related to our industry, may
experience extreme volatility unrelated to our operating performance. These broad market fluctuations may adversely affect the trading price or liquidity of our ordinary shares. Any sudden decline </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the market price of our ordinary shares could trigger securities class-action lawsuits against us. If any of our shareholders were to bring such a lawsuit against us, we could incur
substantial costs defending the lawsuit and the time and attention of our management would be diverted from our business and operations. We also could be subject to damages claims if we are found to be at fault in connection with a decline in our
share price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a substantial number of our ordinary shares in the public market, or the perception that these sales could occur, could cause
our share price to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A substantial portion of our outstanding ordinary shares can be traded without restriction at any time.
If our current shareholders sell, or indicate an intention to sell, substantial amounts of our ordinary shares in the public market, the trading price of our ordinary shares could decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A portion of our outstanding ordinary shares is currently restricted as a result of federal securities laws but can be sold at any time
subject to applicable volume limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Exchangeable Notes are exchangeable for our ordinary shares upon the terms and
conditions specified therein. Pursuant to the Investor Rights Agreement, we have filed a registration statement covering the ordinary shares issuable in connection with the exchange of the Private Placement Exchangeable Notes, among other
securities, and the ordinary shares issuable in connection with the exchange of the Rights Offering Exchangeable Notes are also covered by a registration statement. Also, in connection with our June and July offerings of ordinary shares and
warrants, we filed a registration statement providing for the resale by the purchasers in such offerings of ordinary shares issued and issuable upon exercise of the warrants purchased in such offerings. As a result, the shares issuable upon exchange
of such notes and upon exercise of such warrants are able to be sold by the holders thereof without restrictions, subject to compliance with securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Investor Rights Agreement that we entered into in connection with the January 2020 Private Placement, we are
required to provide Sarissa the opportunity to purchase a number of ordinary shares and Warrants, or Pre-funded Warrants and Warrants, based on Sarissa&#146;s ownership percentage of our ordinary shares on a fully diluted basis as set forth in the
Investor Rights Agreement on the terms and the prices provided for in the offering being made hereby. Based on the assumed aggregate purchase price of $15.0&nbsp;million in this offering, Sarissa would have the right to purchase an aggregate of up
to 3,063,216 ordinary shares and 2,297,412 Warrants or up to 3,063,216 <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants and 2,297,412 Warrants. To the extent Sarissa elects to purchase these securities, any sale to Sarissa will be carried
out in a separate transaction at a price equal to the combined public offering price per ordinary share and Warrant, or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant and Warrant, as applicable, in this offering. The actual number of
ordinary shares, Pre-funded Warrants and Warrants Sarissa will have the right to purchase will depend on the number of securities that are issued in this offering and Sarissa&#146;s percentage ownership of our ordinary shares on a fully diluted
basis, as set forth in the Investor Rights Agreement, immediately prior to the closing of this offering. We have also agreed to grant the placement agent or its designees Placement Agent Warrants to purchase a number of our ordinary shares equal to
7.0% of the aggregate number of ordinary shares and <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants sold to the investors in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any ordinary shares issued in this transaction or issued upon exercise of any <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants or
Warrants issued in this transaction, or ordinary shares issued upon exercise of the Placement Agent Warrants issued in connection with this offering or in connection with the Sarissa Right to Purchase may be sold without restriction, subject to
applicable securities laws. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After this offering, we will have 34,282,571 ordinary shares issued and outstanding, based on 21,239,093
ordinary shares issued and outstanding as of October&nbsp;2, 2020, assuming no sale of <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants in this offering, no exercise of the Warrants being issued in this offering or the Placement Agent
Warrants and no sale of securities to Sarissa. Any of our outstanding shares that are not restricted as a result of securities laws may be resold in the public market without restriction unless purchased by our affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, ordinary shares that are issuable upon exercise of outstanding options or
reserved for future issuance under our equity incentive plans or issuable upon exercise of our other outstanding warrants will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and
Rule 144 and Rule 701 under the Securities Act of 1933, as amended, or the Securities Act. If any of these additional ordinary shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our ordinary
shares could decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The exchange rate of the Exchangeable Notes may be adjusted for certain dilutive events, and we may be required to increase
the exchange rate of the Exchangeable Notes as a result of this offering. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exchange rate of the Exchangeable Notes is
subject to adjustment for certain events, including, but not limited to, the issuance of certain share dividends on our ordinary shares, the issuance of certain rights, options or warrants, subdivisions, combinations, distributions of capital
shares, indebtedness, or assets, cash dividends, certain issuer tender or exchange offers and certain issuances for consideration per share less than the then-current exchange price, which is currently equivalent to approximately $1.00 per ordinary
share (at the current exchange rate of 1,000 shares per $1,000 of principal and interest on the Exchangeable Notes). In the event of an increase in the exchange rate of the Exchangeable Notes, the number of ordinary shares deliverable on an exchange
of the Exchangeable Notes, assuming physical settlement, would increase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether and to what extent the exchange rate of the Exchangeable
Notes will be increased as a result of this offering will depend on the combined public offering price and the number of ordinary shares, or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants, and Warrants that are sold, which will be
determined between us and investors based on market conditions at the time of pricing<B><I></I></B>, in addition to the number of our shares outstanding or deemed to be outstanding immediately prior to the closing of this offering. A $0.25 decrease
in the assumed combined public offering price of $1.15 per ordinary share and Warrant, which is equal to the last reported sale price of our ordinary shares on the Nasdaq Global Market on October&nbsp;20, 2020, would result in an adjustment of the
exchange price of the Exchangeable Notes to $0.9481 per ordinary share (at an adjusted exchange rate of 1,054.7079 shares per $1,000 of principal and interest on the Exchangeable Notes), assuming no sale of Pre-funded Warrants in this offering and
no sale of securities to Sarissa pursuant to the Sarissa Right to Purchase. Depending on the combined public offering price, the number of securities that we sell in this offering and any potential increase to the exchange rate of the Exchangeable
Notes, we may not have sufficient authorized share capital or share issuance authorities to convert all of the Exchangeable Notes into ordinary shares following this offering, and we will likely seek an increase of our authorized shares as a
result.<B><I> </I></B>If such approval is not obtained we could be limited in our ability to issue ordinary shares on exchange of the Exchangeable Notes and could be required to settle any exchanges with cash to the extent we do not have available
authorized shares. If we elect to settle any exchanges in cash, or we do not have authorized and available ordinary shares needed to satisfy physical exchange of the Exchangeable Notes, our liquidity could be adversely affected and/or we may not
have sufficient cash available at that time to satisfy such cash settlement. In addition, in the event we elect to settle exchanges of Exchangeable Notes with ordinary shares, we would be limited in our ability to issue equity for other purposes
which could adversely affect our shareholders and our ability to raise additional capital. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience immediate and substantial
dilution. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumed combined public offering price per ordinary share and Warrant being offered hereby is higher than the as
adjusted net tangible book value per ordinary share. Therefore, if you purchase ordinary shares and Warrants in this offering, you will experience immediate dilution of $2.304 per ordinary share, representing the difference between our as adjusted
net tangible book value per ordinary share after giving effect to this offering and the assumed combined public offering price per ordinary share and Warrant, assuming no sale of Pre-funded Warrants in this offering, no exercise of the Warrants
being issued in this offering or the Placement Agent Warrants and no sale of securities to Sarissa pursuant to the Sarissa Right to Purchase. For a further description of the dilution you will experience immediately after this offering, see
&#147;Dilution&#148; in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience future dilution as a result of future equity offerings or other issuances of
securities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to raise additional capital, we may in the future offer additional ordinary shares or other securities
convertible into or exchangeable for our ordinary shares at prices that may not be the same as the public offering price for the securities in this offering. We may sell shares or other securities in any other offering at prices that are less than
the price paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing shareholders. In addition, we will likely seek to increase our authorized share capital after the
completion of this offering. You may experience dilution as a result of any shares issued as a result of future offerings or other issuances of our securities from our currently authorized share capital or any increased authorized share capital.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never paid cash dividends, do not anticipate paying any cash dividends and our ability to pay dividends, or repurchase or redeem our
ordinary shares, is limited by law. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our ordinary shares and do not anticipate
paying any dividends on our ordinary shares in the foreseeable future. Any determination to pay dividends in the future will be at the sole discretion of our board of directors after considering our financial condition, results of operations,
capital requirements, contractual restrictions, general business conditions and other factors our board of directors deems relevant, and subject to compliance with applicable laws, including the Irish Companies Act which requires Irish companies to
have distributable reserves available for distribution equal to or greater than the amount of the proposed dividend. Distributable reserves are the accumulated realized profits of the company that have not previously been utilized in a distribution
or capitalization less accumulated realized losses that have not previously been written off in a reduction or reorganization of capital. Unless the company creates sufficient distributable reserves from its business activities, the creation of such
distributable reserves would involve a reduction of the company&#146;s share premium account, which would require the approval of (i) 75% of our shareholders present and voting at a shareholder meeting, and (ii)&nbsp;the Irish High Court. In the
event that we do not undertake a reduction of capital to create distributable reserves, no distributions by way of dividends, share repurchases or otherwise will be permitted under Irish law until such time as the company has created sufficient
distributable reserves from its business activities. In addition, our ability to pay cash dividends is currently prohibited by the terms of our secured credit facility with Silicon Valley Bank, or SVB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, the only opportunity for a shareholder to achieve a return on their investment in our company is expected to be if the market
price of our ordinary shares appreciates and they sell their ordinary shares at a profit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is no public market for the Warrants or the <FONT
STYLE="white-space:nowrap">Pre-funded</FONT> Warrants being issued by us in this offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no established public trading
market for the Warrants or the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants, and we do not expect a market to develop. In addition, we do not intend to apply to list the Warrants or the
<FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants on any securities exchange or nationally recognized trading system, including the Nasdaq Global Market. Without an active trading market, the liquidity of the Warrants and the <FONT
STYLE="white-space:nowrap">Pre-funded</FONT> Warrants will be extremely limited. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holders of <FONT STYLE="white-space:nowrap">Pre-funded</FONT>
Warrants or Warrants purchased in this offering will have no rights as ordinary shareholders until such holders exercise their <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants or Warrants and acquire our ordinary shares, except as
otherwise provided in the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants or Warrants. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until holders of <FONT
STYLE="white-space:nowrap">Pre-funded</FONT> Warrants or Warrants acquire ordinary shares upon exercise thereof, such holders will have no rights with respect to the ordinary shares underlying the <FONT STYLE="white-space:nowrap">Pre-funded</FONT>
Warrants and Warrants, except to the extent that holders of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants and Warrants will have certain rights to participate in distributions or dividends paid on our ordinary shares as set forth
in the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants and Warrants. Upon exercise of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants or Warrants, the holders will be entitled to exercise the rights of an ordinary
shareholder only as to matters for which the record date occurs after the exercise date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Warrants are speculative in nature. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Warrants do not confer any rights of ordinary share ownership on their holders, such as voting rights, but rather merely represent the
right to acquire ordinary shares at a fixed price for a limited period of time. Specifically, commencing on the date of issuance, holders of the Warrants may exercise their right to acquire the ordinary shares and pay an exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, subject to certain adjustments, prior to five years from the date of issuance in the case of the Warrants, after which date any unexercised Warrants will expire and have no
further value. Moreover, following this offering, the market value of the Warrants, if any, is uncertain and there can be no assurance that the market value of the Warrants will equal or exceed their imputed offering price. The Warrants will not be
listed or quoted for trading on any market or exchange. There can be no assurance that the market price of the ordinary shares will ever equal or exceed the exercise price of the Warrants, and consequently, it may not ever be profitable for holders
of the Warrants to exercise such Warrants. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>This is a best efforts offering, no minimum amount of securities is required to be sold, and we may
not raise the amount of capital we believe is required for our business plans. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The placement agent has agreed to use its
reasonable best efforts to solicit offers to purchase the securities in this offering. The placement agent has no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the
securities. There is no required minimum number of securities that must be sold as a condition to completion of this offering. Because there is no minimum offering amount required as a condition to the closing of this offering, the actual offering
amount, placement agent fees and proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth above. We may sell fewer than all of the securities offered hereby, which may significantly reduce the
amount of proceeds received by us, and investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to support our planned NDA submission for oral sulopenem for the treatment of uUTI in
patients with a quinolone-resistant pathogen. Thus, we may not raise the amount of capital we believe is required for our operations in the short-term, including for our planned NDA submission, and may need to raise additional funds in the
short-term, which may not be available or available on terms acceptable to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There can be no assurance that we will not be a passive foreign
investment company for any taxable year, which could result in adverse U.S. federal income tax consequences to U.S. investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
general, a corporation organized outside the United States will be classified for U.S. federal tax purposes as a passive foreign investment company, or PFIC, for any taxable year in which either (i)&nbsp;75% or more of its gross income consists of
&#147;passive income,&#148; or (ii)&nbsp;50% or more of the value of its assets (generally determined on an average quarterly basis) consists of assets that produce, or are held for the production of, passive income. For purposes of the above
calculations, a foreign corporation that owns (or is treated as owning) at least 25% by value of the shares of another corporation is treated as if it held its proportionate share of the assets of that other corporation and received directly its
proportionate share of the income derived by that other corporation. &#147;Passive income&#148; generally includes dividends, interest, rents, royalties and certain gains. Cash is a passive asset for these purposes. Goodwill is generally
characterized as a nonpassive or passive asset based on the nature of the income produced in the activity to which the goodwill is attributable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the expected nature and amount of our estimated gross income, the anticipated nature and estimated average value of our gross assets,
the anticipated cash needs of our group&#146;s operations and the nature and extent of the active businesses conducted by our &#147;25% or greater&#148; owned subsidiaries, we do not expect that we will be classified as a PFIC in the current taxable
year. However, our PFIC status for any taxable year can be made only after the end of such year and will depend on the composition of our income and assets and the value of our assets from time to time (which may be determined, in part, by reference
to the market price of our ordinary shares, which could be volatile). Furthermore, the composition of our income and assets for the current and future taxable years will be affected by how, and how quickly, we spend the cash we have on hand.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Accordingly, there can be no assurance that we will not be a PFIC for our current or any future taxable year. If we were a PFIC for any taxable year during which a U.S. investor is treated as
owning our ordinary shares, the U.S. investor generally would be subject to adverse U.S. federal income tax consequences, possibly including increased tax liability on disposition gains and &#147;excess distributions,&#148; and additional reporting
requirements. See &#147;Material Tax Consequences&#151;PFIC Rules.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply or regain compliance with the requirements of
continued listing on the Nasdaq Global Market, we may be delisted and the price of our ordinary shares, our ability to access the capital markets and our financial condition could be negatively impacted and the delisting of our ordinary shares would
result in an event of default and/or fundamental change under our debt instruments. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ordinary shares are currently listed
for quotation on the Nasdaq Global Market. To maintain the listing of our ordinary shares on the Nasdaq Global Market, we are required to meet certain listing requirements, including, among others, a minimum closing bid price of $1.00 per share, a
market value of publicly held shares (excluding shares held by our officers, directors and 10% or more shareholders) of at least $15.0&nbsp;million and a total market value of listed securities of at least $50.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;24, 2020, we received a letter from the Listing Qualifications Department of The Nasdaq Stock Market, LLC, or Nasdaq,
indicating that, based on the closing bid price for the previous 30 consecutive business days, the listing of our ordinary shares was not in compliance with Nasdaq Listing Rule 5450(a)(1) to maintain a minimum bid price of $1.00 per share, or the
Bid Price Rule. Under Nasdaq Listing Rule 5810(c)(3)(A), we have a period of 180 calendar days, or until March&nbsp;23, 2021, to regain compliance with the Bid Price Rule. To regain compliance during this
<FONT STYLE="white-space:nowrap">180-day</FONT> compliance period, the closing bid price of our ordinary shares must be at least $1.00 for a minimum of 10 consecutive business days. In the event that we do not regain compliance with the Bid Price
Rule prior to the expiration of the <FONT STYLE="white-space:nowrap">180-day</FONT> compliance period, we will receive written notification from Nasdaq that our securities are subject to delisting. At that time, we may appeal the delisting
determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance that, if we do appeal the delisting determination by Nasdaq to the panel, that such appeal would be
successful. If we do not regain compliance within the <FONT STYLE="white-space:nowrap">180-day</FONT> compliance period, we may also transfer the listing of our ordinary shares to the Nasdaq Capital Market, provided that we then meet the applicable
requirements for continued listing on the Nasdaq Capital Market. If we do not regain compliance with the Bid Price Rule within the <FONT STYLE="white-space:nowrap">180-day</FONT> compliance period, we may be eligible for an additional 180 calendar
day compliance period. To qualify, we would need to transfer the listing of our ordinary shares to the Nasdaq Capital Market, provided we then meet the continued listing requirement on the Nasdaq Capital Market for the market value of publicly held
shares and all other initial listing standards of the Nasdaq Capital Market, with the exception of its bid price requirement. To effect such a transfer, we would need to submit an online transfer application, pay an application fee to Nasdaq and
provide written notice to Nasdaq of our intention to cure the deficiency during the additional compliance period by effecting a reverse share split if necessary, subject to the conditions set forth in Nasdaq Listing Rule 5810. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;24, 2020 we received a separate letter from the Listing Qualifications Department of Nasdaq indicating that, based on the
market value of publicly held shares for the previous 30 consecutive business days, the listing of our ordinary shares was not in compliance with Nasdaq Listing Rule 5450(b)(2)(C) to maintain a minimum market value of publicly held shares of
$15,000,000, or the MVPHS Rule. Under Nasdaq Listing Rule 5810(c)(3)(D), we have a period of 180 calendar days, or until March&nbsp;23, 2021, to regain compliance with the MVPHS Rule. To regain compliance during this
<FONT STYLE="white-space:nowrap">180-day</FONT> compliance period, the minimum market value of publicly held shares must close at $15,000,000 or more for a minimum of 10 consecutive business days. In the event that we do not regain compliance with
the MVPHS Rule prior to the expiration of the <FONT STYLE="white-space:nowrap">180-day</FONT> compliance period, we will receive written notification from Nasdaq that our securities are subject to delisting. At that time, we may appeal the delisting
determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance that, if we do appeal the delisting determination by Nasdaq to the panel, that such appeal would be
successful. If we do not regain compliance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
within the <FONT STYLE="white-space:nowrap">180-day</FONT> compliance period, we may also transfer the listing of our ordinary shares to the Nasdaq Capital Market, provided that we then meet the
applicable requirements for continued listing on the Nasdaq Capital Market. To effect such a transfer, we would need to submit an online transfer application and pay an application fee to Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;15, 2020, we received a letter from the Listing Qualifications Department of Nasdaq notifying us that the listing of our ordinary
shares was not in compliance with Nasdaq Listing Rule 5450(b)(2)(A), or the MVLS Rule, for continued listing on the Nasdaq Global Market, as the market value of our listed securities was less than $50.0&nbsp;million for the previous 30 consecutive
business days. Under Nasdaq Listing Rule 5810(c)(3)(C), we have a period of 180 calendar days, or until January&nbsp;11, 2021, to regain compliance with the MVLS Rule. To regain compliance, during this <FONT STYLE="white-space:nowrap">180-day</FONT>
compliance period, the market value of our listed securities must be at least $50.0&nbsp;million or more (measured based on closing prices) for a minimum of 10 consecutive business days. In the event that we do not regain compliance with the MVLS
Rule prior to the expiration of the <FONT STYLE="white-space:nowrap">180-day</FONT> compliance period, we will receive written notification from Nasdaq that our securities are subject to delisting. At that time, we may appeal the delisting
determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance that, if we do appeal the delisting determination by Nasdaq to the panel, that such appeal would be
successful. If we do not regain compliance within the <FONT STYLE="white-space:nowrap">180-day</FONT> compliance period, we may also transfer the listing of our ordinary shares to the Nasdaq Capital Market, provided that we then meet the applicable
requirements for continued listing on the Nasdaq Capital Market. To effect such a transfer, we would need to submit an online transfer application and pay an application fee to Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;4, 2020, we received a letter from the Listing Qualifications Department of Nasdaq notifying us that the listing of our ordinary
shares was not in compliance with the MVLS Rule for continued listing on the Nasdaq Global Market, as the market value of our listed securities was less than $50.0&nbsp;million for the previous 30 consecutive business days. Under Nasdaq Listing Rule
5810(c)(3)(C), we had a period of 180 calendar days, or until August&nbsp;31, 2020, to regain compliance with the MVLS Rule. To regain compliance, the market value of our listed securities needed to be at least $50.0&nbsp;million or more (measured
based on closing prices) for a minimum of 10 consecutive business days. On May&nbsp;13, 2020, we received notification from the Listing Qualifications Department of Nasdaq that, for 10 consecutive business days from April&nbsp;29, 2020 to
May&nbsp;12, 2020, the market value of our listed securities had been greater than $50.0&nbsp;million, confirming that we had regained compliance with the MVLS Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we have been able to regain compliance with the listing requirements within the manner and time periods prescribed by Nasdaq in the
past, there can be no assurance that we will be able to regain compliance with respect to the current deficiencies or that we will be able to maintain compliance with the Nasdaq Global Market continued listing requirements in the future or regain
compliance with respect to any future deficiencies or, if transferred, that we will be successful in maintaining the listing of our ordinary shares on the Nasdaq Capital Market. This could impair the liquidity and market price of our ordinary
shares. In addition, the delisting of our ordinary shares from a national exchange could have a material adverse effect on our access to capital markets, and any limitation on market liquidity or reduction in the price of our ordinary shares as a
result of that delisting could adversely affect our ability to raise capital on terms acceptable to us, or at all. The delisting of our ordinary shares from the Nasdaq Global Market could also negatively impact our financial condition as it would
constitute (i)&nbsp;an event of default under our loan agreement with SVB, which could lead to an acceleration of amounts due under the loan agreement and foreclosure upon and/or sale or other liquidation of all of our and our subsidiaries&#146;
assets, including intellectual property; and (ii)&nbsp;a Fundamental Change (as such term is defined in the indenture for the Exchangeable Notes), which could trigger an obligation for us to repurchase the Exchangeable Notes at a repurchase price of
300% of the principal amount of the outstanding Exchangeable Notes. We intend to actively monitor the closing bid price of our listed ordinary shares and the market value of our ordinary shares and, as appropriate, will consider available options to
resolve the deficiencies and regain compliance with the Nasdaq Listing Rules, including applying to transfer to the Nasdaq Capital Market and, in the case of the Bid Price Rule, potentially seeking to effect a reverse share split. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80934_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the information incorporated by reference herein contain &#147;forward-looking statements&#148; within the meaning of
Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act. These statements include statements made regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans,
objectives of management and expected market growth, other than statements of historical facts. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148;
&#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; &#147;would,&#148; or the
negative of these words or other comparable terminology and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements
include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our use of cash reserves; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and
development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to retain the continued service of our key professionals and to identify, hire and retain additional
qualified professionals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance product candidates into, and successfully complete, clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential advantages of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to move forward with our new drug application for oral sulopenem for the treatment of uUTI in patients
with a quinolone-resistant pathogen; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to apply for regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercialization of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our manufacturing plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our sales, marketing and distribution capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market acceptance of any product we successfully commercialize; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing, coverage and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model, strategic plans for our business and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
product candidates and our ability to defend and enforce any such intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enter into strategic arrangements, collaborations and/or commercial partnerships in the United
States and other territories and the potential benefits of such arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, capital requirements and needs for additional financing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding how far into the future our cash on hand will fund our ongoing operations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to continue as a going concern; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact <FONT STYLE="white-space:nowrap">of&nbsp;COVID-19,&nbsp;including</FONT> the responsive measures taken
by governmental authorities and others, on our clinical trials, on future commercialization of, and future demand for, our products, available funding, our operations and the economy in general, which may precipitate or exacerbate other risks and/or
uncertainties; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expected use of proceeds from this offering and the sale of securities, if any, pursuant to the Sarissa Right
to Purchase; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to regain and maintain compliance with the Nasdaq Global Market continued listing requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome, impact, effects and results of our evaluation of corporate, organizational, strategic, financial and
financing alternatives, including the terms, timing, structure, value, benefits and costs of any corporate, organizational, strategic, financial or financing alternative and our ability to complete one at all; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those described in the &#147;Risk Factors&#148; sections of our most
recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and most recent Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;and</FONT> other filings we make with the SEC from time to time, which are
incorporated by reference herein. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not actually achieve the plans, intentions or expectations disclosed in our
forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make.
You are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are referenced in the &#147;Risk Factors&#148; section of this prospectus. You should also carefully review the
risk factors and cautionary statements described in the other documents we file from time to time with the SEC, specifically our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and most recent Quarterly Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-Q.&nbsp;We</FONT> undertake no obligation to revise or update any forward-looking statements, except to the extent required by law.&nbsp;Moreover, we operate in a very competitive and rapidly changing
environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances contained or incorporated by reference
herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we believe&#148; and similar statements contained or incorporated by reference herein reflect our beliefs
and opinions on the relevant subject. These statements are based upon information that was available to us as of the date such statements were made, and while we believe such information forms a reasonable basis for such statements, such information
may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors
are cautioned not to unduly rely upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80934_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from this offering will be approximately $13.1&nbsp;million based on the sale of 13,043,478 ordinary shares
and Warrants to purchase 9,782,608 ordinary shares at an assumed combined public offering price of $1.15 per ordinary share and Warrant, which is equal to the last reported sale price of our ordinary shares on the Nasdaq Global Market on
October&nbsp;20, 2020, after deducting the placement agent fees and estimated offering expenses payable by us, and assuming no sale of <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants in this offering, no exercise of the Warrants being
issued in this offering or the Placement Agent Warrants and no sale of securities to Sarissa pursuant to the Sarissa Right to Purchase. However, because this is a best efforts offering and there is no minimum offering amount required as a condition
to the closing of this offering, the actual offering amount, the placement agent&#146;s fees and net proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth on the cover page of this prospectus.
The aggregate number of ordinary shares, or Pre-funded Warrants, and Warrants we are offering is based on an aggregate purchase price of $15.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These estimates exclude the proceeds, if any, from the exercise of Warrants issued in this offering. If all of the Warrants issued in this
offering were to be exercised in cash at an assumed exercise price of $1.15 per ordinary share, which is equal to the last reported sale price of our ordinary shares on the Nasdaq Global Market on October&nbsp;20, 2020, we would receive additional
proceeds of approximately $11.2&nbsp;million. We cannot predict when or if these Warrants will be exercised. It is possible that these Warrants may expire and may never be exercised. Additionally, the Warrants contain a cashless exercise provision
that permit exercise of Warrants on a cashless basis at any time when there is no effective registration statement under the Securities Act covering the issuance of the underlying shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering to support our planned NDA submission for oral sulopenem for the treatment of uUTI in
patients with quinolone-resistant pathogens, the continued clinical development of sulopenem and for working capital and general corporate purposes. We cannot predict with certainty all of the particular uses for the net proceeds to be received upon
the completion of this offering. The expected use of net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. The
amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the impact of <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> on our business operations, the progress of our
commercialization and development efforts, the outcome of regulatory review of our product candidates, the status of and results from clinical trials, as well as any collaborations that we may enter into with third parties for our product
candidates, and any unforeseen cash needs.&nbsp;Accordingly, our management will have broad discretion and flexibility in applying the net proceeds from the sale of securities issued pursuant to this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that our existing cash and cash equivalents, together with the assumed net proceeds of $13.1&nbsp;million from this offering,
should be sufficient to fund our operating expenses and capital expenditure requirements, including our planned NDA submission for oral sulopenem for the treatment of uUTI in patients with quinolone-resistant pathogens and the potential FDA
acceptance of such NDA submission, into the anticipated FDA review period of such NDA submission. However, we have based this estimate on assumptions that may prove to be wrong, and our operating plans may change as a result of many factors and
various risks and uncertainties. For example, this estimate assumes, among other things, the continuation of regular monthly amortization payments of the principal amount outstanding under our credit facility with SVB and that the balance of the
principal amount does not become due and payable until the maturity date of March 1, 2022. In addition, because this is a best efforts offering, the amount we raise may be substantially lower than the assumed $13.1&nbsp;million in net proceeds. We
could deplete our capital resources sooner than we currently expect. Even if this offering is successful, we will need to secure additional resources to support our continued operations, including resources needed to complete the regulatory approval
process with the FDA for our planned NDA submission for oral sulopenem for the treatment of uUTI patients with quinolone-resistant pathogens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending our use of the net proceeds from this offering and from the sale of any securities to Sarissa pursuant to the Sarissa Right to
Purchase, we may invest the net proceeds in a variety of capital preservation investments, including term deposits, short-term, investment-grade interest-bearing instruments and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80934_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our ordinary shares. We currently intend to retain all available funds and any future
earnings to support operations and to finance the growth and development of our business. In addition, our ability to pay dividends is currently restricted by the terms of our credit facility with SVB. We do not intend to declare or pay cash
dividends on our ordinary shares in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors subject to applicable laws (including the Irish Companies Act 2014, which requires, among
other things, Irish companies to have profits available for distribution (known as distributable reserves) equal to or greater than the amount of the proposed dividend), and will depend upon, among other factors, our results of operations, financial
condition, contractual restrictions and capital requirements. Unless we create sufficient distributable reserves from our business activities, the creation of such distributable reserves would involve a reduction of our share premium account, which
would require the approval of 75% of our shareholders present and voting at a shareholder meeting, and of the Irish High Court. Our future ability to pay cash dividends on our shares may also be limited by the terms of any future debt or preferred
securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80934_7a"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents, as well as our capitalization, as of June&nbsp;30, 2020 as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as adjusted to give effect to the sale by us of 13,043,478 ordinary shares and Warrants to purchase 9,782,608
ordinary shares in this offering at an assumed combined public offering price of $1.15 per ordinary share and Warrant, which is equal to the last reported sale price of our ordinary shares on the Nasdaq Global Market on October&nbsp;20, 2020, after
deducting the placement agent fees and estimated offering expenses payable by us, and assuming no sale of <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants in this offering, no exercise of the Warrants being issued in this offering or the
Placement Agent Warrants and no sale of securities to Sarissa pursuant to the Sarissa Right to Purchase. The aggregate number of ordinary shares, or Pre-funded Warrants, and Warrants we are offering is based on an aggregate purchase price of
$15.0&nbsp;million. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The as adjusted information set forth below is illustrative only and will be adjusted based on
the actual public offering price and other terms of this offering determined at pricing. You should read this information together with our consolidated financial statements and related notes incorporated by reference in this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>June&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Adjusted(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands,<BR>except&nbsp;share&nbsp;amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of royalty linked notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, less current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty-linked notes, less current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, $0.01 nominal value per share: 150,000,000 shares authorized, actual and as
adjusted; 17,852,149 shares issued, actual; 30,895,627 shares issued, as adjusted basis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(263,544</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(263,544</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,789</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A $0.25 increase or decrease in the assumed combined public offering price of $1.15 per ordinary share and
Warrant, which is equal to the last reported sale price of our ordinary shares on the Nasdaq Global Market on October&nbsp;20, 2020, would increase or decrease, as appropriate, our as adjusted cash and cash equivalents, additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital, total shareholders&#146; deficit and total capitalization by approximately $3.0&nbsp;million, assuming the number of ordinary shares and Warrants offered by us as set forth on the cover page of this
prospectus remains the same, after deducting the placement agent fees and estimated offering expenses payable by us, and assuming no sale of <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants in this offering, no exercise of the Warrants
being issued in this offering or the Placement Agent Warrants and no sale of securities to Sarissa pursuant to the Sarissa Right to Purchase. Similarly, a 1.0 million share increase or decrease in the number of ordinary shares and Warrants offered
by us would, based on the assumed combined public offering price of $1.15 per </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
ordinary share and Warrant, increase or decrease our as adjusted cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total shareholders&#146; deficit
and total capitalization by approximately $1.1&nbsp;million, after deducting the placement agent fees and estimated offering expenses payable by us, and assuming no sale of <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants in this
offering, no exercise of the Warrants being issued in this offering or the Placement Agent Warrants and no sale of securities to Sarissa pursuant to the Sarissa Right to Purchase. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total number of ordinary shares reflected in the discussion and the table above is based on 17,852,149 ordinary shares issued and
outstanding as of June&nbsp;30, 2020 and does not include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,168,891 ordinary shares issuable upon the exercise of share options to purchase ordinary shares as of
June&nbsp;30, 2020, at a weighted average exercise price of $7.55 per ordinary share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14,258 ordinary shares issuable upon the vesting of outstanding restricted stock units as of June&nbsp;30, 2020;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,095,000 ordinary shares issuable upon the vesting of outstanding performance restricted stock units as of
June&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,314,447 additional ordinary shares available for future issuance as of June&nbsp;30, 2020 under our 2018 Equity
Incentive Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,713,799 ordinary shares issuable upon exercise of outstanding warrants as of June&nbsp;30, 2020, at a weighted
average exercise price of $1.88 per ordinary share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary shares, or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants, as applicable, and Warrants that
may be sold to Sarissa pursuant to the Sarissa Right to Purchase; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,372,686 ordinary shares issued and sold on July&nbsp;2, 2020 to certain institutional investors in a registered
direct offering for aggregate net proceeds to us of approximately $4.4&nbsp;million, after deducting fees payable to the placement agent and other estimated offering expenses payable by us, or the Registered Direct Offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,686,343 ordinary shares issuable upon exercise of warrants issued and sold on July&nbsp;2, 2020 to certain
institutional investors in a private placement that closed concurrently with the Registered Direct Offering and 236,088 ordinary shares issuable upon exercise of warrants issued to designees of the placement agent in such offering; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$220,000 in aggregate principal amount of Rights Offering Exchangeable Notes and $440 in limited recourse
royalty-linked subordinated notes, in each case issued by Iterum Bermuda on September&nbsp;8, 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance
of doubt, this discussion also assumes no sale of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants, no exercise of the Warrants being issued in this offering or the Placement Agent Warrants, no exchange of the Exchangeable Notes and
no sale of securities to Sarissa pursuant to the Sarissa Right to Purchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80934_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our securities, your interest will be diluted to the extent of the difference between the combined price per ordinary share
and Warrant you pay in this offering and the net tangible book value per ordinary share immediately after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net tangible
book value as of June&nbsp;30, 2020 was approximately $(48.8)&nbsp;million, or $(2.73) per ordinary share. Net tangible book value per ordinary share is determined by dividing our total tangible assets, less total liabilities, by the number of
ordinary shares outstanding as of June&nbsp;30, 2020. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without taking into account any other changes in our net tangible book value
after June&nbsp;30, 2020, other than to give effect to the assumed sale of 13,043,478 ordinary shares and Warrants to purchase 9,782,608 ordinary shares in this offering at an assumed combined public offering price of $1.15 per ordinary share and
Warrant, which is equal to the last reported sale price of our ordinary shares on the Nasdaq Global Market on October&nbsp;20, 2020, after deducting the placement agent fees and estimated offering expenses payable by us and assuming no sale of <FONT
STYLE="white-space:nowrap">Pre-funded</FONT> Warrants in this offering, no exercise of the Warrants being issued in this offering or the Placement Agent Warrants and no sale of securities to Sarissa pursuant to the Sarissa Right to Purchase, our as
adjusted net tangible book value as of June&nbsp;30, 2020 would have been approximately $(35.7)&nbsp;million, or $(1.15) per ordinary share. This represents an immediate increase in net tangible book value of $1.58 per ordinary share to existing
shareholders and immediate dilution of $2.304 per ordinary share to investors purchasing our securities in this offering at the assumed combined public offering price. Dilution per ordinary share to new investors in this offering is the difference
between the assumed combined public offering price per ordinary share and Warrant paid by purchasers in this offering and the as adjusted net tangible book value per ordinary share immediately after this offering. The following table illustrates
this dilution on a per ordinary share basis: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed combined public offering price per ordinary share and Warrant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per ordinary share as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per ordinary share as of June&nbsp;30, 2020, after giving
effect to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per ordinary share as of June&nbsp;30, 2020, after giving
effect to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per ordinary share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dilution information set forth in the table above is illustrative only and will be adjusted based on
the actual combined public offering price and other terms of this offering determined at pricing. In addition, if previously issued options or warrants to acquire ordinary shares are exercised at prices below the combined offering price or the
warrants are accounted for as liabilities, you will experience further dilution. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A $0.25 increase or decrease in the assumed combined
public offering price of $1.15 per ordinary share and Warrant, which is equal to the last reported sale price of our ordinary shares on the Nasdaq Global Market on October&nbsp;20, 2020, would increase or decrease our adjusted net tangible book
value after this offering by approximately $3.0&nbsp;million, and decrease or increase dilution per ordinary share to new investors by approximately $0.15, after deducting the placement agent fees and estimated offering expenses payable by us and
assuming no sale of <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants in this offering, no exercise of the Warrants being issued in this offering or the Placement Agent Warrants and no sale of securities to Sarissa pursuant to the Sarissa
Right to Purchase. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also increase or decrease the number of ordinary shares and Warrants we are offering. An increase of
1.0&nbsp;million in the number of ordinary shares and Warrants offered by us would increase our adjusted net </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
tangible book value per ordinary share after this offering by approximately $1.1&nbsp;million, and decrease dilution per ordinary share to new investors by approximately $(0.07), after deducting
the placement agent fees and estimated offering expenses payable by us and assuming no sale of <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants in this offering, no exercise of the Warrants being issued in this offering or the Placement
Agent Warrants and no sale of securities to Sarissa pursuant to the Sarissa Right to Purchase. A decrease of 1.0&nbsp;million in the number of ordinary shares and Warrants offered by us would decrease our adjusted net tangible book value per
ordinary share after this offering by approximately $1.1&nbsp;million, and increase dilution per ordinary share to new investors by approximately $0.07, after deducting the placement agent fees and estimated offering expenses payable by us and
assuming no sale of <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants in this offering, no exercise of the Warrants being issued in this offering or the Placement Agent Warrants and no sale of securities to Sarissa pursuant to the Sarissa
Right to Purchase. The information discussed above is illustrative only and will adjust based on the actual offering price, the actual number of shares and Warrants we offer in this offering, and other terms of this offering determined at pricing.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total number of ordinary shares reflected in the discussion and the table above is based on 17,852,149 ordinary shares issued
and outstanding as of June&nbsp;30, 2020 and does not include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,168,891 ordinary shares issuable upon the exercise of share options to purchase ordinary shares as of
June&nbsp;30, 2020, at a weighted average exercise price of $7.55 per ordinary share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14,258 ordinary shares issuable upon the vesting of outstanding restricted stock units as of June&nbsp;30, 2020;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,095,000 ordinary shares issuable upon the vesting of outstanding performance restricted stock units as of
June&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,314,447 additional ordinary shares available for future issuance as of June&nbsp;30, 2020 under our 2018 Equity
Incentive Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,713,799 ordinary shares issuable upon exercise of outstanding warrants as of June&nbsp;30, 2020, at a weighted
average exercise price of $1.88 per ordinary share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary shares, or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants, as applicable, and Warrants that
may be sold to Sarissa pursuant to the Sarissa Right to Purchase; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,372,686 ordinary shares issued and sold on July&nbsp;2, 2020 to certain institutional investors in the
Registered Direct Offering for aggregate net proceeds to us of approximately $4.4&nbsp;million, after deducting fees payable to the placement agent and other estimated offering expenses payable by us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,686,343 ordinary shares issuable upon exercise of warrants issued and sold on July&nbsp;2, 2020 to certain
institutional investors in a private placement that closed concurrently with the Registered Direct Offering and 236,088 ordinary shares issuable upon exercise of warrants issued to designees of the placement agent in such offering; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$220,000 in aggregate principal amount of Rights Offering Exchangeable Notes and $440 in limited recourse
royalty-linked subordinated notes, in each case issued by Iterum Bermuda on September&nbsp;8, 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance
of doubt, this discussion also assumes no sale of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants, no exercise of the Warrants being issued in this offering or the Placement Agent Warrants, no exchange of the Exchangeable Notes and
no sale of securities to Sarissa pursuant to the Sarissa Right to Purchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80934_9"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our share capital is intended as a summary only and therefore is not a complete description of our share capital.
This description is based upon, and is qualified by reference to, our Memorandum and Articles of Association, or our Constitution, and applicable provisions of the Irish Companies Act 2014, or the Irish Companies Act. You should read our
Constitution including our Articles of Association, which are filed as an exhibit to the registration statement of which this prospectus forms a part, for the provisions that are important to you. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure&#151;Authorized and Issued Share Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized share capital consists of 150,000,000 ordinary shares of $0.01 each and 100,000,000 undesignated preferred shares of $0.01 each.
As of October&nbsp;2, 2020, we had 21,239,093 ordinary shares outstanding held by approximately 14 shareholders of record and we had no preferred shares outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue shares subject to the maximum authorized share capital contained in our Constitution. The authorized share capital may be
increased or reduced (but not below the number of issued ordinary shares or preferred shares, as applicable) by a resolution approved by a simple majority of the votes of our shareholders cast at a general meeting (referred to under Irish law as an
&#147;ordinary resolution&#148;) (unless otherwise determined by the directors). The shares comprising our authorized share capital may be divided into shares of any nominal value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights and restrictions to which the ordinary shares are subject are prescribed in our Articles of Association. Our Articles of
Association entitle our board of directors, without shareholder approval, to determine the terms of our preferred shares. Preferred shares may be preferred as to dividends, rights upon liquidation or voting in such manner as our board of directors
may resolve. The preferred shares may also be redeemable at the option of the holder of the preferred shares or at our option and may be convertible into or exchangeable for shares of any of our other class or classes, depending on the terms of such
preferred shares. The specific terms of any series of preferred shares offered pursuant to this prospectus will be described in the prospectus supplement relating to that series of preferred shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Irish law does not recognize fractional shares held of record. Accordingly, our Articles of Association do not provide for the issuance of
fractional shares, and our official Irish register will not reflect any fractional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever an alteration or reorganization of
our share capital would result in any of our shareholders becoming entitled to fractions of a share, our board of directors may, on behalf of those shareholders that would become entitled to fractions of a share, arrange for the sale of the shares
representing fractions and the distribution of the net proceeds of sale in due proportion among the shareholders who would have been entitled to the fractions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance of Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a matter of Irish
law, the directors of a company may issue new ordinary or preferred shares for cash without shareholder approval once authorized to do so by the memorandum and articles of association or by an ordinary resolution adopted by the shareholders at a
general meeting. The authorization may be granted for a maximum period of five years, at which point it must be renewed by the shareholders by an ordinary resolution. Our board of directors is authorized pursuant to a shareholder resolution passed
on June&nbsp;10, 2020 to issue new ordinary or preferred shares up to the amount of the authorized but unissued share capital as at that date for cash without shareholder approval for a period of five years from the date of the passing of the
resolution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Pre-emption&nbsp;Rights,&nbsp;Share</FONT> Warrants and Share Options
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Irish law certain <FONT STYLE="white-space:nowrap">statutory&nbsp;pre-emption&nbsp;rights</FONT> apply automatically in favor of
shareholders where shares are to be issued for cash. However, we have opted out of <FONT STYLE="white-space:nowrap">these&nbsp;pre-emption&nbsp;rights</FONT> by way of shareholder resolution passed on June&nbsp;10, 2020 as permitted under Irish
company law. Irish law requires <FONT STYLE="white-space:nowrap">this&nbsp;opt-out&nbsp;to</FONT> be renewed every five years by a resolution approved by not less than 75% of the votes of our shareholders cast at a general meeting (referred to under
Irish law as a &#147;special resolution&#148;) and our <FONT STYLE="white-space:nowrap">current&nbsp;opt-out&nbsp;will</FONT> expire on June&nbsp;10, 2025. If the&nbsp;opt-out&nbsp;is not renewed, shares issued for cash must be offered to our
existing shareholders on a pro rata basis to their existing shareholding before the shares can be issued to any new shareholders. The <FONT STYLE="white-space:nowrap">statutory&nbsp;pre-emption&nbsp;rights</FONT> do not apply where shares are issued
<FONT STYLE="white-space:nowrap">for&nbsp;non-cash&nbsp;consideration</FONT> (such as in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;share-for-share&nbsp;acquisition)</FONT></FONT> and do not apply to the issue <FONT
STYLE="white-space:nowrap">of&nbsp;non-equity&nbsp;shares</FONT> (that is, shares that have the right to participate only up to a specified amount in any income or capital distribution) or where shares are issued pursuant to an employee share option
or similar equity plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Investor Rights Agreement entered into in connection with the January 2020 Private
Placement, for so long as Sarissa owns 10% of our outstanding ordinary shares on a fully diluted basis, Sarissa has a right of first offer with respect to our future proposed equity financings up to that portion of such new securities which equals
Sarissa&#146;s then-percentage ownership of our outstanding ordinary shares on a fully diluted basis, subject to specified exceptions for certain exempt issuances and pursuant to specified procedures. In the event our board of directors determines
in good faith that we must conduct an equity financing on an expedited basis without compliance with the right of first offer described above in order to avoid material harm to us or any of our affiliates, we may effect and consummate such equity
financing and, as promptly as practicable following the consummation of such equity financing, Sarissa will have the opportunity to participate in such equity financing and be put in the same place (including in respect of the percentage ownership
of our equity securities) Sarissa would have been had such equity financing been effected in accordance with the terms of the right of first offer. As set forth in the Investor Rights Agreement, in any 12 month period, we may conduct an equity
financing without compliance with <FONT STYLE="white-space:nowrap">the&nbsp;pre-emptive&nbsp;rights</FONT> described above, or an Excused Issuance; provided that we may not issue new securities (other than specified exempted securities) exceeding
(in the aggregate with all other Excused Issuances during such 12 month period) 5% of the issued and outstanding ordinary shares on a fully diluted basis, and we may not issue new securities (other than specified exempted securities) in exchange for
consideration (whether in cash or other property) the value of which exceeds (in the aggregate with all other Excused Issuances during such 12 month period) $5.0&nbsp;million. We may only consummate two Excused Issuances for so long as the Investor
Rights Agreement is in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Association provide that, subject to any shareholder approval requirement under any laws,
regulations or the rules&nbsp;of any stock exchange to which we are subject, the board of directors is authorized, from time to time, in its discretion, to grant such persons, for such periods and upon such terms as the board of directors deems
advisable, options to purchase such number of shares of any class or classes or of any series of any class as the board of directors may deem advisable, and to cause warrants or other appropriate instruments evidencing such options to be issued. The
Irish Companies Act provides that directors may issue share warrants or options without shareholder approval once authorized to do so by the Articles of Association. We are subject to the rules&nbsp;of the Nasdaq Global Market that require
shareholder approval of certain equity plans and share issuances. Our board of directors may authorize the issuance of shares upon exercise of warrants or options without shareholder approval or authorization (up to the relevant authorized share
capital limit). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Irish law, we are prohibited from allotting shares without consideration. Accordingly, at least the nominal value
of the shares issued underlying any restricted share award, restricted share unit, performance share award, bonus share or any other share based grant must be paid pursuant to the Irish Companies Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Irish law, dividends and
distributions may only be made from distributable reserves. Distributable reserves, broadly, means the accumulated realized profits of a company, so far as not previously utilized by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distribution or capitalization, less accumulated realized losses of a company, so far as not previously written off in a reduction or reorganization of capital, and includes reserves created by
way of capital reduction, on a standalone basis. In addition, no distribution or dividend may be made unless our net assets are equal to, or in excess of, the aggregate of our called up share capital plus undistributable reserves and the
distribution does not reduce our net assets below such aggregate. Undistributable reserves include the undenominated capital, the amount by which our accumulated unrealized profits, so far as not previously utilized by any capitalization, exceed our
accumulated unrealized losses, so far as not previously written off in a reduction or reorganization of capital and any other reserve that we are prohibited from distributing by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The determination as to whether or not we have sufficient distributable reserves to fund a dividend must be made by reference to the
&#147;relevant financial statements&#148; of the company. The &#147;relevant financial statements&#148; are either the last set of unconsolidated annual audited financial statements or unaudited financial statements properly prepared in accordance
with the Irish Companies Act, which give a &#147;true and fair view&#148; of the company&#146;s unconsolidated financial position in accordance with accepted accounting practice in Ireland. The &#147;relevant financial statements&#148; must be filed
in the Companies Registration Office (the official public registry for companies in Ireland) prior to the making of the distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consistent with Irish law, our Articles of Association authorize the directors to declare interim dividends without shareholder approval out
of funds lawfully available for the purpose, to the extent they appear justified by profits and subject always to the requirement to have distributable reserves at least equal to the amount of the proposed dividend. The board of directors may also
recommend a dividend to be approved and declared by our shareholders at a general meeting. The board of directors may direct that the payment be made by distribution of assets, shares or cash and no dividend declared or paid may exceed the amount
recommended by the directors. Dividends may be paid in U.S. dollars or any other currency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors may deduct from any dividend
payable to any shareholder any amounts payable by such shareholder to us in relation to our shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors may also authorize the
issuance of shares with preferred rights to participate in our declared dividends. The holders of preferred shares may, depending on their terms, rank senior to our ordinary shares in terms of dividend rights and/or be entitled to claim arrears of a
declared dividend out of subsequently declared dividends in priority to ordinary shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Repurchases, Redemptions and Conversions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of
Association provide that, in general, any ordinary share which we have agreed to acquire shall be deemed to be a redeemable share. Accordingly, for Irish company law purposes, the repurchase of ordinary shares by us may technically be effected as a
redemption of those shares as described below under &#147;Repurchases and Redemptions.&#148; If our Articles of Association did not contain such provisions, all repurchases by us would be subject to many of the same rules that apply to purchases of
our shares by subsidiaries described below under &#147;&#151;Purchases by Subsidiaries&#148; including the shareholder approval requirements described below. Except where otherwise noted, when we refer elsewhere in this prospectus to repurchasing or
buying back our ordinary shares, we are referring to the redemption of ordinary shares by us pursuant to the Articles of Association or the purchase of our ordinary shares by a subsidiary of the Company, in each case in accordance with our Articles
of Association and Irish law as described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Repurchases and Redemptions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Irish law, a company may issue redeemable shares and redeem them out of distributable reserves (which are described above under
&#147;Dividends&#148;) or, if the company proposes to cancel the shares on redemption, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the proceeds of a new issue of shares for that purpose. The redemption of redeemable shares may only be made by us where the nominal value of the issued share capital that is not redeemable is
not less than 10% of the nominal value of the total issued share capital of the company. All redeemable shares must also be fully-paid and the terms of redemption of the shares must provide for payment on redemption. Redeemable shares may, upon
redemption, be cancelled or held in treasury. Based on the provisions of our articles described above, shareholder approval will not be required to redeem our shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also be given an additional general authority by our shareholders to purchase our own
<FONT STYLE="white-space:nowrap">shares&nbsp;on-market,&nbsp;which</FONT> would take effect on the same terms and be subject to the same conditions as applicable to purchases by our subsidiaries as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may also issue preferred shares or other classes or series of shares which may be redeemed at either our option or the
option of the shareholder, depending on the terms of such preferred shares. Please see &#147;Capital Structure&#151;Authorized and Issued Share Capital.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Repurchased and redeemed shares may be cancelled or held as treasury shares. The nominal value of treasury shares held by us at any time must
not exceed 10% of the nominal value of our issued share capital. We may not exercise any voting rights in respect of any shares held as treasury shares. Treasury shares may be cancelled by us
<FONT STYLE="white-space:nowrap">or&nbsp;re-issued&nbsp;subject</FONT> to certain conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Purchases by Subsidiaries </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Irish law, an Irish <FONT STYLE="white-space:nowrap">or&nbsp;non-Irish&nbsp;subsidiary</FONT> of the Company may purchase our shares
either as overseas market purchases on a recognized stock exchange such as the Nasdaq <FONT STYLE="white-space:nowrap">or&nbsp;off-market.&nbsp;For</FONT> a subsidiary of ours to make market purchases of our shares, our shareholders must provide
general authorization for such purchase by way of ordinary resolution. However, as long as this general authority has been granted, no specific shareholder authority for a particular market purchase by a subsidiary of our shares is required. We may
elect to seek such general authority, which must expire no later than 18 months after the date on which it was granted, at our annual general meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For <FONT STYLE="white-space:nowrap">an&nbsp;off-market&nbsp;purchase</FONT> by a subsidiary of ours, the proposed purchase contract must be
authorized by special resolution of the shareholders before the contract is entered into. The person whose shares are to be bought back cannot vote in favor of the special resolution and from the date of the notice of the meeting at which the
resolution approving the contract is proposed, the purchase contract must be on display or must be available for inspection by shareholders at our registered office from the date of the notice of the meeting at which the resolution approving the
contract is to be proposed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order for a subsidiary of ours to make
<FONT STYLE="white-space:nowrap">an&nbsp;on-market&nbsp;purchase</FONT> of our shares, such shares must be purchased on a &#147;recognized stock exchange.&#148; The Nasdaq Global Market, on which our ordinary shares are listed, is specified as a
recognized stock exchange for this purpose by Irish company law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares held by our subsidiaries at any time will count as
treasury shares and will be included in any calculation of the permitted treasury share threshold of 10% of the nominal value of our issued share capital. While a subsidiary holds shares of ours, it cannot exercise any voting rights in respect of
those shares. The acquisition of our shares by a subsidiary of ours must be funded out of distributable reserves of the subsidiary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lien on Shares,
Calls on Shares and Forfeiture of Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Association provide that we will have a first and paramount lien on every
share for all debts and liabilities of any shareholder to the company, whether presently due or not, payable in respect of such share. Subject to the terms of their allotment, directors may call for any unpaid amounts in respect of any shares to be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
paid, and if payment is not made within 14 days after notice demanding payment, we may sell the shares. These provisions are standard inclusions in the Articles of Association of an Irish company
limited by shares and will only be applicable to our shares that have not been fully paid up. See &#147;&#151;Transfer and Registration of Shares.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation and Division; Subdivision </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our Articles of Association, we may, by ordinary resolution (unless the directors determine otherwise), divide all or any of our issued
share capital into shares of smaller nominal value than our existing shares (often referred to as a share split) or consolidate all or any of our issued share capital into shares of larger nominal value than is fixed by our memorandum of association
(often referred to as a reverse share split), provided that the proportion between the amount paid for such share and the amount, if any, unpaid on each reduced share after the subdivision remains the same. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reduction of Share Capital </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may, by
ordinary resolution (unless the directors determine otherwise), reduce our authorized but unissued share capital in any way. We also may, by special resolution and subject to confirmation by the Irish High Court, reduce or cancel our issued share
capital in any manner permitted by the Irish Companies Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annual General Meetings of Shareholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to hold an annual general meeting within 18 months of incorporation and at intervals of no more than 15 months thereafter,
provided that an annual general meeting is held in each calendar year following the first annual general meeting and no more than nine months after our <FONT STYLE="white-space:nowrap">fiscal&nbsp;year-end.&nbsp;Any</FONT> annual general meeting may
be held outside Ireland, provided that technological means are provided to enable shareholders to participate in the meeting without leaving Ireland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice of an annual general meeting must be given to all of our shareholders and to our auditors. Our Articles of Association provide for a
minimum notice period of 21 clear days (i.e. 21 days excluding the day when the notice is given or deemed to be given and the day of the event for which it is given or on which it is to take effect), which is the minimum permitted under Irish law.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The only matters which must, as a matter of Irish company law, be transacted at an annual general meeting are (i)&nbsp;the consideration
of the statutory financial statements, report of the directors, and report of the statutory auditors, (ii)&nbsp;review by the members of the company&#146;s affairs and (iii)&nbsp;the appointment
<FONT STYLE="white-space:nowrap">or&nbsp;re-appointment&nbsp;of</FONT> the statutory auditors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any annual general meeting, only such
business may be conducted as has been brought before the meeting: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the notice of the meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by or at the direction of the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in certain circumstances, at the direction of the Irish High Court; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as required by law; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the chairman of the meeting determines is properly within the scope of the meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, and subject to compliance with our Articles of Association, shareholders entitled to vote at an annual general meeting may
propose business in advance of the meeting to be considered thereat. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Extraordinary General Meetings of Shareholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our extraordinary general meetings may be convened by (i)&nbsp;the board of directors, (ii)&nbsp;on requisition of the shareholders holding not
less than 10% of our paid up share capital carrying voting rights, (iii)&nbsp;in certain circumstances, on requisition of our auditors; or (iv)&nbsp;in exceptional cases, by order of the Irish High Court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Extraordinary general meetings are generally held for the purpose of approving shareholder resolutions as may be required from time to time.
At any extraordinary general meeting, only such business will be conducted as is set forth in the notice thereof or is proposed pursuant to and in accordance with the procedures and requirements set out in our Articles of Association. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice of an extraordinary general meeting must be given to all of our shareholders and to our auditors. Under Irish law and our Articles of
Association, the minimum notice periods are 21 clear days&#146; notice in writing for an extraordinary general meeting to approve a special resolution and 14 clear days&#146; notice in writing for any other extraordinary general meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of an extraordinary general meeting convened by our shareholders, the proposed purpose of the meeting must be set out in the
requisition notice. Upon receipt of any such valid requisition notice, our board of directors has 21 days to convene a meeting of our shareholders to vote on the matters set out in the requisition notice. This meeting must be held within two months
of the receipt of the requisition notice. If the board of directors does not convene the meeting within such 21 day period, the requisitioning shareholders, or any of them representing more than one half of the total voting rights of all of them,
may themselves convene a meeting, which meeting must be held within three months of our receipt of the requisition notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the board
of directors becomes aware that our net assets are not greater than half of the amount of <FONT STYLE="white-space:nowrap">our&nbsp;called-up&nbsp;share</FONT> capital, our directors must convene an extraordinary general meeting of our shareholders
not later than 28 days from the date that the fact is known to a director to be held not later than 56 days from such date. This meeting must be convened for the purposes of considering whether any, and if so what, measures should be taken to
address the situation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quorum for General Meetings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Association provide that no business shall be transacted at any general meeting unless a quorum is present. One or more
shareholders present in person or by proxy at any meeting of shareholders holding not less than a majority of the issued shares that carry the right to vote at the meeting constitutes a quorum for the conduct of any business at a general meeting.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Association
provide that all votes at a general meeting will be decided on a poll and that the board or the chairman may determine the manner in which the poll is to be taken and the manner in which the votes are to be counted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Every shareholder is entitled to one vote for each ordinary share that he or she holds as of the record date for the meeting. Voting rights
may be exercised by shareholders registered in our share register as of the record date for the meeting or by a duly appointed proxy, which proxy need not be a shareholder. Where interests in shares are held by a nominee trust company, this company
may exercise the rights of the beneficial holders on their behalf as their proxy. All proxies must be appointed in the manner prescribed by our Articles of Association, which provide that our board of directors may permit shareholders to notify us
of their proxy appointments electronically. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with our Articles of Association, our directors may from time to time authorize
the issuance of preferred shares or any other class or series of shares. These shares may have such voting rights as may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
specified in the terms of such shares (e.g., they may carry more votes per share than ordinary shares or may entitle their holders to a class vote on such matters as may be satisfied in the terms
of such shares). Treasury shares or shares of ours that are held by our subsidiaries will not be entitled to be voted at general meetings of shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Irish company law requires special resolutions of the shareholders at a general meeting to approve certain matters. Examples of matters
requiring special resolutions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amending the objects as contained in our memorandum of association; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amending our Articles of Association; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving a change of name; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorizing the entering into of a guarantee or provision of security in connection with a loan, quasi-loan or
credit; transaction to a director or connected person; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">opting out <FONT STYLE="white-space:nowrap">of&nbsp;pre-emption&nbsp;rights</FONT> on the issuance of new shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">re-registration&nbsp;from</FONT> a public limited company to a private company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase of own <FONT STYLE="white-space:nowrap">shares&nbsp;off-market;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduction of issued share capital; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sanctioning a compromise/scheme of arrangement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">resolving that the company be wound up by the Irish courts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">resolving in favor of a shareholders&#146; <FONT STYLE="white-space:nowrap">voluntary&nbsp;winding-up;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">re-designation&nbsp;of</FONT> shares into different share classes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">setting <FONT STYLE="white-space:nowrap">the&nbsp;re-issue&nbsp;price</FONT> of treasury shares; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variation of class rights attaching to classes of shares (where our Articles of Association do not provide
otherwise). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither Irish law nor any of our constituent documents places limitations on the right <FONT
STYLE="white-space:nowrap">of&nbsp;non-resident&nbsp;or</FONT> foreign owners to vote or hold our shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Variation of Rights Attaching to a
Class&nbsp;or Series of Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our Articles of Association and the Irish Companies Act, any variation of class rights attaching
to our issued shares must be approved by an ordinary resolution passed at a general meeting of the shareholders of the affected class or with the consent in writing of the holders of a majority of the issued shares of that class of shares entitled
to vote on such variation. The rights conferred upon the holder of <FONT STYLE="white-space:nowrap">any&nbsp;pre-existing&nbsp;issued</FONT> shares shall not be deemed to be varied by the issuance of any preferred shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of our Articles of Association relating to general meetings apply to general meetings of the holders of any class of shares
except that the necessary quorum is determined in reference to the shares of the holders of the class. Accordingly, for general meetings of holders of a particular class of shares, a quorum consists of one or more shareholders present in person or
by proxy holding not less than a majority of the issued and outstanding shares of the class entitled to vote at the meeting in question. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Record Date
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Association provide that the board may fix in advance a date as the record date (i)&nbsp;for any such determination of
members entitled to notice of or to vote at a general meeting of the members, which record </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date shall not be more than 60 days before the date of such meeting, and (ii)&nbsp;for the purpose of determining the members entitled to receive payment of any dividend or other distribution, or
in order to make a determination of members for any other proper purpose, which record date shall not be more than 60 days prior to the date of payment of such dividend or other distribution or the taking of any action to which such determination of
members is relevant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If no record date is fixed for the determination of members entitled to notice of or to vote at a meeting of
members, the date immediately preceding the date on which notice of the meeting is deemed given under our Articles of Association will be the record date for such determination of members. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholder Proposals </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Irish law,
there is no general right for a shareholder to put items on the agenda of an annual general meeting of a U.S.-listed company, other than as set out in the Articles of Association of a company. Under our Articles of Association, in addition to any
other applicable requirements, for business or nominations to be properly brought before an annual general meeting by a shareholder, such shareholder must have given timely notice thereof in proper written form to our corporate secretary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be timely for an annual general meeting, a shareholder&#146;s notice to our secretary as to the business or nominations to be brought
before the meeting must be delivered to or mailed and received at our registered office (i)&nbsp;with respect to our first annual general meeting as a public limited company, not later than the 10th day following the day on which public announcement
of the date of such annual general meeting is made and (ii)&nbsp;with respect to all other annual general meetings not less than 90 days nor more than 120 days before the first anniversary of the notice convening our annual general meeting for the
prior year. In the event that the date of the annual general meeting is changed by more than 30 days from the first anniversary date of the preceding year&#146;s annual general meeting, notice by the member must be so delivered by close of business
on the day that is not earlier than 120 days prior to such annual general meeting and not later than the close of business on the later of (a) 90 days prior to the day of the contemplated annual general meeting or (b) 10 days after the day on which
public announcement of the date of the contemplated annual general meeting is first made by us. In no event shall the public announcement of an adjournment or postponement of an annual general meeting commence a new time period (or extend any time
period) for the giving of a shareholder&#146;s notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be timely for business or nominations of a director at an extraordinary general
meeting, notice must be delivered, or mailed and received not less than 90 days nor more than 120 days prior to the date of such extraordinary general meeting or, if the first public announcement of the date of the extraordinary general meeting is
less than 100 days prior to the date of the meeting, by close of business 10 days after the day on which the public announcement of the date of the extraordinary general meeting is first made by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For nominations to the board, the notice must include all information about the director nominee that is required to be disclosed by SEC rules
regarding the solicitation of proxies for the election of directors pursuant to Regulation 14A under the Exchange Act. For other business that a shareholder proposes to bring before the meeting, the notice must include a brief description of the
business, the reasons for proposing the business at the meeting and a discussion of any material interest of the shareholder in the business. Whether the notice relates to a nomination to the board of directors or to other business to be proposed at
the meeting, the notice also must include information about the shareholder and the shareholder&#146;s holdings of our shares. The chairman of the meeting shall have the power and duty to determine whether any business proposed to be brought before
the meeting was made or proposed in accordance with these procedures (as set out in our Articles of Association), and if any proposed business is not in compliance with these provisions, to declare that such defective proposal shall be disregarded.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Suits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
Ireland, the decision to institute proceedings on behalf of a company is generally taken by the company&#146;s board of directors. In certain limited circumstances, a shareholder may be entitled to bring a derivative action on
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our behalf. The central question at issue in deciding whether a minority shareholder may be permitted to bring a derivative action is whether, unless the action is brought, a wrong committed
against us would otherwise go unredressed. The cause of action may be against a director, another person or both. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder may also
bring proceedings against us in his or her own name where the shareholder&#146;s rights as such have been infringed or where our affairs are being conducted, or the powers of the board of directors are being exercised, in a manner oppressive to any
shareholder or shareholders or in disregard of their interests as shareholders. Oppression connotes conduct that is burdensome, harsh or wrong. This is an Irish statutory remedy under Section&nbsp;212 of the Irish Companies Act and the court can
grant any order it sees fit, including providing for the purchase or transfer of the shares of any shareholder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inspection of Books and Records
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Irish law, shareholders have the right to: (i)&nbsp;receive a copy of our Constitution; (ii)&nbsp;inspect and obtain copies of
the minutes of general meetings and any resolutions; (iii)&nbsp;inspect and receive a copy of the register of shareholders, register of directors and secretaries, register of directors&#146; interests and other statutory registers maintained by us;
(iv)&nbsp;inspect copies of directors&#146; service contracts; (v)&nbsp;inspect copies of instruments creating charges; (vi)&nbsp;receive copies of statutory financial statements and directors&#146; and auditors&#146; reports which have previously
been sent to shareholders prior to an annual general meeting; and (vii)&nbsp;receive financial statements of a subsidiary company of ours which have previously been sent to shareholders prior to an annual general meeting for the preceding 10 years.
Our auditors will also have the right to inspect all of our books, records and vouchers. The auditors&#146; report must be circulated to the shareholders with our financial statements prepared in accordance with Irish law with the notice of annual
general meeting and must be presented to our shareholders at our annual general meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Acquisitions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a number of mechanisms for acquiring an Irish public limited company, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a court-approved scheme of arrangement under the Irish Companies Act. A scheme of arrangement with one or more
classes of shareholders requires a court order from the Irish High Court and the approval of (i)&nbsp;more than 50% in number of the shareholders of each participating class or series voting on the scheme of arrangement, and (ii)&nbsp;representing
75% in value of the shares of such participating class or series held by the shareholders voting on the scheme of arrangement, in each case at the relevant meeting or meetings. A scheme of arrangement, if authorized by the shareholder of each
participating class or series and the court, is binding on all of the shareholders of each participating class or series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a tender or takeover offer by a third party, in accordance with the Irish Takeover Rules and the Irish
Companies Act, for all of our shares. Where the holders of 80% or more of our shares (excluding any shares already beneficially owned by the bidder) have accepted an offer for their shares, the remaining shareholders may also be statutorily required
to transfer their shares, unless, within one month, <FONT STYLE="white-space:nowrap">the&nbsp;non-tendering&nbsp;shareholders</FONT> can obtain an Irish court order otherwise providing. If the offeror has acquired acceptances of 80% of all of our
shares but does not exercise <FONT STYLE="white-space:nowrap">its&nbsp;&#147;squeeze-out&#148;&nbsp;right,</FONT> then <FONT STYLE="white-space:nowrap">the&nbsp;non-accepting&nbsp;shareholders</FONT> also have a statutory right to require the bidder
to acquire their shares on the same terms as the original offer, or such other terms as the bidder and <FONT STYLE="white-space:nowrap">the&nbsp;non-tendering&nbsp;shareholders</FONT> may agree or on such term as an Irish court, on application of
the bidder <FONT STYLE="white-space:nowrap">or&nbsp;non-tendering&nbsp;shareholder,</FONT> may order. If our shares were to be listed on the Euronext Dublin or another regulated stock exchange in the European Union, the aforementioned 80% threshold
would be increased to 90%; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by way of a transaction with a company incorporated in the European Economic Area which includes all member
states of the European Union and Norway, Iceland and Liechtenstein (EEA) under the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
European Communities (Cross-Border Mergers) Regulations 2008 (as amended). Such a transaction must be approved by a special resolution and by the Irish High Court. If we are being merged with
another EEA company under the EU Cross-Border Mergers Directive (EU) 2019/2121 and the consideration payable to our shareholders is not all in the form of cash, our shareholders may be entitled to require their shares to be acquired at fair value;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by way of a merger with another Irish company under the Irish Companies Act which must be approved by a special
resolution and by the Irish High Court. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appraisal Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, under Irish law, shareholders of an Irish company do not have statutory appraisal rights. If we are being merged as the transferor
company with another EEA company under the European Communities (Cross-Border Merger) Regulations 2008 (as amended) or if we are being merged with another Irish company under the Irish Companies Act, (i)&nbsp;any of our shareholders who voted
against the special resolution approving the merger or (ii)&nbsp;if 90% of our shares are held by the successor company, any other of our shareholders, may be entitled to require that the successor company acquire its shares for cash. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disclosure of Interests in Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
the Irish Companies Act, there is a notification requirement for shareholders who acquire or cease to be interested in 3% of the shares of an Irish public limited company. Our shareholders must therefore make such a notification to us if, as a
result of a transaction, the shareholder will become interested in 3% or more of our shares or if, as a result of a transaction, a shareholder who was interested in 3% or more of our shares ceases to be so interested. Where a shareholder is
interested in 3% or more of our shares, the shareholder must notify us of any alteration of his or her interest that brings his or her total holding through the nearest whole percentage number, whether an increase or a reduction. The relevant
percentage figure is calculated by reference to the aggregate nominal value of the shares in which the shareholder is interested as a proportion of the entire nominal value of our issued share capital (or any such class of share capital in issue).
Where the percentage level of the shareholder&#146;s interest does not amount to a whole percentage, this figure may be rounded down to the next whole number. All such disclosures should be notified to us within five business days of the transaction
or alteration of the shareholder&#146;s interests that gave rise to the notification requirement. If a shareholder fails to comply with these notification requirements, the shareholder&#146;s rights in respect of any of our shares it holds will not
be enforceable, either directly or indirectly. However, such person may apply to the court to have the rights attaching to such shares reinstated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to these disclosure requirements, under the Irish Companies Act, we may by notice in writing, require a person whom we know or
have reasonable cause to believe to be, or at any time during the three years immediately preceding the date on which such notice is issued to have been, interested in shares comprised in our relevant share capital to: (i)&nbsp;indicate whether or
not it is the case and (ii)&nbsp;where such person holds or has during that time held an interest in our ordinary shares, to provide additional information, including the person&#146;s own past or present interests in our shares. If the recipient of
the notice fails to respond within the reasonable time period specified in the notice, we may apply to court for an order directing that the affected shares be subject to certain restrictions, as prescribed by the Irish Companies Act, as follows:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transfer of those shares, or in the case of unissued shares any transfer of the right to be issued with
shares and any issue of shares, will be void; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no voting rights will be exercisable in respect of those shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no further shares will be issued in right of those shares or in pursuance of any offer made to the holder of
those shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no payment will be made of any sums due from us on those shares, whether in respect of capital or otherwise.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where our shares are subject to these restrictions, the court may order the shares to be
sold and may also direct that the shares shall cease to be subject to these restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event we are in an offer period pursuant
to the Irish Takeover Rules, accelerated disclosure provisions apply for persons holding an interest in our securities of 1.0% or more. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Irish Takeover
Rules </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A transaction in which a third party seeks to acquire 30% or more of our voting rights will be governed by the Irish Takeover
Panel Act 1997 and the Irish Takeover Rules made thereunder and will be regulated by the Irish Takeover Panel. The &#147;General Principles&#148; of the Irish Takeover Rules and certain important aspects of the Irish Takeover Rules are described
below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General Principles </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Irish Takeover Rules are built on the following General Principles, which will apply to any transaction regulated by the Irish Takeover
Panel: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event of an offer, all holders of securities of the target company should be afforded equivalent treatment
and, if a person acquires control of a company, the other holders of securities must be protected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of the securities in the target company must have sufficient time and information to enable them to
reach a properly informed decision on the offer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where it advises the holders of securities, the board of the target company must give its views on the effects of
implementation of the offer on employment, conditions of employment and the locations of the target company&#146;s places of business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the board of the target company must act in the interests of the company as a whole and must not deny the holders
of securities the opportunity to decide on the merits of the offer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">false markets must not be created in the securities of the target company, the bidder or of any other company
concerned by the offer in such a way that the rise or fall of the prices of the securities becomes artificial and the normal functioning of the markets is distorted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a bidder must announce an offer only after ensuring that he or she can fulfil in full, any cash consideration, if
such is offered, and after taking all reasonable measures to secure the implementation of any other type of consideration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a target company must not be hindered in the conduct of its affairs for longer than is reasonable by an offer for
its securities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a substantial acquisition of securities (whether such acquisition is to be effected by one transaction or a
series of transactions) shall take place only at an acceptable speed and shall be subject to adequate and timely disclosure. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mandatory Bid </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under certain
circumstances, a person who acquires shares or other of our voting rights may be required under the Irish Takeover Rules to make a mandatory cash offer for our remaining outstanding shares at a price not less than the highest price paid for the
shares by the acquirer (or any parties acting in concert with the acquirer) during the previous 12 months. This mandatory bid requirement is triggered if an acquisition of shares would (i)&nbsp;increase the aggregate holding of an acquirer
(including the holdings of any parties acting in concert with the acquirer) to shares representing 30% or more of our voting rights, or (ii)&nbsp;in the case of a person holding (together with its concert parties) shares representing 30% or more of
our voting rights, after giving effect to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acquisition, increase the percentage of the voting rights held by that person (together with its concert parties) by 0.05% within
<FONT STYLE="white-space:nowrap">a&nbsp;12-month&nbsp;period.</FONT> Any person (excluding any parties acting in concert with the holder) holding shares representing more than 50% of the voting rights of a company is not subject to these mandatory
offer requirements in purchasing additional securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voluntary Bid; Requirements to Make a Cash Offer and Minimum Price Requirements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A voluntary offer is an offer that is not a mandatory offer. If a person makes a voluntary offer to acquire outstanding ordinary
shares of ours, the offer price must be no less than the highest price paid for our shares by the bidder or its concert parties during the three-month period prior to the commencement of the offer period. The Irish Takeover Panel has the power to
extend the &#147;look back&#148; period to 12 months if the Irish Takeover Panel, taking into account the General Principles, believes it is appropriate to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the bidder or any party acting in concert with it has acquired our ordinary shares (i)&nbsp;during the period of 12 months prior to the
commencement of the offer period which represent more than 10% of our total ordinary shares or (ii)&nbsp;at any time after the commencement of the offer period, the offer must be in cash (or accompanied by a full cash alternative) and the price per
ordinary share must not be less than the highest price paid by the bidder or any party acting in concert with it during, in the case of (i), <FONT STYLE="white-space:nowrap">the&nbsp;12-month&nbsp;period</FONT> prior to the commencement of the offer
period and, in the case of (ii), the offer period. The Irish Takeover Panel may apply this rule to a bidder who, together with any party acting in concert with it, has acquired less than 10% of our total ordinary shares in <FONT
STYLE="white-space:nowrap">the&nbsp;12-month&nbsp;period</FONT> prior to the commencement of the offer period if the Irish Takeover Panel, taking into account the General Principles, considers it just and proper to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An offer period will generally commence from the date of the first announcement of the offer or proposed offer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Substantial Acquisition Rules </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Irish Takeover Rules also contain rules governing substantial acquisitions of shares which restrict the speed at which a person may increase his or her holding of shares and rights over shares to an aggregate of between 15% and 30% of our voting
rights. Except in certain circumstances, an acquisition or series of acquisitions of shares or rights over shares representing 10% or more of our voting rights is prohibited if such acquisition(s), when aggregated with shares or rights already held,
would result in the acquirer holding 15% or more but less than 30% of our voting rights and such acquisitions are made within a period of seven days. These rules also require accelerated disclosure of acquisitions of shares or rights over shares
relating to such holdings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shareholder Rights Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
Articles of Association expressly authorize our board of directors to adopt a shareholder rights plan, subject to applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Frustrating
Action </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Irish Takeover Rules, our board of directors is not permitted to take any action which might frustrate an offer
for our shares once our board of directors has received an approach which may lead to an offer or has reason to believe an offer is imminent, subject to certain exceptions. Potentially frustrating actions such as (i)&nbsp;the issue of shares,
options or convertible securities, (ii)&nbsp;material acquisitions or disposals, (iii)&nbsp;entering into contracts other than in the ordinary course of business or (iv)&nbsp;any action, other than seeking alternative offers, which may result in
frustration of an offer, are prohibited during the course of an offer or at any time during </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which the board of directors has reason to believe an offer is imminent. Exceptions to this prohibition are available where: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the action is approved by our shareholders at a general meeting; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Irish Takeover Panel has given its consent, where: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is satisfied the action would not constitute frustrating action; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shareholders that hold 50% of the voting rights state in writing that they approve the proposed action and
would vote in favor of it at a general meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the action is taken in accordance with a contract entered into prior to the announcement of the offer; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the decision to take such action was made before the announcement of the offer and either has been at least
partially implemented or is in the ordinary course of business. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business Combinations with Interested Shareholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Association provide that, subject to certain exceptions, we may not engage in certain business combinations with any person
that acquires beneficial ownership of 15% or more of our outstanding voting shares for a period of three years following the date on which the person became a 15% shareholder unless: (i)&nbsp;prior to the date on which the person becomes a 15%
shareholder, a committee of our disinterested directors approved the business combination; and (ii)&nbsp;in certain circumstances, the business combination is authorized by a special resolution of disinterested shareholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Further Provisions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain other
provisions of Irish law or our Constitution may be considered to have anti-takeover effects, including advance notice requirements for director nominations and other shareholder proposals, as well as those described under the headings
&#147;&#151;Description of Share Capital&#151;Capital Structure&#151;Authorized and Issued Share Capital&#148; (regarding issuance of preferred shares), &#147;Description of
<FONT STYLE="white-space:nowrap">Share&nbsp;Capital&#151;Pre-emption&nbsp;Rights,</FONT> Share Warrants and Share Options,&#148; &#147;&#151;Description of Share Capital&#151;Disclosure of Interests in Shares,&#148; &#147;&#151;Description of Share
Capital&#151;Appointment of Directors,&#148; &#147;&#151;Description of Share Capital&#151;Removal of Directors.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Insider Dealing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Irish Takeover Rules also provide that no person, other than the bidder, who is privy to confidential price-sensitive information
concerning an offer made in respect of the acquisition of a company (or a class of its securities) or a contemplated offer shall deal in relevant securities of the target during the period from the time at which such person first has reason to
suppose that such an offer, or an approach with a view to such an offer being made, is contemplated to the time of (i)&nbsp;the announcement of such offer or approach or (ii)&nbsp;the termination of discussions relating to such offer, whichever is
earlier. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Governance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
Articles of Association allocate authority over <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;day-to-day&nbsp;management</FONT></FONT> of the company to the board of directors. Our board of directors may then delegate
management of the Company to committees of the board or such other persons as it thinks fit. Regardless of any delegation, the board of directors will remain responsible, as a matter of Irish law, for the proper management of the affairs of our
Company. The board of directors may create new committees or change the responsibilities of existing committees from time to time. Committees may meet and adjourn as they determine proper. Unless otherwise determined by the board of directors, the
quorum necessary for the transaction of business at any committee meeting shall be a majority of the members of the committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Name; Incorporation; Fiscal Year; Registered Office </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our legal and commercial name is Iterum Therapeutics plc. We were incorporated in Ireland in June 2015
<FONT STYLE="white-space:nowrap">and&nbsp;re-registered&nbsp;as</FONT> a public limited company in March 2018. Our registered address is Block 2 Floor 3, Harcourt Centre, Harcourt Street, Dublin 2. As set forth in our memorandum of association, our
purpose, among other things, is to carry on the business of a holding company and to coordinate the administration, finances and activities of any subsidiaries or associated companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appointment of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Irish
Companies Act provides for a minimum of two directors. Our Articles of Association provide that the number of directors will be not less than two and not more than 13. The authorized number of directors within the prescribed range will be determined
solely by our board of directors and does not require approval or ratification by the shareholders in a general meeting. Our directors will be elected by way of an ordinary resolution at a general meeting save that directors in contested elections
will be elected by a plurality of the votes of the shares present in person or represented by proxy at the relevant general meeting and entitled to vote on the election of directors. If the number of the directors is reduced below the fixed minimum
number, the remaining director or directors may appoint an additional director or additional directors to make up such minimum or may convene a general meeting for the purpose of making such appointment. Casual vacancies may be filled by the board
of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Association provide that our board of directors is divided into three classes serving staggered three-year
terms. Shareholders do not have cumulative voting rights. Accordingly, the holder of a majority of the voting rights attaching to our ordinary shares will, as a practical matter, be entitled to control the election of all directors. At each annual
general meeting, directors will be elected for a full term of three years to succeed those directors of the relevant class whose terms are expiring. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our Articles of Association, our board of directors has the authority to appoint directors to the board either to fill a vacancy or as
an additional director. A vacancy on the board of directors created by the removal of a director may be filled by an ordinary resolution of the shareholders at the meeting at which such director is removed and, in the absence of such election or
appointment, the remaining directors may fill the vacancy. The board of directors may fill a vacancy by an affirmative vote of a majority of the directors constituting a quorum. If there is an insufficient number of directors to constitute a quorum,
the board may nonetheless act to fill such vacancies or call a general meeting of the shareholders. Under our Articles of Association, if the board fills a vacancy, the director will hold this position as a director for a term that will coincide
with the remaining term of the relevant class of director. If there is an appointment to fill a casual vacancy or an addition to the board, the total number of directors shall not at any time exceed the number of directors from time to time fixed by
the board in accordance with our Articles of Association. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Investor Rights Agreement entered into in
connection with the January 2020 Private Placement, for so long as Sarissa owns at least 5% or 12.5%, as applicable, of our outstanding ordinary shares on a fully diluted basis, promptly, and in any event no more than 5 business days following
written request of Sarissa, we will cause our board of directors to increase the size of the board by one or two members (such number being sufficient to allow the Investor Designees (as defined below) to be appointed to our board of directors), as
applicable, and we will cause our board of directors to consist of no more than 10 members without the prior written consent of Sarissa. In addition, for so long as Sarissa owns at least 12.5% of our outstanding ordinary shares on a fully diluted
basis, Sarissa will have the right to designate two directors to our board of directors and, for so long as Sarissa owns at least 5% but less than 12.5%, Sarissa will have the right to designate one director to our board of directors, or the
Investor Designees, in each case subject to certain limitations. Pursuant to the terms of the Investor Rights Agreement, such Investor Designees will be appointed to our board of directors and to be members of the class of directors that was subject
to reelection at our most recent annual general meeting of shareholders. The Investor Designees will be entitled to be a member of any committee of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
board of directors subject to the terms of the Investor Rights Agreement. Pursuant to the terms of the Investor Rights Agreement, the January 2020 Private Placement Investors, subject to
specified exceptions, have agreed with us to vote in favor of the election of the Investor Designees, and we have agreed to cause the Investor Designees to be named in any relevant proxy statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Removal of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Irish Companies
Act provides that, notwithstanding anything contained in the Articles of Association of a company or in any agreement between that company and a director, the shareholders may, by an ordinary resolution, remove a director from office before the
expiration of his or her term, provided that notice of the intention to move any such resolution be given by the shareholders to the company not less than 28 days before the meeting at which the director is to be removed, and the director will be
entitled to be heard at such meeting. The power of removal is without prejudice to any claim for damages for breach of contract (e.g., employment agreement) that the director may have against us in respect of his or her removal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Interested Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
the Irish Companies Act and our Articles of Association, a director who has an interest in a proposal, arrangement or contract is required to declare the nature of his or her interest at the first opportunity either (i)&nbsp;at a meeting of the
board at which such proposal, arrangement or contract is first considered (provided such director knows this interest then exists, or in any other case, at the first meeting of the board after learning that he or she is or has become so interested)
or (ii)&nbsp;by providing a general notice to the directors declaring that he or she is to be regarded as interested in any proposal, arrangement or contract with a particular person, and after giving such general notice will not be required to give
special notice relating to any particular transaction. Provided the interested director makes such required disclosure, he or she shall be counted in determining the presence of a quorum at a meeting regarding the relevant proposal, arrangement or
contract and will be permitted to vote on such proposal, arrangement or contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our Articles of Association, it is within
the directors&#146; sole discretion to determine their compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Borrowing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our Articles of Association, among the directors&#146; powers are the right to borrow money and to mortgage or charge the
company&#146;s undertaking, property and uncalled capital or any part thereof and to issue debentures, debenture stock, mortgages, bonds or such other securities whether outright or as security for any debt, liability or obligation of the company or
of any third party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Duration; Dissolution; Rights upon Liquidation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our duration will be unlimited. We may be dissolved and wound up at any time by way of a shareholders&#146; voluntary winding up or a
creditors&#146; winding up. In the case of a shareholders&#146; <FONT STYLE="white-space:nowrap">voluntary&nbsp;winding-up,&nbsp;a</FONT> special resolution of shareholders is required. We may also be dissolved by way of court order on the
application of a creditor, or by the Companies Registration Office as an enforcement measure where we have failed to file certain returns. We may also be dissolved by the Director of Corporate Enforcement in Ireland where the affairs of the company
have been investigated by an inspector and it appears from the report or any information obtained by the Director of Corporate Enforcement that we should be wound up. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of the shareholders to a return of our assets on dissolution or winding up, following the settlement of all claims of creditors,
are prescribed in our Articles of Association or the terms of any shares issued by the directors from time to time. The holders of preferred shares in particular may have the right to priority in a dissolution or winding up. If the Articles of
Association and terms of issue of the shares of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company contain no specific provisions in respect of a dissolution or winding up then, subject to the shareholder priorities and the rights of any creditors, the assets will be distributed to
shareholders in proportion to <FONT STYLE="white-space:nowrap">the&nbsp;paid-up&nbsp;nominal</FONT> value of the shares held. Our Articles of Association provide that our ordinary shareholders may be entitled to participate in a winding up, and the
method by which the property will be divided shall be determined by the liquidator, subject to a special resolution of the shareholders, but such rights of ordinary shareholders to participate may be subject to the rights of any preferred
shareholders to participate under the terms of any series or class of preferred shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Certificates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Irish Companies Act, a shareholder is entitled to be issued a share certificate on request and subject to payment of a nominal
fee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Exchange Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
ordinary shares are traded on the Nasdaq Global Market under the symbol &#147;ITRM.&#148; Our ordinary shares are not listed on the Euronext Dublin. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sinking Fund </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our shares have no
sinking fund provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer and Registration of Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our transfer agent is Computershare Trust Company, N.A. The transfer agent maintains our share register, and registration in the share register
will be determinative of membership in us. A shareholder of ours who only holds shares beneficially will not be the holder of record of such shares. Instead, the depository or other nominee will be the holder of record of those shares. Accordingly,
a transfer of shares from a person who holds such shares beneficially to a person who also holds such shares beneficially through a depository or other nominee will not be registered in our official share register, as the depository or other nominee
will remain the record holder of any such shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A written instrument of transfer is required under Irish law in order to register on
our official share register any transfer of shares (i)&nbsp;from a person who holds such shares directly to any other person, (ii)&nbsp;from a person who holds such shares beneficially to a person who holds such shares directly or (iii)&nbsp;from a
person who holds such shares beneficially to another person who holds such shares beneficially where the transfer involves a change in the depository or other nominee that is the record owner of the transferred shares. An instrument of transfer is
also required for a shareholder who directly holds shares to transfer those shares into his or her own broker account (or vice versa). Such instruments of transfer may give rise to Irish stamp duty, which must be paid prior to registration of the
transfer on our official Irish share register. However, a shareholder who directly holds shares may transfer those shares into his or her own broker account (or vice versa) without giving rise to Irish stamp duty provided there is no change in the
ultimate beneficial ownership of the shares as a result of the transfer and the transfer is not made in contemplation of a sale of the shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any transfer of our shares that is subject to Irish stamp duty will not be registered in the name of the buyer unless an instrument of
transfer is duly stamped and provided to our transfer agent. Our Articles of Association allow us, in our absolute discretion, to create an instrument of transfer and pay (or procure the payment of) any stamp duty, which is the legal obligation of a
transferee. In the event of any such payment, we are (on behalf of ourselves or our affiliates) entitled to (i)&nbsp;seek reimbursement from the transferee or transferor (at its discretion),
<FONT STYLE="white-space:nowrap">(ii)&nbsp;set-off&nbsp;the</FONT> amount of the stamp duty against future dividends payable to the transferee or transferor (at its discretion) and (iii)&nbsp;have a lien against the shares on which it has paid stamp
duty. Parties to a share transfer may assume that any stamp duty arising in respect of a transaction in our shares has been paid unless one or both of such parties is otherwise notified by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Association delegate to our secretary (or such other person as may be
nominated by the secretary for this purpose) the authority to execute an instrument of transfer on behalf of a transferring party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
Articles of Association grant our board of directors general discretion to decline to register an instrument of transfer unless the transfer is in respect of one class of shares only, the instrument of transfer is accompanied by the certificate of
shares to which it relates (if any) and such other evidence as the directors may reasonably require to show the right of the transferor to make the transfer, the instrument of transfer is in favor of not more than four transferees and it is lodged
at our registered office or such other place as our directors or secretary may appoint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The directors may suspend registration of
transfers from time to time, not exceeding 30 days in aggregate each year, as our board of directors may from time to time determine (except as may be required by law). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80934_10"></A>DESCRIPTION OF SECURITIES WE ARE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are offering 13,043,478 ordinary shares, together with Warrants to purchase 9,782,608 ordinary shares. Each ordinary share will be offered
and sold together with a Warrant to purchase 0.75 of an ordinary share. We are also offering 13,043,478 <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants to those purchasers whose purchase of ordinary shares in this offering would result
in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding ordinary shares following the consummation of this offering in lieu of
the ordinary shares that would result in such excess ownership. Each <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant will be exercisable for one ordinary share. The <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants will be
offered and sold together with the same Warrants that will be offered and sold with the ordinary shares offered hereby. Each Pre-funded Warrant will be offered and sold together with a Warrant to purchase 0.75 of an ordinary share. The ordinary
shares or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants, as the case may be, and the Warrants, can only be purchased together in this offering, but the ordinary shares or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants, as
the case may be, and the Warrants are immediately separable and will be issued separately in this offering. No Warrant for fractional ordinary shares will be issued, rather Warrants will be issued only for whole ordinary shares. We are also
registering the ordinary shares and the ordinary shares issuable from time to time upon exercise of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants and Warrants offered hereby. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ordinary Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The description of our
ordinary shares under the section &#147;Description of Share Capital&#148; in this prospectus is incorporated by reference herein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of certain terms and provisions of the <FONT
STYLE="white-space:nowrap">Pre-funded</FONT> Warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant, the form of
which is filed as an exhibit to the registration statement of which this prospectus forms&nbsp;a part. Prospective investors should carefully review the terms and provisions of the form of <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant
for a complete description of the terms and conditions of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Duration and Exercise
Price </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant offered hereby will have an initial exercise price per
ordinary share equal to $0.01. The <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants will be immediately exercisable and will expire when exercised in full. The exercise price and number of ordinary shares issuable upon exercise is subject
to appropriate adjustment in the event of share dividends, share splits, reorganizations or similar events affecting our ordinary shares and the exercise price. Subject to the rules and regulations of the applicable trading market, we may at any
time during the term of the Pre-funded Warrant, subject to the prior written consent of the holders, reduce the then current exercise price to any amount and for any period of time deemed appropriate by our board of directors. The <FONT
STYLE="white-space:nowrap">Pre-funded</FONT> Warrants will be issued separately from the Warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exercisability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants will be exercisable, at the option of each holder, in whole or in part, by
delivering to us a duly executed exercise notice accompanied by payment in full for the number of ordinary shares purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates)
may not exercise any portion of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant to the extent that the holder would own more than 4.99% of the outstanding ordinary shares immediately after exercise, except that upon at least
61&nbsp;days&#146; prior notice from the holder to us, the holder may increase the amount of beneficial ownership of outstanding shares after exercising the holder&#146;s <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants up to 9.99% of the
number of our ordinary shares outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants. Purchasers of <FONT
STYLE="white-space:nowrap">Pre-funded</FONT> Warrants in this offering may also elect prior to the issuance of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants to have the initial exercise limitation set at 9.99% of our outstanding
ordinary shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cashless Exercise </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the
holder may elect instead to receive upon such exercise (either in whole or in part) the net number of ordinary shares determined according to a formula set forth in the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fractional Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional
ordinary share will be issued upon the exercise of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants. Rather, the number of ordinary shares to be issued will be rounded down to the nearest whole number. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transferability </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to
applicable laws, a <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant may be transferred at the option of the holder upon surrender of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant to us together with the appropriate
instruments of transfer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trading Market </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no trading market available for the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants on any securities exchange or
nationally recognized trading system, and we do not expect a trading market to develop. We do not intend to list the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants on any securities exchange or nationally recognized trading market.
Without a trading market, the liquidity of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants will be extremely limited. The ordinary shares issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants are
currently traded on the Nasdaq Global Market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Right as a Shareholder </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants or by virtue of such holder&#146;s ownership of
ordinary shares, the holders of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants do not have the rights or privileges of holders of our ordinary shares, including any voting rights, until they exercise their <FONT
STYLE="white-space:nowrap">Pre-funded</FONT> Warrants. The <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants will provide that holders have the right to participate in distributions or dividends paid on our ordinary shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fundamental Transaction </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
event of a fundamental transaction, as described in the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants and generally including any reorganization, recapitalization or reclassification of our ordinary shares, the sale, transfer or other
disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding ordinary shares, or any person or group becoming the beneficial owner
of 50% of the voting power represented by our outstanding ordinary shares, the holders of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants will be entitled to receive upon exercise of the
<FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants immediately
prior to such fundamental transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of certain terms and provisions of the Warrants included with the ordinary shares and the
<FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the Warrants, the form of which is filed as an exhibit to the
registration statement of which this prospectus forms&nbsp;a part. Prospective investors should carefully review the terms and provisions of the form of Warrant for a complete description of the terms and conditions of the Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Duration and Exercise Price </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Warrant offered hereby will be a Warrant to purchase 0.75 of an ordinary share and will have an initial exercise price equal to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share. The Warrants will be immediately exercisable and will expire five&nbsp;years from the date of issuance. The exercise price and
number of ordinary shares issuable upon exercise is subject to appropriate adjustment in the event of share dividends, share splits, reorganizations or similar events affecting our ordinary shares and the exercise price. Subject to the rules and
regulations of the applicable trading market, we may at any time during the term of the Warrant, subject to the prior written consent of the holders, reduce the then current exercise price to any amount and for any period of time deemed appropriate
by our board of directors. The Warrants will be issued separately from the ordinary shares, or the <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants, as the case may be. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exercisability </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Warrants will
be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of ordinary shares purchased upon such exercise (except in the case of a cashless
exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the Warrant to the extent that the holder would own more than 4.99% of the outstanding ordinary shares immediately after exercise, except that upon
at least 61&nbsp;days&#146; prior notice from the holder to us, the holder may increase the amount of beneficial ownership of outstanding shares after exercising the holder&#146;s Warrants up to 9.99% of the number of our ordinary shares outstanding
immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Warrants. Purchasers of Warrants in this offering may also elect prior to the issuance of the Warrants to have the
initial exercise limitation set at 9.99% of our outstanding ordinary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cashless Exercise </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, at the time a holder exercises its Warrants, a registration statement registering the issuance of the ordinary shares underlying the
Warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price and
subject to the nominal value of the shares being paid up as described below, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of ordinary shares determined according to a formula set forth in the
Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Irish law, we are prohibited from issuing shares without at least the nominal value of the share being paid up.
Therefore, in advance of undertaking a cashless exercise of Warrants, the holder will be required to pay the aggregate nominal amount of the shares issuable upon exercise of the Warrants (the aggregate amount equal to the product of (i)&nbsp;the
number of ordinary shares underlying the Warrants multiplied by (ii)&nbsp;$0.01). Investors shall pay such aggregate nominal amount upfront in addition to the combined public offering price and we will hold the aggregate nominal amount on trust and
will apply it as applicable in connection with cashless exercises of the Warrants by such investor or any assignee of the Warrants. Upon the exercise of the Warrants, other than by way of cashless exercise, or upon the termination of the Warrants
prior to exercise of all or any portion of such Warrants, we will return to such holder the applicable portion of the aggregate nominal amount of the shares in connection with such Warrants that have been exercised other than by way of cashless
exercise on a periodic six-month basis or promptly upon request by the holder and, upon termination of the Warrants prior to exercise of all or any portion of such Warrants, we will promptly return to the holder in full the remaining amount of the
aggregate nominal amount of the shares in connection with such Warrants. Notwithstanding the foregoing, each holder shall have the right, upon three (3) trading days&#146; notice to us, to require us to return the remaining amount of the aggregate
nominal amount of the shares issuable upon exercise of such holder&#146;s Warrants that was paid by such holder, provided that any future cashless exercise of the Warrants by such holder shall require delivery of such aggregate nominal amount of the
shares before the shares underlying such Warrants are issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fractional Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Warrant for fractional ordinary shares will be issued, rather Warrants will be issued only for whole ordinary shares. No fractional ordinary
share will be issued upon the exercise of the Warrants. Rather, the number of ordinary shares to be issued will be rounded down to the nearest whole number. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transferability </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to
applicable laws, a Warrant may be transferred at the option of the holder upon surrender of the Warrant to us together with the appropriate instruments of transfer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trading Market </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no
trading market available for the Warrants on any securities exchange or nationally recognized trading system, and we do not expect a trading market to develop. We do not intend to list the Warrants on any securities exchange or nationally recognized
trading market. Without a trading market, the liquidity of the Warrants will be extremely limited. The ordinary shares issuable upon exercise of the Warrants are currently traded on the Nasdaq Global Market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Right as a Shareholder </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as
otherwise provided in the Warrants or by virtue of such holder&#146;s ownership of ordinary shares, the holders of the Warrants do not have the rights or privileges of holders of our ordinary shares, including any voting rights, until they exercise
their Warrants. The Warrants will provide that holders have the right to participate in distributions or dividends paid on our ordinary shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fundamental Transaction </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
the event of a fundamental transaction, as described in the Warrants and generally including any reorganization, recapitalization or reclassification of our ordinary shares, the sale, transfer or other disposition of all or substantially all of our
properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding ordinary shares, or any person or group becoming the beneficial owner of 50% of the voting power represented by our
outstanding ordinary shares, the holders of the Warrants will be entitled to receive upon exercise of the Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Warrants
immediately prior to such fundamental transaction. In addition, in the event of a fundamental transaction, the holders of the Warrants have the right, at the option of the holder, to exercise on a &#147;cashless&#148; basis to receive (i)&nbsp;a
number of ordinary shares equal to the Black-Scholes value of the unexercised portion of the Warrant on the date of the consummation of the fundamental transaction divided by the average of the volume weighted average price of the ordinary shares
during the five trading days immediately preceding the announcement of the fundamental transaction or (ii)&nbsp;the consideration receivable as a result of such fundamental transaction by a holder of the number of ordinary shares for which the
Warrant is exercisable immediately prior to such fundamental transaction based on the Black-Scholes value of the unexercised portion of the Warrant on the date of the consummation of the fundamental transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Placement Agent Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed
to grant to H.C. Wainwright&nbsp;&amp; Co., LLC, or its designees, as partial consideration for the placement agent services, Placement Agent Warrants to purchase a number of our ordinary shares equal to 7.0% of the aggregate number of ordinary
shares and <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants sold to the investors in this offering. The Placement Agent Warrants will have an exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (125% of the combined public offering price per ordinary share and Warrant) and will terminate on the five year anniversary of the commencement of
sales in this offering. A holder (together with its affiliates) may not exercise any portion of the Placement Agent Warrant to the extent that the holder would own more than 4.99% of the outstanding ordinary shares immediately after exercise, except
that upon at least 61 days&#146; prior notice from the holder to us, the holder may increase the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amount of beneficial ownership of outstanding shares after exercising the holder&#146;s Placement Agent Warrant up to 9.99% of the number of our ordinary shares outstanding immediately after
giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Placement Agent Warrants. The Placement Agent Warrants have substantially the same terms as the Warrants being sold to investors. The
Placement Agent Warrants are registered on the registration statement of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary of certain
terms and provisions of the Placement Agent Warrants is not complete and is subject to, and qualified in its entirety by, the provisions of the Placement Agent Warrants, the form of which is filed as an exhibit to the registration statement of which
this prospectus forms&nbsp;a part. See also &#147;Plan of Distribution&#148; on page&nbsp;57 of this prospectus for more information regarding the Placement Agent Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80934_11"></A>MATERIAL TAX CONSEQUENCES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Irish Tax Consequences </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The
following is a summary of the material Irish tax consequences for certain beneficial holders of our ordinary shares, Warrants and/or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants. The summary is based upon Irish tax laws and the
practice of the Irish Revenue Commissioners in effect on the date of this prospectus and correspondence with the Irish Revenue Commissioners. Changes in law and/or administrative practice may result in alteration of the tax considerations described
below, possibly with retrospective effect. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary does not constitute tax advice and is intended only as a general guide. The
summary is not exhaustive and holders of our ordinary shares, Warrants and/or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants should consult their own tax advisors about the Irish tax consequences (and the tax consequences under the laws
of other relevant jurisdictions) of this offering, including the acquisition, ownership and disposal of our ordinary shares, Warrants and/or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants. The summary applies only to shareholders and
holders of Warrants and/or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants who will own our ordinary shares, Warrants and/or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants as capital assets and does not apply to other
categories of shareholders or holders of Warrants and/or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants, such as dealers in securities, trustees, insurance companies, collective investment schemes and shareholders or holders of Warrants
and/or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants who have, or who are deemed to have, acquired our ordinary shares, Warrants or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants by virtue of an Irish office or employment
(performed or carried on in Ireland). Such persons may be subject to special rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax on Chargeable Gains </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current rate of tax on chargeable gains (where applicable) in Ireland is 33%. A disposal of our ordinary shares, Warrants or <FONT
STYLE="white-space:nowrap">Pre-funded</FONT> Warrants by a shareholder or holder of Warrants or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants who is not resident or ordinarily resident for tax purposes in Ireland will not give rise to
Irish tax on any chargeable gain realized on such disposal unless such shares, Warrants or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are used, held or acquired for the purposes of a trade or business carried on by such shareholder
or holder of Warrants or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants through a branch or agency in Ireland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of
our ordinary shares, Warrants or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants who is an individual and who is temporarily <FONT STYLE="white-space:nowrap">non-resident</FONT> in Ireland may, under Irish anti-avoidance legislation, be
liable to Irish tax on any chargeable gain realized on a disposal of our ordinary shares, Warrants or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants during the period in which such individual is
<FONT STYLE="white-space:nowrap">non-resident.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stamp Duty </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rate of stamp duty (where applicable) on transfers of shares of Irish incorporated companies is 1% of the price paid or the market value of
the shares acquired, whichever is greater. Where Irish stamp duty arises, it is generally a liability of the transferee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rate of
stamp duty on the grant or transfer of Warrants or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants is 1% of the price paid or the market value of the warrant, whichever is greater, and is payable by the recipient or transferee of the
Warrants or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants, as applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Shares Held Through DTC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A transfer of our ordinary shares effected by means of the transfer of book entry interests in DTC will not be subject to Irish stamp duty. On
the basis that most of our ordinary shares are expected to be held through DTC, it is anticipated that most transfers of our ordinary shares will be exempt from Irish stamp duty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shares Held Outside of DTC or Transferred Into or Out of DTC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A transfer of our ordinary shares where any party to the transfer holds such shares outside of DTC may be subject to Irish stamp duty.
Shareholders wishing to transfer their shares into (or out of) DTC may do so without giving rise to Irish stamp duty provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there is no change in the beneficial ownership of such shares as a result of the transfer; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the transfer into (or out of) DTC is not effected in contemplation of a sale of such shares by a beneficial owner
to a third party. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Withholding Tax on Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted elsewhere in this prospectus, we do not expect to pay dividends for the foreseeable future. To the extent that we do make dividend
payments (or other returns to shareholders that are treated as &#147;distributions&#148; for Irish tax purposes), it should be noted that such distributions made by us will, in the absence of one of many exemptions, be subject to Irish dividend
withholding tax, which is referred to in this prospectus as DWT, currently at a rate of 25%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For DWT purposes, a distribution includes
any distribution that may be made by us to our shareholders, including cash dividends, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividends and additional stock taken in lieu of a cash dividend. Where an exemption does not apply in respect of
a distribution made to a particular shareholder, we are responsible for withholding DWT prior to making such distribution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General Exemptions
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a general overview of the scenarios where it will be possible for us to make payments of dividends without
deduction of DWT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Irish domestic law provides that a <FONT STYLE="white-space:nowrap">non-Irish</FONT> resident shareholder is not
subject to DWT on dividends received from us if such shareholder is beneficially entitled to the dividend and is either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a person (not being a company) resident for tax purposes in a Relevant Territory (including the
United&nbsp;States) and is neither resident nor ordinarily resident in Ireland (Relevant Territories for DWT purposes include the following: Albania, Armenia, Australia, Austria, Bahrain, Belarus, Belgium, Bosnia&nbsp;&amp; Herzegovina, Botswana,
Bulgaria, Canada, Chile, China, Croatia, Cyprus, Czech Republic, Denmark, Egypt, Estonia, Ethiopia, Finland, France, Georgia, Germany, Ghana, Greece, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kazakhstan, Korea, Kuwait, Latvia,
Lithuania, Luxembourg, Macedonia, Malaysia, Malta, Mexico, Moldova, Montenegro, Morocco, Netherlands, New Zealand, Norway, Pakistan, Panama, Poland, Portugal, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak Republic, Slovenia, South
Africa, Spain, Sweden, Switzerland, Thailand, The Republic Of Turkey, Ukraine, United Arab Emirates, United Kingdom, United States, Uzbekistan, Vietnam and Zambia); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a company resident for tax purposes in a Relevant Territory, provided such company is not under the control,
whether directly or indirectly, of a person or persons who is or are resident in Ireland; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a company, wherever resident, that is controlled, directly or indirectly, by persons resident in a Relevant
Territory and who is or are (as the case may be) not controlled by, directly or indirectly, persons who are not resident in a Relevant Territory; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a company, wherever resident, whose principal class of shares (or those of its 75% direct or indirect parent) is
substantially and regularly traded on a stock exchange in Ireland, on a recognized stock exchange in a Relevant Territory or on such other stock exchange approved by the Irish Minister for Finance; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a company, wherever resident, that is wholly owned, directly or indirectly, by two or more companies where the
principal class of shares of each of such companies is substantially and regularly traded on a stock exchange in Ireland, on a recognized stock exchange in a Relevant Territory or on such other stock exchange approved by the Irish Minister for
Finance, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">and provided, in all cases noted above, we have received from the shareholder, where required, the relevant DWT
Form(s) prior to the payment of the dividend and such DWT Form(s) remain valid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For <FONT STYLE="white-space:nowrap">non-Irish</FONT>
resident shareholders that cannot avail themselves of one of Ireland&#146;s domestic law exemptions from DWT, it may be possible for such shareholders to rely on the provisions of a double tax treaty to which Ireland is party to reduce the rate of
DWT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our shareholders that do not fall within any of the categories specifically referred to above may nonetheless fall within other
exemptions from DWT. If any shareholders are exempt from DWT, but receive dividends subject to DWT, such shareholders may apply for refunds of such DWT from the Irish Revenue Commissioners. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Tax on Dividends Paid on our Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Irish income tax may arise for certain persons in respect of dividends received from Irish resident companies. A shareholder that is not
resident or ordinarily resident in Ireland and that is entitled to an exemption from DWT generally has no liability to Irish income tax or the universal social charge on a dividend received from us. An exception to this position may apply where such
shareholder holds our ordinary shares through a branch or agency in Ireland through which a trade is carried on. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder that is
not resident or ordinarily resident in Ireland and that is not entitled to an exemption from DWT generally has no additional Irish income tax liability or a liability to the universal social charge. The DWT deducted by us discharges the liability to
income tax. An exception to this position may apply where the shareholder holds our ordinary shares through a branch or agency in Ireland through which a trade is carried on. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Capital Acquisitions Tax </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Irish
capital acquisitions tax, or CAT, comprises principally gift tax and inheritance tax. CAT could apply to a gift or inheritance of our ordinary shares, Warrants or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants irrespective of the place
of residence, ordinary residence or domicile of the parties. This is because our ordinary shares, Warrants and <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants are regarded as property situated in Ireland for Irish CAT purposes as our
share register must be held in Ireland. The person who receives the gift or inheritance has primary liability for CAT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CAT is levied at a
rate of 33% above certain <FONT STYLE="white-space:nowrap">tax-free</FONT> thresholds. The appropriate tax free threshold is dependent upon (i)&nbsp;the relationship between the donor and the donee, and (ii)&nbsp;the aggregation of the values of
previous gifts and inheritances received by the donee from persons within the same group threshold. Gifts and inheritances passing between spouses of the same marriage or civil partners of the same civil partnership are exempt from CAT. Children
have a tax free threshold of &#128;335,000 in respect of taxable gifts or inheritances received from their parents. Our shareholders and holders of Warrants or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants should consult their own tax
advisors as to whether CAT is creditable or deductible in computing any domestic tax liabilities. There is also a &#147;small gift exemption&#148; from CAT whereby the first &#128;3,000 of the taxable value of all taxable gifts taken by a donee from
any one donor, in each calendar year, is exempt from CAT and is also excluded from any future aggregation. This exemption does not apply to an inheritance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE IRISH TAX CONSIDERATIONS SUMMARIZED ABOVE ARE FOR GENERAL INFORMATION ONLY. HOLDERS OF OUR ORDINARY SHARES, WARRANTS OR
<FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS SHOULD CONSULT WITH THEIR TAX ADVISORS REGARDING THE TAX CONSEQUENCES IN IRELAND, INCLUDING THE ACQUISITION, OWNERSHIP AND DISPOSAL OF OUR ORDINARY SHARES, WARRANTS AND <FONT
STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. Tax Consequences </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Introduction </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section
describes the material U.S. federal income tax consequences of the acquisition, ownership and disposition of our ordinary shares, <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants and Warrants by U.S. holders (as defined below). It applies
to you only if you acquire your ordinary shares and Warrants, or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants and Warrants, as applicable, in this offering and hold those securities as capital assets within the meaning of the U.S.
federal tax laws (generally, property held for investment), and the discussion below assumes this to be the case. This section does not purport to be a comprehensive description of all tax considerations that may be relevant in light of a U.S.
holder&#146;s particular circumstances, including any state, foreign or local tax considerations, any U.S. federal gift, estate or generation skipping transfer tax considerations and tax consequences applicable to special classes of U.S. holders,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers or dealers in securities, or traders in securities who use a mark to market method of tax accounting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts or regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities including pension plans, &#147;individual retirement
accounts&#148; or &#147;Roth IRAs&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">life insurance companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons liable for alternative minimum tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold our ordinary shares, <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants or Warrants as
part of a straddle, wash sale, notional principal contract, conversion transaction or integrated transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold our ordinary shares, <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants or Warrants
in, through or for the account of a &#147;qualified business unit,&#148; &#147;disregarded entity&#148; or branch of those persons situated outside the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold (directly, indirectly or constructively) in the aggregate 10% or more of our outstanding shares
(measured by either voting power or value); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except as specifically described below, entities classified as partnerships or other pass-through entities for
U.S. federal income tax purposes, including beneficial owners of such entities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquired our ordinary shares pursuant to the exercise of an employee stock option or otherwise as
compensation for services; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. holders whose functional currency is not the U.S. dollar. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section is based on the Internal Revenue Code of 1986, as amended, or the Code, its legislative history, existing and proposed
regulations, published rulings and court decisions, all as currently in effect. These laws are subject to change, possibly on a retroactive basis. No ruling has been or will be sought from the Internal Revenue Service, or IRS, with respect to the
matters discussed below, and there can be no assurance the IRS will not take a contrary position regarding the tax consequences of the acquisition, ownership or disposition of our ordinary shares, <FONT STYLE="white-space:nowrap">Pre-funded</FONT>
Warrants or Warrants, or that any such contrary position would not be sustained by a court. You should consult a competent tax advisor with respect to the U.S. federal, state and local tax consequences to you of acquiring, holding and disposing of
ordinary shares, <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants or Warrants, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You are a U.S. holder if you are
a beneficial owner of our ordinary shares, <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants or Warrants and you are, for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation, or other entity taxable as a corporation, (1)&nbsp;created or organized in or under the laws of
the United States, any state therein or the District of Columbia, or (2)&nbsp;treated as such under the Code; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate whose income is subject to U.S. federal income tax regardless of its source; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust if (1)&nbsp;a U.S. court can exercise primary supervision over the trust&#146;s administration and one or
more U.S. persons are authorized to control all substantial decisions of the trust; or (2)&nbsp;the trust has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity classified as a partnership for U S. federal income tax purposes holds our ordinary shares,
<FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants or Warrants, the U.S. federal income tax treatment of a partner in that partnership with respect to its holdings of our ordinary shares, <FONT STYLE="white-space:nowrap">Pre-funded</FONT>
Warrants or Warrants generally will depend upon the status of the partner and the activities of the partnership. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Allocation of Offering Price to
Ordinary Shares, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Warrants </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For U.S. federal income tax purposes,
the ordinary shares and Warrants, or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants and Warrants, as applicable, will be treated as an &#147;investment unit&#148; consisting of one ordinary share or one
<FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant to purchase one ordinary share, as applicable, and a Warrant to acquire 0.75 of an ordinary share, subject to adjustment. The purchase price for each investment unit will be allocated
between the relevant components in proportion to their relative fair market values at the time the investment unit is purchased by the holder. This allocation of the combined purchase price for each investment unit will establish the holder&#146;s
initial tax basis for U.S. federal income tax purposes in the ordinary share or <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant, as applicable, and the Warrant included in each investment unit. The separation of the ordinary share or <FONT
STYLE="white-space:nowrap">Pre-funded</FONT> Warrant, as applicable, and Warrant included in each investment unit should not be a taxable event for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Treatment of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the matter is not entirely free from doubt, a <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant should be treated as an
ordinary share for U.S. federal income tax purposes, and a U.S. holder of a <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant should generally be taxed in the same manner as a U.S. holder of an ordinary share as described below.
Accordingly, upon exercise, the holding period of a <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant should carry over to the ordinary share received. Similarly, the tax basis of the <FONT STYLE="white-space:nowrap">Pre-funded</FONT>
Warrant should carry over to the ordinary share received upon exercise increased by the exercise price of $0.01. The balance of this discussion generally assumes that the characterization described above is respected for U.S. federal income tax
purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ownership and Disposition of Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exercise and Expiration of Warrants </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
general, a U.S. holder will not recognize gain or loss for U.S. federal income tax purposes upon exercise of a Warrant. The U.S. holder will take a tax basis in the ordinary share acquired upon the exercise of a Warrant equal to the exercise price
of the Warrant, increased by the U.S. holder&#146;s adjusted tax basis in the Warrant exercised (as determined pursuant to the rules discussed above). The U.S. holder&#146;s holding period for the ordinary share acquired upon exercise of the Warrant
will begin on the day following the date of that exercise and will not include any period during which the U.S. holder held the Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In certain limited circumstances, a U.S. holder may be permitted to undertake a cashless exercise of Warrants into our ordinary shares. The
U.S. federal income tax treatment of a cashless exercise of Warrants into our ordinary shares is unclear, and the tax consequences of such a cashless exercise could differ from the consequences upon the exercise of a Warrant described in the
preceding paragraph. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The lapse or expiration of a Warrant will be treated as if the U.S. holder sold or exchanged
the Warrant and recognized a capital loss equal to the U.S. holder&#146;s tax basis in the Warrant. The deductibility of capital losses is subject to limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain Adjustments to and Distributions on our Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An adjustment to the number of our ordinary shares issued upon the exercise of a Warrant, or an adjustment to the exercise price of a Warrant,
may be treated as a constructive distribution to a U.S. holder of the Warrant if, and to the extent that, such adjustment has the effect of increasing such U.S. holder&#146;s proportionate interest in our &#147;earnings and profits&#148; or assets,
depending on the circumstances of such adjustment (for example, if such adjustment is to compensate for a distribution of cash or other property to holders of our ordinary shares). An adjustment made pursuant to a bona fide reasonable adjustment
formula that has the effect of preventing dilution should generally not be considered to result in a constructive distribution. Any such constructive distribution would be taxable whether or not there is an actual distribution of cash or other
property to the U.S. holder of the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In certain circumstances, if we were to make a distribution in cash or other property with
respect to our ordinary shares after the issuance of the Warrants, then we may make a corresponding distribution to a holder of a Warrant. The taxation of a distribution received with respect to a Warrant is unclear. It is possible that such a
distribution would be treated as a distribution (or constructive distribution), although other treatments are possible. For more information regarding the tax considerations related to distributions, see the discussion below under &#147;Ownership
and Disposition of our Ordinary Shares&#151;Taxation of Dividends.&#148; U.S. holders should consult their tax advisors regarding the proper treatment of any adjustments to and distributions on the Warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Disposition of our Warrants </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to
the PFIC rules discussed below, if you are a U.S. holder and you sell or otherwise dispose of a Warrant, you will recognize capital gain or loss for U.S. federal income tax purposes equal to the difference between the U.S. dollar value of the amount
that you realize and your tax basis, determined in U.S. dollars, in the Warrant. Capital gains of a <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holder generally are taxed at preferential rates where the property is held for more than
one year. The gain or loss generally will be income or loss from sources within the United&nbsp;States for foreign tax credit limitation purposes. The deductibility of capital losses is subject to limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ownership and Disposition of our Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Taxation of Dividends </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described above,
we have never paid and do not expect to pay cash dividends. If we were to make current distributions in respect of our ordinary shares, under the U.S. federal income tax laws, and subject to the passive foreign investment company, or PFIC, rules
discussed below, if you are a U.S. holder, the gross amount of any dividend paid by us out of our current or accumulated earnings and profits (as determined for U.S. federal income tax purposes) is subject to U.S. federal income taxation. However,
because we do not expect to calculate our earnings and profits in accordance with U.S. federal income tax principles, the entire amount of any distribution may be treated as a dividend. If you are a
<FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holder, with some exceptions dividends that constitute qualified dividend income will be taxable to you at the preferential rates applicable to long-term capital gains provided that you hold
your ordinary shares for more than 60&nbsp;days during the <FONT STYLE="white-space:nowrap">121-day</FONT> period beginning 60&nbsp;days before the <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date and meet other holding period requirements.
If we were determined to be a PFIC during either a given taxable year or the preceding taxable year, dividends paid by us during the later taxable year would not be qualified dividend income and, therefore, would be ineligible for the preferential
rates described above; instead, any such dividend would be subject to tax at the rates applicable to ordinary income. The dividend is taxable to you when you receive the dividend, actually or constructively. The
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dividend will not be eligible for the dividends-received deduction generally allowed to U.S. corporations in respect of dividends received from other corporations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of the dividend distribution that you must include in your income as a U.S. holder will be the U.S. dollar value of the payments
made, determined at the spot rate on the date the dividend distribution is includable in your income, regardless of whether the payment is in fact converted into U.S. dollars. You must include any Irish tax withheld from the dividend payment in this
amount, even though you will not in fact receive the amount of that tax. Generally, any gain or loss resulting from currency exchange fluctuations during the period from the date you include the dividend payment in income to the date you convert the
payment into U.S. dollars will be treated as ordinary income or loss and will not be eligible for the special tax rates applicable to qualified dividend income. The gain or loss generally will be income or loss from sources within the
United&nbsp;States for foreign tax credit limitation purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Distributions (or portions thereof) from corporations demonstrated to be
in excess of current and accumulated earnings and profits, as determined for U.S. federal income tax purposes, will be treated as a <FONT STYLE="white-space:nowrap">non-taxable</FONT> return of capital to the extent of the receiving
shareholder&#146;s basis in its shares and thereafter as capital gain. However, as noted above, because we do not expect to calculate our earnings and profits in accordance with U.S. federal income tax principles, the entire amount of any
distribution may be treated as a dividend. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends generally will be income from sources outside the United States for foreign tax
credit limitation purposes. Dividends will, depending on your circumstances, generally be either passive category income or general category income for purposes of computing the foreign tax credit allowable to you. Subject to certain limitations,
any Irish tax withheld and paid over to Ireland will be creditable or deductible (at your option) against your U.S. federal income tax liability. However, no foreign tax credit would be allowed if you qualified for an exemption from Irish
withholding tax, as described more fully above in &#147;&#151;Material Irish Tax Consequences&#151;General Exemptions.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Taxation of Capital Gains
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the PFIC rules discussed below, if you are a U.S. holder and you sell or otherwise dispose of your ordinary shares, you
will recognize capital gain or loss for U.S. federal income tax purposes equal to the difference between the U.S. dollar value of the amount that you realize and your tax basis, determined in U.S. dollars, in your ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capital gains of a <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holder generally are taxed at preferential rates where the
property is held for more than one year. The gain or loss generally will be income or loss from sources within the United&nbsp;States for foreign tax credit limitation purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PFIC Rules </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special rules apply to
U.S. holders who hold shares or Warrants in a foreign corporation that is treated as a PFIC for U.S. federal income tax purposes. The determination of whether a foreign corporation is a PFIC is primarily factual and cannot be made definitively until
after the close of the tax year. We do not expect to be a PFIC for the taxable year ending December&nbsp;31, 2020, but this conclusion is not free from doubt as described more fully in the &#147;Risk Factors&#148; section of this prospectus under
the caption &#147;There can be no assurance that we will not be a passive foreign investment company for any taxable year, which could result in adverse U.S. federal income tax consequences to U.S. investors.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we were to be treated as a PFIC for any taxable year, and you are a U.S. holder that did not make either election described below, you
would be subject to special (default) rules with respect to: (1)&nbsp;any gain realized on the sale or other disposition of our ordinary shares, <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants or Warrants and (2)&nbsp;any &#147;excess
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distribution&#148; that we make to you (generally, any distribution during a single taxable year that, when added to all other distributions made during that year, is greater than
125&nbsp;percent of the average annual distribution received in respect of your ordinary shares during the three preceding taxable years or, if shorter, your holding period for the ordinary shares). Neither of the elections described below is
effective with respect to shares treated as owned by reason of holding unexercised Warrants; whether the same is true with respect to unexercised <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants is unclear. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under these default rules: (1)&nbsp;the gain or excess distribution will be allocated ratably over the applicable holding period for the
ordinary shares, <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants or Warrants, as the case may be, (2)&nbsp;the amount allocated to the taxable year in which you realize the gain or excess distribution will be taxed as ordinary income,
(3)&nbsp;the amount allocated to each prior year, with certain exceptions, will be taxed at the highest tax rate in effect for that year, and (4)&nbsp;the interest charge generally applicable to underpayments of tax will be imposed in respect of the
tax attributable to each such year. Special rules apply for calculating the amount of the foreign tax credit with respect to excess distributions by a PFIC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Your actual or deemed holdings of our ordinary shares will be treated as holdings of shares in a PFIC if we were a PFIC at any time during
your holding period for our ordinary shares, <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants or Warrants, even if we are not currently a PFIC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you own ordinary shares in a PFIC that are treated as &#147;marketable stock,&#148; you may make a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. If you make a valid and timely <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election, you will not be subject to the default PFIC
rules described above. Instead, in general, you will include as ordinary income each year the excess, if any, of the fair market value of your ordinary shares at the end of the taxable year over your adjusted basis in your ordinary shares. These
amounts of ordinary income will not be eligible for the favorable tax rates applicable to long-term capital gains. You will also be allowed to claim an ordinary loss in respect of the excess, if any, of the adjusted basis of your ordinary shares
over their fair market value at the end of the taxable year (but only to the extent of the net amount of previously included income as a result of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT>
election). Your basis in your ordinary shares will be adjusted to reflect any such income included or loss claimed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alternatively, if you
own ordinary shares in a PFIC, you may make a &#147;qualified electing fund,&#148; or QEF, election. If you make a valid and timely QEF election and we provide certain required information to you, you will not be subject to the default PFIC rules
described above with respect to those ordinary shares. Instead, for each taxable year to which such an election applies, you will be subject to U.S. federal income tax on your pro rata share of our net capital gain and ordinary earnings, regardless
of whether such amounts are actually distributed to you in that year or any later year. However, we do not expect to provide U.S. Holders with the information necessary to make a valid QEF election, and U.S. Holders should therefore assume that a
QEF election will not be available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, notwithstanding any election you make with regard to the ordinary shares and as noted
above, dividends that you receive from us would not constitute qualified dividend income to you if we were a PFIC either in the taxable year of the distribution or the preceding taxable year. Dividends that you receive that do not constitute
qualified dividend income are not eligible for taxation at the preferential rates applicable to qualified dividend income; instead, such dividends are subject to tax at rates applicable to ordinary income. In addition, as noted above, because we do
not expect to calculate earnings and profits in accordance with U.S. federal income tax principles, the entire amount of any distribution may be treated as a dividend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you own our ordinary shares, <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants or Warrants during any year that we are a PFIC,
you generally will be required to file an Internal Revenue Service, or IRS, Form&nbsp;8621. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Medicare Tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. holder that is an individual or estate, or a trust that does not fall into a special class of trusts that is exempt from such tax, will
be subject to a 3.8&nbsp;percent tax on the lesser of (1)&nbsp;the U.S. holder&#146;s &#147;net investment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
income&#148; for the relevant taxable year and (2)&nbsp;the excess of the U.S. holder&#146;s modified adjusted gross income for the taxable year over a certain threshold (which in the case of
individuals will be between $125,000 and $250,000, depending on the individual&#146;s circumstances). A holder&#146;s net investment income will generally include its dividend income and its net gains from the disposition of shares or Warrants,
unless such dividend income or net gains are derived in the ordinary course of the conduct of a trade or business (other than a trade or business that consists of certain passive or trading activities). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information with Respect to Foreign Financial Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Owners of &#147;specified foreign financial assets&#148; with an aggregate value in excess of $50,000 (and in some circumstances, a higher
threshold) may be required to file an information report with respect to such assets with their tax returns. &#147;Specified foreign financial assets&#148; may include financial accounts maintained by foreign financial institutions, as well as the
following, if they are not held in accounts maintained by financial institutions: (i)&nbsp;stocks and securities issued by <FONT STYLE="white-space:nowrap">non-U.S.</FONT> persons, (ii)&nbsp;financial instruments and contracts held for investment
that have <FONT STYLE="white-space:nowrap">non-U.S.</FONT> issuers or counterparties, and (iii)&nbsp;interests in foreign entities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Backup
Withholding and Information Reporting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holder, information
reporting generally will apply to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dividend payments or other taxable distributions made to you within the United States, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the payment of proceeds to you from the sale of our ordinary shares effected at a U.S. office of a broker.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, backup withholding may apply to such payments if you are a
<FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holder that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fails to provide an accurate taxpayer identification number, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is notified by the IRS that you have failed to report all interest and dividends required to be shown on your
federal income tax returns, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in certain circumstances, fails to comply with applicable certification requirements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the proceeds from the sale of our ordinary shares effected at a foreign office of a broker generally will not be subject to
information reporting or backup withholding unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proceeds are transferred to an account maintained by you in the United States, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the payment of proceeds or the confirmation of the sale is mailed to you at a U.S. address, or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sale has some other specified connection with the United States as provided in U.S. Treasury regulations,
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except if the broker does not have actual knowledge or reason to know that you are a U.S. person and the documentation requirements
described above are met or you otherwise establish an exemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a sale of our ordinary shares effected at a foreign office
of a broker will be subject to information reporting if the broker is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a U.S. person, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a controlled foreign corporation for U.S. tax purposes, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual or entity that is not a U.S. person and 50&nbsp;percent or more of whose gross income is
effectively connected with the conduct of a U.S. trade or business for a specified three-year period, or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a foreign partnership, if at any time during its tax year (1)&nbsp;one or more of its partners are &#147;U.S.
persons&#148;, who in the aggregate hold more than 50&nbsp;percent of the income or capital interest in the partnership, or (2)&nbsp;such foreign partnership is engaged in the conduct of a U.S. trade or business, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">unless the broker does not have actual knowledge or reason to know that you are a U.S. person and the documentation requirements described above are met or
you otherwise establish an exemption. Backup withholding will apply if the sale is subject to information reporting and the broker has actual knowledge that you are a U.S. person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You generally may obtain a refund of any amounts withheld under the backup withholding rules that exceed your income tax liability by timely
filing a refund claim with the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE U.S. FEDERAL INCOME TAX CONSIDERATIONS SUMMARIZED ABOVE ARE FOR GENERAL INFORMATION ONLY.
HOLDERS OF OUR ORDINARY SHARES, <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS OR WARRANTS SHOULD CONSULT WITH THEIR TAX ADVISORS REGARDING THE U.S. FEDERAL, STATE, AND LOCAL AND FOREIGN TAX CONSEQUENCES OF THE ACQUISITION, OWNERSHIP
AND DISPOSAL OF OUR ORDINARY SHARES, <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS OR WARRANTS, INCLUDING THE EFFECT OF ANY APPLICABLE INCOME TAX TREATY, SUCH AS THE TAX TREATY BETWEEN THE UNITED STATES AND IRELAND. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80934_12"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We engaged H.C. Wainwright&nbsp;&amp;&nbsp;Co.,&nbsp;LLC, which we refer to herein as &#147;H.C. Wainwright&#148; or the &#147;placement
agent&#148;, to act as our exclusive placement agent to solicit offers to purchase the securities offered by this prospectus on a reasonable best efforts basis. H.C. Wainwright is not purchasing or selling any securities, nor are they required to
arrange for the purchase and sale of any specific number or dollar amount of securities, other than to use their &#147;reasonable best efforts&#148; to arrange for the sale of the securities by us. Therefore, we may not sell the entire amount of
securities being offered. There is no minimum amount of proceeds that is a condition to closing of this offering. We will enter into a securities purchase agreement directly with the institutional investors, at the investors&#146; option, who
purchase our securities in this offering. Investors who do not enter into a securities purchase agreement shall rely solely on this prospectus in connection with the purchase of our securities in this offering. H.C.&nbsp;Wainwright may engage one or
more <FONT STYLE="white-space:nowrap">sub-placement</FONT> agents or selected dealers to assist with the offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fees and Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the per ordinary share and Warrant and <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant and Warrant
placement agent cash fees and total placement agent cash fees we will pay in connection with the sale of the securities in this offering, assuming the purchase of all of the securities we are offering. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per ordinary share and Warrant placement agent cash fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant and Warrant placement agent cash
fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to pay the placement agent a total cash fee equal to 7.0% of the gross proceeds of this
offering and a management fee equal to 0.75% of the gross proceeds raised in this offering. We will also reimburse the placement agent&#146;s reasonable and documented expenses in connection with this offering, including fees and expenses of outside
counsel, in the amount of up to $90,000, the placement agent&#146;s clearing expenses in the amount of up to $12,900 and reasonable and documented expenses incurred by the placement agent for electronic roadshow expenses. We estimate the total
offering expenses of this offering that will be payable by us, excluding the placement agent fees and expenses, will be approximately $610,000. After deducting the placement agent fees and our estimated offering expenses, we expect the net proceeds
from this offering to be approximately $13.1 million, assuming the sale of all of the ordinary shares and Warrants, no sale of any Pre-funded Warrants in this offering, no exercise of any Warrants issued in this offering or the Placement Agent
Warrants and no sale of securities to Sarissa pursuant to the Sarissa Right to Purchase. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Placement Agent Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to grant to H.C. Wainwright, or its designees, as partial consideration for the placement agent services, Placement Agent
Warrants to purchase a number of ordinary shares equal to 7.0% of the aggregate number of ordinary shares and <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants sold to the investors in this offering. The Placement Agent Warrants will have
an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (125% of the combined public offering price per ordinary share and Warrant) and will terminate on the five year anniversary of the commencement of sales in this offering. The
Placement Agent Warrants are registered on the registration statement of which this prospectus forms a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The placement agent acted as the placement agent in connection with our offerings consummated in June 2020 and July 2020, for which it has
received customary fees and expenses. With respect to our June 2020 offering, we paid the placement agent $350,000 in commissions, and as partial consideration for the placement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agent services, we issued placement agent warrants to purchase an aggregate of 208,023 ordinary shares to designees of H.C. Wainwright at an exercise price of $2.1031 per ordinary share. In our
July 2020 offering, we paid the placement agent $350,000 in commissions, and as partial consideration for the placement agent services, we issued placement agent warrants to purchase an aggregate of 236,088 ordinary shares to designees of H.C.
Wainwright at an exercise price of $1.8531 per ordinary share. In connection with each such offering, we agreed to reimburse the placement agent&#146;s reasonable and documented expenses, including fees and expenses of outside counsel, in the amount
of up to $90,000 and the placement agent&#146;s clearing expenses in the amount of up to $12,900 and we granted a right of first refusal to H.C. Wainwright pursuant to which it had the right to act as the sole manager, underwriter or agent, as
applicable, for our capital raises for a certain period of time. The placement agent may, from time to time, engage in transactions with or perform services for us in the ordinary course of its business and may continue to receive compensation from
us for such services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Determination of Offering Price </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined public offering price per ordinary share and Warrant and the combined public offering price per
<FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrant and Warrant we are offering and the exercise prices and other terms of the Warrants were negotiated between us and the investors, in consultation with the placement agent based on the
trading of our ordinary shares prior to this offering, among other things. Other factors considered in determining the public offering prices of the securities we are offering and the exercise prices and other terms of the Warrants include the
history and prospects of our company, the stage of development of our business, our business plans for the future and the extent to which they have been implemented, an assessment of our management, general conditions of the securities markets at
the time of the offering and such other factors as were deemed relevant. The securities offered hereby will be sold at a fixed price until the completion of the offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of our officers and directors has agreed with the placement agent to be subject to a <FONT STYLE="white-space:nowrap">lock-up</FONT>
period of 45 days following the date of this prospectus. This means that, during the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> period, our officers and directors may not offer for sale, contract to sell, or sell any of our ordinary
shares or any securities convertible into, or exercisable or exchangeable for, our ordinary shares in each case other than, (A) transfers of securities (i) to an immediate family member or to a trust, or other entity formed for estate planning
purposes, formed for the direct or indirect benefit of the holder or of holder&#146;s immediate family member, (ii) as a bona fide gift, (iii) if the holder is a corporation, partnership, limited liability company or other business entity, to
another business entity that controls, is controlled by or is under common control with the holder or as part of a disposition, transfer or distribution by the holder to its members, limited partners or equity holders, (iv) to the holder&#146;s
affiliates or any investment fund or other entity controlled or managed by the holder, or (v) if the holder is a trust, to a trustor or beneficiary of the trust; (B) receipt of ordinary shares upon exercise of options or upon vesting of restricted
share awards pursuant to our equity incentive plans or the transfer or disposition, or withholding, of ordinary shares or any securities convertible into ordinary shares upon a vesting event or upon exercise of options or warrants to purchase our
securities, in each case on a cashless or net exercise basis or to cover the holder&#146;s tax obligations, provided that any filing under the Exchange Act shall clearly indicate in the footnotes thereto that the filing relates to such exercise,
vesting, or sale or transfer to cover tax withholding obligations; (C) the transfer of securities pursuant to agreements under which we have the option to repurchase or right of first refusal with respect to transfers of such securities or in
connection with a termination of the holder&#146;s services to us provided that any filing under Section 16 of the Exchange Act made in connection with such transfer shall clearly indicate in the footnotes thereto that the filing relates to the
circumstances described in this clause (C); (D) the sale of securities by the holder pursuant to a trading plan under Rule 10b5-1 under the Exchange Act that was established prior to the date of the registration statement of which this prospectus
forms a part provided that (i) such plan does not provide for the transfer of our ordinary shares during the 45-day period described above and (ii) no public announcement or filing under the Exchange Act is required of or voluntarily made by or on
behalf of the holder or us regarding the establishment of such plan; (E) the transfer of securities by will or intestacy or that occurs by operation of law including pursuant to a qualified domestic order or in connection with a divorce settlement;
or (F) the transfer or disposition of securities acquired in this offering or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acquired on the open market following this offering provided that in the case of any transfer or disposition pursuant to this clause (F), no filing by any party under the Exchange Act or other
public announcement reporting a reduction in the beneficial ownership of the holder&#146;s ordinary shares shall be required or shall be made voluntarily in connection with such transfer or disposition (other than a filing on a Form 5 made after the
expiration of the 45-day period referred to above). The placement agent may, in its sole discretion and without notice, waive the terms of any of these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have agreed to not issue any ordinary shares or securities exercisable or convertible into ordinary shares for a period of 45
days following the closing date of this offering, except for the issuance of (A) ordinary shares or options or restricted share units or other equity awards to our employees, officers or directors pursuant to our equity incentive plans, (B)
securities upon the exercise or exchange or conversion of any securities issued pursuant to this offering and/or other securities exercisable or exchangeable for or convertible into ordinary shares issued and outstanding as of the effective date of
the registration statement of which this prospectus forms a part, provided that such securities have not been amended since the effective date of the registration statement of which this prospectus forms a part to increase the number of such
securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in accordance with their terms) or to extend the term of such securities, (C) securities issued pursuant to the Investor Rights
Agreement, (D) securities issued pursuant to acquisitions or strategic transactions approved by a majority of our disinterested directors, provided that such securities are issued as &#147;restricted securities&#148; (as defined in Rule 144) and
carry no registration rights that require or permit the filing of any registration statement in connection therewith during the 45 days following the closing date of this offering, and provided that any such issuance shall only be to a person (or to
the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with our business and shall provide to us additional benefits in addition to the investment of funds,
but shall not include a transaction in which we are issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities and (E) the ordinary shares, Warrants, and the Pre-funded Warrants
issued to other investors pursuant to the registration statement of which this prospectus forms a part, clauses&nbsp;(A) through (E) together, the Exempt Issuances. We have also agreed to not enter into any &#147;variable rate transactions&#148;,
including the issuance of securities that are based on trading prices of our ordinary shares after issuance of such securities or are subject to a price reset upon a specified or contingent event in the future, or the entry into an agreement to
issue securities at a future determined price, for a period of one year following the closing date of this offering; provided that an &#147;at the market&#148; offering pursuant to an &#147;at the market&#148; equity distribution or sales agreement
with the Placement Agent is not considered a &#147;variable rate transaction.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our ordinary shares is Computershare Trust Company, N.A. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Listing </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ordinary shares
are currently traded on the Nasdaq Global Market under the symbol &#147;ITRM.&#148; On October&nbsp;20, 2020, the reported closing price per share of our ordinary shares was $1.15. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to
indemnify the placement agent against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the placement agent may be required to make with respect to any of these liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulation&nbsp;M </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The placement agent may be deemed to be an underwriter within the meaning of Section&nbsp;2(a)(11) of the Securities Act and any fees received
by it and any profit realized on the sale of the securities by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. The placement agent will be required to comply with the requirements of
the Securities Act and the Exchange Act, including, without limitation, <FONT STYLE="white-space:nowrap">Rule&nbsp;10b-5</FONT> and Regulation&nbsp;M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of
our securities by the placement agent. Under these rules and regulations, the placement agent may not (i)&nbsp;engage in any stabilization activity in connection with our securities; and (ii)&nbsp;bid for or purchase any of our securities or attempt
to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until they have completed their participation in the distribution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80934_13"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legal matters of U.S. federal law and New York State law in connection with this offering will be passed upon for us by Wilmer Cutler
Pickering Hale and Dorr LLP, New York, New York. Certain legal matters with respect to Irish law in connection with the validity of the securities in respect of which this prospectus is being delivered and other legal matters will be passed upon for
us by A&amp;L Goodbody, Dublin, Ireland.&nbsp;Ellenoff Grossman&nbsp;&amp; Schole&nbsp;LLP, New&nbsp;York, New&nbsp;York, has acted as counsel for the placement agent in connection with certain legal matters related to this offering. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80934_14"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Iterum Therapeutics plc as of December&nbsp;31, 2019 and 2018, and for each of the years in the
three-year period ended December&nbsp;31, 2019, have been incorporated by reference herein in reliance upon the report of KPMG, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as
experts in accounting and auditing. The audit report covering the December&nbsp;31, 2019 consolidated financial statements contains an explanatory paragraph that states that the Company&#146;s recurring losses from operations and net capital
deficiency raise substantial doubt about the entity&#146;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty. The audit report covering
the December&nbsp;31, 2019 financial statements refers to a change to the method of accounting for leases as of January&nbsp;1, 2019 due to the adoption of ASC Topic 842, <I>Leases</I>. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80934_15"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to you on
the SEC&#146;s Internet site at <I>www.sec.gov</I>. Copies of certain information filed by us with the SEC are also available on our website at www.iterumtx.com. Information contained on, or accessible through, our website is not a part of, and is
not incorporated by reference into, this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the SEC. This prospectus does not contain all of the information
included in the registration statement, including certain exhibits and schedules. You should review the information and exhibits in the registration statement for further information about us and the securities we are offering. Statements in this
prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete
document to evaluate these statements. You can obtain a copy of the registration statement and exhibits from the SEC&#146;s Internet site. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc80934_16"></A>INCORPORATION OF DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference into this prospectus information and reports that we file with the SEC. This means that we can
disclose important information to you by referring to other documents that contain that information. Any information that we incorporate by reference is considered part of this prospectus. The documents and reports that we list below are
incorporated by reference into this prospectus, other than any portion of any such documents that are not deemed &#147;filed&#148; under the Exchange Act in accordance with the Exchange Act and applicable SEC rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, all documents and reports which we file pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of
this prospectus and prior to the termination of the offering made hereby are incorporated by reference into this prospectus as of the respective filing dates of these documents and reports. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed the following documents with the SEC (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-38503).</FONT> These documents are
incorporated in this prospectus by reference as of their respective dates of filing: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020010242/itrm-10k_20191231.htm">Form<U></U><FONT STYLE="white-space:nowrap">&nbsp;10-K</FONT></A>&nbsp;for the fiscal year ended December&nbsp;31, 2019, filed with the SEC on
March&nbsp;12, 2020, as amended by our Annual Report on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520211364/d681266d10ka.htm">Form<U></U><FONT STYLE="white-space:nowrap">&nbsp;10-K/A</FONT></A>, filed with the SEC on
August&nbsp;6, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Information under the caption &#147;Certain Relationships and Related Party Transactions&#148; from our
definitive proxy statement on Schedule 14A filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459019013037/itrm-def14a_20190613.htm">April&nbsp;25, 2019</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Quarterly Report on&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020025261/itrm-10q_20200331.htm">Form<U></U><FONT STYLE="white-space:nowrap">&nbsp;10-Q</FONT></A>&nbsp;for the quarter ended March&nbsp;31, 2020, filed with the SEC on May&nbsp;14,
2020, as amended by our&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520211366/d681265d10qa.htm">Form<U></U><FONT STYLE="white-space:nowrap">&nbsp;10-Q/A</FONT></A>, filed with the SEC on August&nbsp;6, 2020;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Quarterly Report on&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020037240/itrm-10q_20200630.htm">Form<U></U><FONT STYLE="white-space:nowrap">&nbsp;10-Q</FONT></A>&nbsp;for the quarter ended June&nbsp;30, 2020, filed with the SEC on August&nbsp;6,
2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Current Reports <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;8-K&nbsp;filed</FONT> with the SEC
on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520009454/d869502d8k.htm">January<U></U>&nbsp;17, 2020</A>,&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020004834/itrm-8k_20200212.htm">February<U></U>&nbsp;14, 2020</A>,&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020009200/itrm-8k_20200331.htm">March<U></U>&nbsp;6, 2020</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020025814/itrm-8k_20200521.htm">May<U></U>&nbsp;
15, 2020</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520158937/d936467d8k.htm">June<U></U>&nbsp;3, 2020</A>,&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520160848/d938174d8k.htm">June<U></U>&nbsp;4, 2020</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020029381/itrm-8k_20200610.htm">June<U></U>&nbsp;15,
2020</A>&nbsp;(excluding Item 7.01 and Exhibit 99.2),&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020030909/itrm-8k_20200629.htm">June<U></U>&nbsp;29, 2020</A>,&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520184372/d936614d8k.htm">July<U></U>&nbsp;1, 2020</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020032262/itrm-8k_20200713.htm">July<U></U>&nbsp;13,
2020</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020032605/itrm-8k_20200721.htm">July<U></U>&nbsp;17, 2020</A>,&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020039127/itrm-8k_20200811.htm">August<U></U>&nbsp;11, 2020</A>,&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020042192/itrm-8k_20200901.htm">September<U></U>&nbsp;1, 2020</A>&nbsp;(as amended by our Current Report on&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020042249/itrm-8ka_20200902.htm">Form<U></U><FONT STYLE="white-space:nowrap">&nbsp;8-K/A</FONT></A>&nbsp;filed with the SEC on September&nbsp;
2, 2020), <A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020044659/itrm-8k_20200930.htm">September&nbsp;25, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020045315/itrm-8k_20200930.htm">September&nbsp;
30, 2020</A>; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our ordinary shares contained in our Registration Statement on&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518170412/d588677d8a12b.htm">Form<U></U><FONT STYLE="white-space:nowrap">&nbsp;8-A</FONT><U></U>&nbsp;filed on May<U></U>&nbsp;
22, 2018, including any amendments or supplements filed for the purpose of updating such description.</A> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may
request a copy of these documents, which will be provided to you at no cost, by writing or telephoning us at: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Iterum Therapeutics plc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Block 2 Floor 3 Harcourt Centre, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Harcourt Street, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dublin 2, Ireland
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">+353 1 9038920 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Statements
contained in documents that we file with the SEC and that are incorporated by reference into this prospectus will automatically update and supersede information contained in this prospectus, including information in previously filed documents or
reports that have been incorporated by reference into this prospectus, to the extent the new information differs from or is inconsistent with the old information. Any statement so modified or superseded will not be deemed to be a part of this
prospectus, except as so modified or superseded. Because information that we later file with the SEC will update and supersede previously incorporated information, you should look at all of the SEC filings that we incorporate by reference to
determine if any of the statements in this prospectus or in any documents previously incorporated by reference have been modified or superseded. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80934g49n79.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>13,043,478 Ordinary Shares and </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants to Purchase 9,782,608 Ordinary Shares </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants to Purchase 13,043,478 Ordinary Shares and </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants to Purchase 9,782,608 Ordinary Shares </B></P>  <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Preliminary Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>H.C. Wainwright&nbsp;&amp;&nbsp;Co. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;OTHER</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXPENSES OF ISSUANCE AND DISTRIBUTION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the estimated costs and expenses payable by the registrant expected to be incurred in connection with the
issuance and distribution of the securities being registered hereby (other than placement agent fees). All of such expenses are estimates, except for the Securities and Exchange Commission (&#147;SEC&#148;) registration fee and the Financial
Industry Regulatory Authority, Inc. (&#147;FINRA&#148;) filing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;to<BR>be Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,007.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,634.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">480,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Placement agent expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,400.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,958.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">825,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;INDEMNIFICATION</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OF DIRECTORS AND OFFICERS. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the fullest extent permitted by Irish law, our Articles of Association confer an indemnity on our directors and officers. However, this
indemnity is limited by the Irish Companies Act, which prescribes that an advance commitment to indemnify only permits a company to pay the costs or discharge the liability of a director or corporate secretary where judgment is given in favor of the
director or corporate secretary in any civil or criminal action in respect of such costs or liability, or where an Irish court grants relief because the director or corporate secretary acted honestly and reasonably and ought fairly to be excused.
Any provision whereby an Irish company seeks to commit in advance to indemnify its directors or corporate secretary over and above the limitations imposed by the Irish Companies Act will be void under Irish law, whether contained in its Articles of
Association or any contract between the company and the director or corporate secretary. This restriction does not apply to our executives who are not directors, the corporate secretary or other persons who would be considered &#147;officers&#148;
within the meaning of that term under the Irish Companies Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Articles of Association also contain indemnification and expense
advancement provisions for persons who are not directors or our corporate secretary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also entered into indemnification agreements
with each of our directors and executive officers.&nbsp;In addition, our subsidiary, Iterum Therapeutics US Limited, has entered into an indemnification agreement with each of our directors and executive officers.&nbsp;These agreements, among other
things, require us to indemnify an indemnitee to the fullest extent permitted by applicable law, including indemnification of expenses such as attorneys&#146; fees, judgments, fines and settlement amounts incurred by the indemnitee in any action or
proceeding, including any action or proceeding by us or in our right, arising out of the person&#146;s services as a director or executive officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are permitted under our Articles of Association and the Irish Companies Act to take out directors&#146; and officers&#146; liability
insurance, as well as other types of insurance, for our directors, officers, employees and agents. We have purchased and maintain a directors&#146; and officers&#146; liability policy for such purpose for the benefit of our directors and officers
and directors and officers of its subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;RECENT</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SALES OF UNREGISTERED SECURITIES. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following sets forth information regarding all securities issued and sold by us within the past three years that were not registered under
the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), which share numbers have been adjusted, as appropriate, for the one for 15.71 reverse stock split of our ordinary shares that became effective on May&nbsp;15, 2018: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From March&nbsp;7, 2017 through the filing of our registration statement on Form
<FONT STYLE="white-space:nowrap">S-8</FONT> on May&nbsp;25, 2018, we granted stock options under our 2015 Equity Incentive Plan to purchase an aggregate of 198,798 ordinary shares with exercise prices ranging between $3.30 and $4.40 per ordinary
share to 31 employees, directors and consultants, of which 180,395 remain outstanding. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On February&nbsp;16, 2018, we issued an aggregate of 1,709,650 of our Series
<FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares to 17&nbsp;accredited investors at a purchase price of $18.85 per share, for an aggregate purchase price of $32.2&nbsp;million. Upon the closing of our initial public offering, all such
Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares converted into ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On April&nbsp;27, 2018, we issued warrants to purchase an aggregate of 19,890 of our Series <FONT
STYLE="white-space:nowrap">B-2</FONT> preferred shares to two accredited investors at an exercise price of $18.85 per share, for an aggregate exercise price of $374,927. Upon the closing of our initial public offering, all such warrants converted
into warrants to purchase ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the terms of a subscription agreement with a supplier, as described in Note 9 to our consolidated
financial statements appearing in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2019, (i) on December&nbsp;14, 2018, we issued 190,615 ordinary shares to a supplier at a price of
$7.14 per ordinary share for an aggregate subscription price of $1.36&nbsp;million; (ii)&nbsp;on July&nbsp;15, 2019, we issued 17,222 ordinary shares to a supplier at a price of $6.53 per ordinary share for an aggregate subscription price of
$0.11&nbsp;million; (iii)&nbsp;on August&nbsp;19, 2019, we issued 245,493 ordinary shares to a supplier at a price of $6.79 per ordinary share for an aggregate subscription price of $1.67&nbsp;million; and (iv)&nbsp;on September&nbsp;30, 2019, we
issued 199,056 ordinary shares to a supplier at a price of $6.32 per ordinary share for an aggregate subscription price of $1.26&nbsp;million. Our wholly owned subsidiary, Iterum Therapeutics International Limited, paid the aggregate subscription
price for each subscription to us in satisfaction of the supplier&#146;s obligation to pay the subscription monies to us and Iterum Therapeutics International Limited&#146;s obligation to pay certain amounts due and owing under certain commercial
agreements entered into between such subsidiary and the supplier. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On January&nbsp;21, 2020, Iterum Therapeutics Bermuda Limited (&#147;Iterum Bermuda&#148;) issued, and we and
each of our other subsidiaries guaranteed, an aggregate of 51,588 Units consisting of (i) 6.500% Exchangeable Senior Subordinated Notes due 2025, issued by Iterum Bermuda in the aggregate original principal amount of $51.6&nbsp;million, fully and
unconditionally guaranteed on an unsecured senior subordinated basis by us and each of our other subsidiaries, and (ii)&nbsp;Limited Recourse Royalty-Linked Subordinated Notes, issued by Iterum Bermuda in the aggregate original principal amount of
$0.1&nbsp;million, fully and unconditionally guaranteed on an unsecured senior subordinated basis by us and each of our other subsidiaries, for an aggregate purchase price of $51.6&nbsp;million, before deducting placement agent fees and estimated
offering expenses. SVB Leerink acted as the exclusive placement agent and received commissions of $1.4&nbsp;million in connection with the private placement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On June&nbsp;3, 2020, we entered into a securities purchase agreement with Intracoastal Capital, LLC, Armistice
Capital Master Fund, Ltd., and Lincoln Park Capital Fund, LLC. Pursuant to the securities purchase agreement, we issued to such investors warrants to purchase up to 1,485,885 ordinary shares. The warrants have an exercise price of $1.62 per ordinary
share, are immediately exercisable and expire on December&nbsp;5, 2025. H. C. Wainwright&nbsp;&amp; Co., LLC (&#147;Wainwright&#148;) acted as placement agent for the offering and received commissions of $350,000 in connection with the offering. As
partial consideration for the services provided to us by Wainwright as placement agent for the offering, we issued placement agent warrants to purchase an aggregate of 208,023 ordinary shares to designees of
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Wainwright. The placement agent warrants have an exercise price of $2.1031 per ordinary share, are immediately exercisable and expire on June&nbsp;3, 2025. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On June&nbsp;30, 2020, we entered into a securities purchase agreement with Intracoastal Capital, LLC,
Armistice Capital Master Fund, Ltd., and Anson Investments Master Fund LP. Pursuant to the securities purchase agreement, we issued to such investors warrants to purchase up to 1,686,343 ordinary shares. The warrants have an exercise price of $1.42
per ordinary share, are immediately exercisable and expire on January&nbsp;2, 2026. Wainwright acted as placement agent for the offering and received commissions of $350,000 in connection with the offering. As partial consideration for the services
provided to us by Wainwright as placement agent for the offering, we issued placement agent warrants to purchase an aggregate of 236,088 ordinary shares to designees of Wainwright. The placement agent warrants have an exercise price of $1.8531 per
ordinary share, are immediately exercisable and expire on June&nbsp;30, 2025. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offer, sale and issuance of the
securities described in paragraph 1 above were exempt from registration under compensatory benefit plans and contracts relating to compensation as provided under either (a)&nbsp;Rule 701 promulgated under the Securities Act or (b)&nbsp;under
Section&nbsp;4(a)(2) of the Securities Act (or Regulation D promulgated thereunder). All recipients had adequate access, through their employment or other relationship with us or through other access to information provided by us, to information
about it. We did not pay or give, directly or indirectly, any commission or other remuneration, including underwriting discounts and commissions, in connection with any of the issuances of securities described in paragraph 1 above. The sales of
these securities were made without any general solicitation or advertising. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offers, sales and issuances of the securities described
in paragraphs 2 and 3 above were exempt from registration under Section&nbsp;4(a)(2) of the Securities Act (or Regulation D promulgated thereunder) in that the transactions were by an issuer not involving any public offering. We did not pay or give,
directly or indirectly, any commission or other remuneration, including underwriting discounts and commissions, in connection with any of the issuances of securities listed above. The recipients of the securities in each of these transactions
represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the share certificates issued in these transactions.
The sales of these securities were made without any general solicitation or advertising. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offer, sale and issuance of the securities
described in paragraph 4 above were exempt from registration under Section&nbsp;4(a)(2) of the Securities Act (or Regulation D promulgated thereunder) in that the transaction was by an issuer not involving any public offering or were exempt from the
registration requirements of the Securities Act in reliance on Regulation S promulgated under the Securities Act on the basis that the shares will not be offered, sold, pledged or transferred in the United States or to a U.S. person for a defined
period. We did not pay or give, directly or indirectly, any commission or other remuneration, including underwriting discounts and commissions, in connection with any of the issuances of securities listed above. The recipients of the securities in
each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the share certificates
issued in these transactions. The sales of these securities were made without any general solicitation or advertising. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offer, sale
and issuance of the securities in the private placement transactions described in paragraphs 5, 6 and 7 above were exempt from registration under Section&nbsp;4(a)(2) of the Securities Act (or Regulation D promulgated thereunder) in that the
transactions were by an issuer not involving any public offering and appropriate legends were placed upon the securities issued in these transactions. The sale of these securities were made without any general solicitation or advertising. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;EXHIBITS</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>AND FINANCIAL STATEMENT SCHEDULES. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Description of Document</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filed with</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>this</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registration</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Statement</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporated</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>by Reference</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>herein
from</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Form or</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Schedule</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Filing Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>SEC File</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520273093/d80934dex11.htm">Form of Placement Agency Agreement to be entered into by and between Iterum Therapeutics plc and H.C. Wainwright&nbsp;&amp; Co., LLC
</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form S-1 (Exhibit&nbsp;1.1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10/21/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">333-249432</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020029381/itrm-ex31_10.htm">Amended and Restated Constitution of Iterum Therapeutics plc </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">8-K</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;3.1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6/15/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-38503</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518146797/d522368dex41.htm">Form of Ordinary Share Certificate of Registrant </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;4.1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/1/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520160848/d938174dex41.htm">Form of Warrant to Subscribe for Ordinary Shares issued to purchasers in connection with Securities Purchase Agreement dated June&nbsp;
3, 2020</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">8-K</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;4.1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6/4/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-38503</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520160848/d938174dex42.htm">Form of Placement Agent Warrant to Subscribe for Ordinary Shares issued to designees of Placement Agent in connection with Securities Purchase
 Agreement dated June&nbsp;3, 2020</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">8-K</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;4.2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6/4/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-38503</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520184372/d936614dex41.htm">Form of Warrant to Subscribe for Ordinary Shares issued to purchasers in connection with Securities Purchase Agreement dated June&nbsp;
30, 2020</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">8-K</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;4.1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">7/1/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-38503</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520184372/d936614dex42.htm">Form of Placement Agent Warrant to Subscribe for Ordinary Shares issued to designees of Placement Agent in connection with Securities Purchase
 Agreement dated June&nbsp;30, 2020</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">8-K</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;4.2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">7/1/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-38503</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;4.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020010242/itrm-ex42_407.htm">Indenture (including form of note), dated January&nbsp;
21, 2020, by and among Iterum Therapeutics Bermuda Limited, Iterum Therapeutics plc, Iterum Therapeutics International Limited, Iterum Therapeutics US Limited, Iterum Therapeutics US Holding Limited and U.S. Bank National Association, as trustee
</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">10-K</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;4.2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/12/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-38503</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;4.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020010242/itrm-ex42_407.htm">Form of 6.500% Exchangeable Senior Subordinated Note due 2025 (included within Exhibit&nbsp;4.6) </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">10-K</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;4.3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/12/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-38503</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;4.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020010242/itrm-ex44_406.htm">Indenture (including form of note), dated January&nbsp;
21, 2020, by and among Iterum Therapeutics Bermuda Limited, Iterum Therapeutics plc, Iterum Therapeutics International Limited, Iterum Therapeutics US Limited, Iterum Therapeutics US Holding Limited, Iterum Holders&#146; Representative LLC and Computershare
 Trust Company, N.A., as trustee </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">10-K</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;4.4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/12/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-38503</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;4.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020010242/itrm-ex44_406.htm">Form of Limited Recourse Royalty-Linked Subordinated Note (included within Exhibit&nbsp;4.8) </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">10-K</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;4.5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/12/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-38503</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;4.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520273093/d80934dex410.htm">Form of Warrant </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form S-1</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;4.10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10/21/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">333-249432</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;4.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520273093/d80934dex411.htm">Form of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form S-1</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;4.11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10/21/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">333-249432</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;4.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520273093/d80934dex412.htm">Form of Placement Agent Warrant </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form S-1</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;4.12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10/21/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">333-249432</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d80934dex51.htm">Opinion of A&amp;L Goodbody</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;5.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d80934dex52.htm">Opinion of Wilmer Cutler Pickering Hale and Dorr LLP</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.1&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518146797/d522368dex101.htm">License Agreement by and among Registrant, Iterum Therapeutics International Limited and Pfizer Inc. dated as of November&nbsp;18, 2015
</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;10.1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/1/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518146797/d522368dex102.htm">Amended and Restated Investor Rights Agreement by and between Registrant and certain of its shareholders dated May&nbsp;18, 2017 </A></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit 10.2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/1/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518146797/d522368dex103.htm">2015 Equity Incentive Plan </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit 10.3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/1/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518146797/d522368dex104.htm">Forms of U.S. Stock Option Agreement, Stock Option Grant Notice and Notice of Exercise under the 2015 Equity Incentive Plan</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit 10.4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/1/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518146797/d522368dex105.htm">Forms of Irish Stock Option Agreement, Stock Option Grant Notice and Notice of Exercise under the 2015 Equity Incentive Plan </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit 10.5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/1/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020029381/itrm-ex991_9.htm">Amended and Restated 2018 Equity Incentive Plan </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">8-K</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit 99.1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6/15/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-38503</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518146797/d522368dex107.htm">Forms of U.S. Stock Option Terms and Conditions and Stock Option Grant Notice under the 2018 Equity Incentive Plan </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit 10.7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/1/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518146797/d522368dex108.htm">Forms of International Stock Option Terms and Conditions and Stock Option Grant Notice under the 2018 Equity Incentive Plan </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit 10.8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/1/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518146797/d522368dex109.htm">Form of Restricted Share Unit Award Agreement under the 2018 Equity Incentive Plan </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;10.9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/1/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020010242/itrm-ex1010_408.htm">Form of 2020 Restricted Share Unit Award Agreement under the 2018 Equity Incentive Plan </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">10-K</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit 10.10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/12/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-38503</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518146797/d522368dex1010.htm">Form of Indemnity Agreement by and between the Registrant and its directors and officers </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit 10.10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/1/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518146797/d522368dex1011.htm">Form of Indemnity Agreement by and between Iterum Therapeutics US Limited and its directors and officers</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;10.11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/1/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518146797/d522368dex1012.htm">Employment Terms by and between Iterum Therapeutics US Limited and Corey N. Fishman dated November&nbsp;18, 2015</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit 10.12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/1/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518152964/d522368dex1013.htm">Amendment to Employment Agreement by and between Iterum Therapeutics US Limited and Corey N. Fishman dated May&nbsp;2, 2018 </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1/A</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit 10.13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/4/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518146797/d522368dex1014.htm">Employment Terms by and between Iterum Therapeutics US Limited and Michael W. Dunne dated November&nbsp;18, 2015 </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit 10.14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/1/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518146797/d522368dex1015.htm">Employment Terms by and between Iterum Therapeutics US Limited and Judith M. Matthews dated November&nbsp;18, 2015 </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit 10.15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/1/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518152964/d522368dex1016.htm">Amendment to Employment Agreement by and between Iterum Therapeutics US Limited and Judith M. Matthews dated May&nbsp;2, 2018</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1/A</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit 10.16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/4/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518164732/d522368dex1018.htm"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1/A</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit 10.18)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/16/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518152964/d522368dex1019.htm">Loan and Security Agreement by and among Silicon Valley Bank, Iterum Therapeutics International Limited, Iterum Therapeutics US Holding Limited,
 and Iterum Therapeutics US Limited, dated April&nbsp;27, 2018</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1/A</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit 10.19)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/4/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518152964/d522368dex1020.htm">Intellectual Property Security Agreement by and among Silicon Valley Bank, the Registrant, Iterum Therapeutics International Limited, Iterum
 Therapeutics US Holding Limited, and Iterum Therapeutics US Limited, dated April&nbsp;27, 2018 </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1/A</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit 10.20)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/4/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518152964/d522368dex1021.htm">Warrant to Subscribe for Shares, issued to Silicon Valley Bank, dated April&nbsp;27, 2018 </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1/A</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;10.21)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/4/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518152964/d522368dex1022.htm">Warrant to Subscribe for Shares, issued to Life Sciences Fund II LLC, dated April&nbsp;27, 2018 </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1/A</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;10.22)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/4/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518152964/d522368dex1023.htm">Additional Form of Warrant to Subscribe for Ordinary Shares as may be issued to Silicon Valley Bank pursuant to the Loan and Security Agreement
 </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1/A</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit 10.23)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/4/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.24</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312518152964/d522368dex1024.htm">Additional Form of Warrant to Subscribe for Ordinary Shares as may be issued to Life Sciences Fund II LLC pursuant to the Loan and Security
 Agreement </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">S-1/A</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;10.24)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/4/2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-224582</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520009454/d869502dex101.htm">Securities Purchase Agreement, dated as of January&nbsp;
16, 2020, by and among Iterum Therapeutics Bermuda Limited, Iterum Therapeutics plc, Iterum Therapeutics International Limited, Iterum Therapeutics US Limited, Iterum Therapeutics US Holding Limited and the Investors party thereto </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">8-K</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;10.1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1/17/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-38503</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.26</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020010242/itrm-ex1026_404.htm">Investor Rights Agreement, dated January&nbsp;
21, 2020, by and among Iterum Therapeutics Bermuda Limited, Iterum Therapeutics plc, Iterum Therapeutics International Limited, Iterum Therapeutics US Limited, Iterum Therapeutics US Holding Limited and the Investors party thereto</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">10-K</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;10.26)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/12/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-38503</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.27</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520009454/d869502dex103.htm">First Amendment to Loan and Security Agreement, dated as of January&nbsp;
16, 2020, by and among Iterum Therapeutics Bermuda Limited, Iterum Therapeutics International Limited, Iterum Therapeutics US Limited, Iterum Therapeutics US Holding Limited and Silicon Valley Bank </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">8-K</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;10.3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1/17/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-38503</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.28</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020037240/itrm-ex101_268.htm">Securities Purchase Agreement, dated as of June&nbsp;3, 2020, by and among Iterum Therapeutics plc and the purchasers party
thereto</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">10-Q</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;10.1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8/6/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-38503</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.29</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020037240/itrm-ex102_267.htm">Securities Purchase Agreement, dated as of June&nbsp;30, 2020, by and among Iterum Therapeutics plc and the purchasers party
thereto</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">10-Q</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit 10.2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8/6/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-38503</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.30</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520273093/d80934dex1030.htm">Form of Securities Purchase Agreement </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form S-1</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;10.30)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10/21/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">333-249432</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000156459020010242/itrm-ex211_9.htm">Subsidiaries of the Registrant </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">10-K</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Exhibit&nbsp;21.1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/12/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-38503</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d80934dex231.htm">Consent of KPMG, Independent Registered Public Accounting Firm </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d80934dex51.htm">Consent of A&amp;L Goodbody (included in Exhibit 5.1) </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">23.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d80934dex52.htm">Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.2) </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520267344/d80934ds1.htm#sig">Powers of Attorney (included on the signature pages to the Registration Statement) </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form S-1 (Exhibit 24.1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10/9/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">333-249432</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">25.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520250397/d85535dex251.htm">The Statement of Eligibility on Form <FONT STYLE="white-space:nowrap">T-1</FONT> under the Trust Indenture Act of 1939, as amended, of the Trustee
 under the Indenture, dated as of January&nbsp;21, 2020 by and among Iterum Therapeutics Bermuda Limited, Iterum Therapeutics plc, Iterum Therapeutics International Limited, Iterum Therapeutics US Limited, Iterum Therapeutics US Holding Limited and
U.S. Bank National Association, as trustee </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form <FONT STYLE="white-space:nowrap">S-1</FONT> (Exhibit 25.1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">9/21/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-248956</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">25.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1659323/000119312520250397/d85535dex252.htm">The Statement of Eligibility on Form <FONT STYLE="white-space:nowrap">T-1</FONT> under the Trust Indenture Act of 1939, as amended, of the Trustee
 under the Indenture, dated as of January&nbsp;21, 2020, by and among Iterum Therapeutics Bermuda Limited, Iterum Therapeutics plc, Iterum Therapeutics International Limited, Iterum Therapeutics US Limited, Iterum Therapeutics US Holding Limited,
Iterum Holders&#146; Representative LLC and Computershare Trust Company, N.A., as trustee </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form <FONT STYLE="white-space:nowrap">S-1</FONT> (Exhibit 25.2)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">9/21/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-248956</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment granted as to portions of the exhibit. Confidential materials omitted and filed
separately with the SEC. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;UNDERTAKINGS.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)(1)&nbsp;To file, during any period in which offers or sales are being made, a post-effective amendment to this registration
statement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933, as amended
(the &#147;Securities Act&#148;); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;To reflect in the prospectus any facts or events arising after the
effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding
the foregoing, any increase or decrease in the volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering
range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&nbsp;424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the
&#147;Calculation of Registration Fee&#148; table in the effective registration statement; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;To include any
material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided, however</I>, that paragraphs&nbsp;(1)(i), (1)(ii) and (1)(iii) do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;),
that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule&nbsp;424(b) that is part of the registration statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;That, for the purposes of determining any liability under the Securities Act, each such
post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at the time shall be deemed to be the initial bona fide offering thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3)&nbsp;&nbsp;&nbsp;&nbsp;To remove from registration by means of a post-effective amendment any of the securities being
registered which remain unsold at the termination of the offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4)&nbsp;&nbsp;&nbsp;&nbsp;That, for the purpose of
determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to
this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will
be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;Any
preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&nbsp;424; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used
or referred to by the undersigned registrant; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;The portion of any other free writing prospectus relating to the
offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(5)&nbsp;&nbsp;&nbsp;&nbsp;That, for purposes of determining any liability under the Securities Act: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;the information omitted from the form of prospectus filed as part of the registration statement in reliance upon
Rule&nbsp;430A and contained in the form of prospectus filed by the Registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of the registration statement as of the time it was declared
effective; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;each post-effective amendment that contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned registrant hereby undertakes
that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#146;s annual report pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit
plan&#146;s annual report pursuant to Section&nbsp;15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Insofar as indemnification for liabilities arising under the Securities Act may be permitted to
directors, officers and controlling persons of the registrant pursuant to the indemnification provisions described herein, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as
expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its
counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Amendment No. 2 to the Registration Statement
on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Chicago, State of Illinois, on October&nbsp;22, 2020. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ITERUM&nbsp;THERAPEUTICS&nbsp;PLC</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October&nbsp;22, 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Corey N.&nbsp;Fishman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Corey N. Fishman</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:&nbsp;Chief&nbsp;Executive&nbsp;Officer</P></TD></TR>
</TABLE>  <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment No. 2 to the Registration Statement has been signed by the following
persons in the capacities and on the dates indicated. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Corey N. Fishman</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Corey N. Fishman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief&nbsp;Executive&nbsp;Officer&nbsp;and&nbsp;Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Executive Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">October&nbsp;22,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Judith M. Matthews</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Judith M. Matthews</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Financial
and Accounting Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">October&nbsp;22,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Brenton K.
Ahrens</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Interim Chairman of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">October&nbsp;22, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark
Chin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">October&nbsp;22, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Patrick J.
Heron</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">October&nbsp;22, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Ronald M.
Hunt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">October&nbsp;22, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">David G.
Kelly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">October&nbsp;22, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Shahzad
Malik, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">October&nbsp;22, 2020</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">*By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Corey N. Fishman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Corey N. Fishman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Attorney-in-fact</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-12 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d80934dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="6" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">


<IMG SRC="g80934img51.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B><B>A&amp;L Goodbody</B><B></B><B></B></TD>
<TD VALIGN="bottom" ROWSPAN="6">&nbsp;&nbsp;</TD>
<TD ROWSPAN="6" VALIGN="top"><B></B>&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD ROWSPAN="6" VALIGN="top" ALIGN="right"><B></B>Dublin<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Belfast</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">London</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">New York</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">San&nbsp;Francisco</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Palo Alto</P></TD>

<TD ROWSPAN="6" NOWRAP VALIGN="top"><B></B>&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">International&nbsp;Financial&nbsp;Services&nbsp;Centre</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">25-28 North Wall Quay, Dublin 1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">D01 H104</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">T: +353 1 649 2000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">DX:&nbsp;29&nbsp;Dublin&nbsp;&nbsp;|&nbsp;&nbsp;www.algoodbody.com</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>|&nbsp;&nbsp;</B> 22 October 2020</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Our ref</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>|&nbsp;&nbsp;</B> 01416740</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Your ref</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>|&nbsp;&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Iterum Therapeutics plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Block
2, Floor 3 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Harcourt Centre, Harcourt Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dublin 2, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ireland </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Iterum Therapeutics plc</B> (the <B>Company</B>)
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Sirs </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are acting as Irish Counsel to the Company,
a public limited company incorporated under the laws of Ireland (registration number 563531), in connection with the filing of a registration statement (the <B>Registration Statement</B>) on Form <FONT STYLE="white-space:nowrap">S-1</FONT> to be
filed by the Company under the Securities Act of 1933, as amended (the <B>Securities Act</B>), pursuant to which we understand the Company will register the offering, issuance and sale by the Company of the following securities (the
<B>Securities</B>): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary shares in the capital of the Company with a nominal value of US$0.01 each (<B>Ordinary Shares</B>) up to
a maximum aggregate amount of $15,000,000 (the <B>Offering</B> <B>Shares</B>); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (the
<B><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</B>) to purchase Ordinary Shares up to a maximum aggregate amount of $15,000,000 (the <B><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares</B>); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warrants (the <B>Warrants</B>) to purchase Ordinary Shares up to a maximum aggregate amount of $11,250,000 (the
<B>Warrant Shares</B>); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">placement agent warrants (the <B>Placement Agent Warrants</B>) to purchase Ordinary Shares up to a maximum
aggregate amount of $1,312,500 (the <B>Placement Agent Shares</B>, and together with the Offering Shares, the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares and the Warrant Shares,<B> </B>the<B> Shares</B>), </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">pursuant to the terms of the Registration Statement, the prospectus contained therein, and any amendments or supplements thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this Opinion, we have reviewed copies of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Registration Statement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">copies of such corporate records of the Company as we have deemed necessary as a basis for the opinions
hereinafter expressed. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">CE Gill&nbsp;&nbsp;&#149;&nbsp;&nbsp;JG Grennan&nbsp;&nbsp;&#149;&nbsp;&nbsp;PD White&nbsp;&nbsp;&#149;&nbsp;&nbsp;VJ Power&nbsp;&nbsp;&#149;&nbsp;&nbsp;LA
Kennedy&nbsp;&nbsp;&#149;&nbsp;&nbsp;SM Doggett&nbsp;&nbsp;&#149;&nbsp;&nbsp;B McDermott&nbsp;&nbsp;&#149;&nbsp;&nbsp;C Duffy&nbsp;&nbsp;&#149;&nbsp;&nbsp;PV Maher&nbsp;&nbsp;&#149;&nbsp;&nbsp;S O&#146;Riordan&nbsp;&nbsp;&#149;&nbsp;&nbsp;MP
McKenna&nbsp;&nbsp;&#149;&nbsp;&nbsp;KA Feeney&nbsp;&nbsp;&#149;&nbsp;&nbsp;M Sherlock&nbsp;&nbsp;&#149;&nbsp;&nbsp;E MacNeill </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">KP
Allen&nbsp;&nbsp;&#149;&nbsp;&nbsp;EA Roberts&nbsp;&nbsp;&#149;&nbsp;&nbsp;C Rogers&nbsp;&nbsp;&#149;&nbsp;&nbsp;G O&#146;Toole&nbsp;&nbsp;&#149;&nbsp;&nbsp;JN Kelly&nbsp;&nbsp;&#149;&nbsp;&nbsp;N O&#146;Sullivan&nbsp;&nbsp;&#149;&nbsp;&nbsp;MJ
Ward&nbsp;&nbsp;&#149;&nbsp;&nbsp;AC Burke&nbsp;&nbsp;&#149;&nbsp;&nbsp;D Widger&nbsp;&nbsp;&#149;&nbsp;&nbsp;C Christle&nbsp;&nbsp;&#149;&nbsp;&nbsp;S O&#146;Croinin&nbsp;&nbsp;&#149;&nbsp;&nbsp;JW Yarr&nbsp;&nbsp;&#149;&nbsp;&nbsp;DR
Baxter&nbsp;&nbsp;&#149;&nbsp;&nbsp;A McCarthy &nbsp;&nbsp;&#149;&nbsp;&nbsp;JF Whelan </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">JB Somerville&nbsp;&nbsp;&#149;&nbsp;&nbsp;MF
Barr&nbsp;&nbsp;&#149;&nbsp;&nbsp;AM Curran&nbsp;&nbsp;&#149;&nbsp;&nbsp;A Roberts&nbsp;&nbsp;&#149;&nbsp;&nbsp;M Dale&nbsp;&nbsp;&#149;&nbsp;&nbsp;RM Moore&nbsp;&nbsp;&#149;&nbsp;&nbsp;D Main&nbsp;&nbsp;&#149;&nbsp;&nbsp;J
Cahir&nbsp;&nbsp;&#149;&nbsp;&nbsp;M Traynor&nbsp;&nbsp;&#149;&nbsp;&nbsp;PM Murray&nbsp;&nbsp;&#149;&nbsp;&nbsp;P Walker&nbsp;&nbsp;&#149;&nbsp;&nbsp;K Furlong&nbsp;&nbsp;&#149;&nbsp;&nbsp;PT Fahy&nbsp;&nbsp;&#149;&nbsp;&nbsp;D
Inverarity&nbsp;&nbsp;&#149;&nbsp;&nbsp;M Coghlan&nbsp;&nbsp;&#149;&nbsp;&nbsp;DR Francis </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">A Casey&nbsp;&nbsp;&#149;&nbsp;&nbsp;B
Hosty&nbsp;&nbsp;&#149;&nbsp;&nbsp;M O&#146;Brien&nbsp;&nbsp;&#149;&nbsp;&nbsp;L Mulleady&nbsp;&nbsp;&#149;&nbsp;&nbsp;K Ryan&nbsp;&nbsp;&#149;&nbsp;&nbsp;E Hurley&nbsp;&nbsp;&#149;&nbsp;&nbsp;G Stanley&nbsp;&nbsp;&#149;&nbsp;&nbsp;D
Dagostino&nbsp;&nbsp;&#149;&nbsp;&nbsp;R Grey&nbsp;&nbsp;&#149;&nbsp;&nbsp;R Lyons&nbsp;&nbsp;&#149;&nbsp;&nbsp;J Sheehy&nbsp;&nbsp;&#149;&nbsp;&nbsp;C Morrissey&nbsp;&nbsp;&#149;&nbsp;&nbsp;C Carroll&nbsp;&nbsp;&#149;&nbsp;&nbsp;SE
Carson&nbsp;&nbsp;&#149;&nbsp;&nbsp;P Diggin </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">J Williams&nbsp;&nbsp;&#149;&nbsp;&nbsp;A O&#146;Beirne&nbsp;&nbsp;&#149;&nbsp;&nbsp;MD
Cole&nbsp;&nbsp;&#149;&nbsp;&nbsp;G Conheady&nbsp;&nbsp;&#149;&nbsp;&nbsp;J Dallas&nbsp;&nbsp;&#149;&nbsp;&nbsp;SM Lynch&nbsp;&nbsp;&#149;&nbsp;&nbsp;M McElhinney&nbsp;&nbsp;&#149;&nbsp;&nbsp;C Owens&nbsp;&nbsp;&#149;&nbsp;&nbsp;AD
Ion&nbsp;&nbsp;&#149;&nbsp;&nbsp;K O&#146;Connor&nbsp;&nbsp;&#149;&nbsp;&nbsp;JH Milne&nbsp;&nbsp;&#149;&nbsp;&nbsp;T Casey&nbsp;&nbsp;&#149;&nbsp;&nbsp;M Doyle&nbsp;&nbsp;&#149;&nbsp;&nbsp;CJ Comerford &nbsp;&nbsp;&#149;&nbsp;&nbsp;R Marron </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">D Berkery&nbsp;&nbsp;&#149;&nbsp;&nbsp;K O&#146;Shaughnessy&nbsp;&nbsp;&#149;&nbsp;&nbsp;S O&#146;Connor&nbsp;&nbsp;&#149;&nbsp;&nbsp;SE
Murphy&nbsp;&nbsp;&#149;&nbsp;&nbsp;D Nangle&nbsp;&nbsp;&#149;&nbsp;&nbsp;L Butler&nbsp;&nbsp;&#149;&nbsp;&nbsp;A Lawler&nbsp;&nbsp;&#149;&nbsp;&nbsp;C &Oacute; Conluain&nbsp;&nbsp;&#149;&nbsp;&nbsp;N McMahon&nbsp;&nbsp;&#149;&nbsp;&nbsp;HP
Brandt&nbsp;&nbsp;&#149;&nbsp;&nbsp;A Sheridan </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">Consultants: SW Haughey&nbsp;&nbsp;&#149;&nbsp;&nbsp;Professor JCW Wylie&nbsp;&nbsp;&#149;&nbsp;&nbsp;AF
Browne&nbsp;&nbsp;&#149;&nbsp;&nbsp;MA Greene&nbsp;&nbsp;&#149;&nbsp;&nbsp; AV Fanagan&nbsp;&nbsp;&#149;&nbsp;&nbsp; PM Law </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g80934img51.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In rendering this Opinion, we have examined, and have assumed the truth and accuracy of the contents of, all
such corporate records, documents and certificates of officers of the Company and of public officials as to factual matters and have conducted such searches on 22 October 2020 (being the last practicable date on which searches could be conducted) in
public registries in Ireland as we have deemed necessary or appropriate for the purposes of this Opinion but have made no independent investigation regarding such factual matters. In our examination we have assumed the (continued) truth and accuracy
of the information contained in such documents, the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified or photostatic
copies and the authenticity of the originals of such documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have further assumed: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that as of today&#146;s date and at each time Securities are issued, none of the resolutions and authorities of
the shareholders or directors of the Company upon which we have relied have been varied, amended or revoked in any respect or have expired, and that the Securities will be issued in accordance with such resolutions and authorities and the terms of
the applicable agreement relating to the Securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that at each time Shares will be issued, a sufficient number of ordinary shares of the Company, nominal value
$0.01 per share, will remain authorised and available for issuance by the Board pursuant to the constitution of the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that any issue of Shares will be paid up in consideration of the receipt by the Company prior to, or
simultaneously with, the issue of the Shares of cash at least equal to the nominal value of such Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the issuance of the Securities will be in compliance with the Companies Act 2014, the Irish Takeover Panel
Act 1997, Takeover Rules 2013, and all applicable Irish company, takeover, securities, market abuse, insider dealing laws and other rules and regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the filing of the Registration Statement with the Securities and Exchange Commission (<B>SEC</B>) has been
authorised by all necessary actions under all applicable laws other than Irish law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that when filed with the SEC, the Registration Statement will not differ in any material respect from the
drafts that we have examined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the absence of fraud on the part of the Company and its respective officers, employees, agents and advisors;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that: (i)&nbsp;the Company will be fully solvent at the time of and immediately following the issue of any
Securities; (ii)&nbsp;no resolution or petition for the appointment of a liquidator or examiner will be passed or presented prior to the issue of any Securities; (iii)&nbsp;no receiver will have been appointed in relation to any of the assets or
undertaking of the Company prior to the issue of any Securities; and (iv)&nbsp;no composition in satisfaction of debts, scheme of arrangement, or compromise or arrangement with creditors or members (or any class of creditors or members) will be
proposed, sanctioned or approved in relation to the Company prior to the issue of the Securities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and to the
within additional qualifications and assumptions, and based upon searches carried out in the Irish Companies Registration Office and the Central Office of the High Court on 22 October 2020, we are of the opinion that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company is a company duly incorporated under the laws of Ireland and validly existing under the laws of
Ireland; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Offering Shares, when delivered against due payment thereof, will be validly issued, fully paid and not
subject to calls for any additional payments <FONT STYLE="white-space:nowrap">(&#147;non-assessable&#148;);</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g80934img51.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Warrants, the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the Placement Agent Warrants
when (i)&nbsp;delivered against due payment therefor; and (ii)&nbsp;the applicable Warrant, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant or Placement Agent Warrant has been duly authorized, executed and delivered by the Company and the
other parties thereto, will be duly authorized, validly issued and binding obligations of the Company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Warrant Shares, the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares and the Placement Agent
Shares when (i)&nbsp;delivered against due payment therefor; and (ii)&nbsp;the applicable Warrant, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant or Placement Agent Warrant has been duly authorized, executed and delivered by the Company
and the other parties thereto, will be validly issued, fully paid and not subject to calls for any additional payments <FONT STYLE="white-space:nowrap">(&#147;non-assessable&#148;).</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In rendering this Opinion we have confined ourselves to matters of Irish law. We express no opinion on any laws other than the laws of Ireland (and the
interpretation thereof) in force as at the date hereof. This Opinion speaks only as of its date. We are not under any obligation to update this Opinion from time to time, nor to notify you of any change of law, facts or circumstances referred to or
relied upon in the giving of this Opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Opinion is given solely for the benefit of the addressee of this Opinion and may not be relied upon by
any other person without our prior written consent, provided, however, that it may be relied upon by persons entitled to rely on it pursuant to applicable provisions of US federal securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Opinion is also strictly confined to the matters expressly stated herein and is not to be read as extending by implication or otherwise to any other
matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this Opinion with the SEC as an exhibit to the Registration Statement in accordance with the requirements of
Item 601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> of the Securities Act, and to the use of our name therein and in the related prospectus and in any prospectus supplement under the caption &#147;Legal Matters.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Opinion is governed by and construed in accordance with the laws of Ireland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours faithfully </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>/s/ A&amp;L Goodbody </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">M-51904722-3</FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>3
<FILENAME>d80934dex52.htm
<DESCRIPTION>EX-5.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g80934img52.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">October&nbsp;22, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">+1 212 230 8800 (t)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">+1 212 230 8888 (f)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">wilmerhale.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Iterum Therapeutics plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Block 2
Floor 3, Harcourt Centre </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Harcourt Street, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dublin 2, Ireland
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT></U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is furnished to you in
connection with&nbsp;the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-249432)</FONT> (the &#147;Registration Statement&#148;) filed by Iterum Therapeutics plc, an
Irish public limited company (the &#147;Company&#148;), with the Securities and Exchange Commission (the &#147;Commission&#148;) under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), for the registration of (i)&nbsp;ordinary
shares (the &#147;Shares&#148;) of the Company, nominal value $0.01 per share (the &#147;Ordinary Shares&#148;), with a proposed maximum aggregate offering price of up to $15,000,000, (ii)&nbsp;warrants to purchase Ordinary Shares (the
&#147;Ordinary Share Warrants&#148;), with a proposed maximum aggregate offering price of up to $11,250,000, <FONT STYLE="white-space:nowrap">(iii)&nbsp;pre-funded</FONT> warrants to purchase Ordinary Shares (the
<FONT STYLE="white-space:nowrap">&#147;Pre-Funded</FONT> Warrants&#148;), with a proposed maximum aggregate offering price of up to $15,000,000, and (iv)&nbsp;placement agent warrants to purchase Ordinary Shares (the &#147;Placement Agent
Warrants,&#148; and together with the Ordinary Share Warrants and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the &#147;Warrants&#148;), with a proposed maximum aggregate price of $1,312,500. The Shares and the Warrants are herein
collectively referred to as the &#147;Securities.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shares, Ordinary Share Warrants, and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrants are to be offered and sold by the Company pursuant to a securities purchase agreement (the &#147;Purchase Agreement&#148;), between the Company and the purchasers named therein (the &#147;Purchasers&#148;), the form of which has been filed
as Exhibit 10.30 to the Registration Statement, and the prospectus contained in such Registration Statement (the &#147;Prospectus&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are acting
as United States counsel for the Company in connection with the issue and sale by the Company of the Securities. We have examined copies of the Registration Statement and the Prospectus as filed with the Commission. We have examined and relied upon
the Purchase Agreement and the forms of Warrants, which have been filed as Exhibit 4.10, Exhibit 4.11, and Exhibit 4.12 to the Registration Statement. For purposes of this opinion, we have also examined the opinion letter of A&amp;L Goodbody, Irish
counsel for the Company, dated the date hereof and filed as Exhibit 5.1 to the Company&#146;s Registration Statement (the &#147;ALG Opinion&#148;). We have also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80934001.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g80934img52.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;22, 2020 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
examined and relied upon originals or copies of such corporate records of the Company, such other agreements and instruments, such certificates of public officials, and such other documents,
instruments and certificates as we have deemed necessary as a basis for the opinions hereinafter expressed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our examination of the documents referred
to above, we have assumed the genuineness of all signatures, the legal capacity and competence of all individual signatories, the authenticity, accuracy and completeness of all documents submitted to us as originals, the conformity to original
documents of all documents submitted to us as copies, the authenticity of such original documents and the completeness and accuracy of the corporate records of the Company provided to us by the Company. Insofar as this opinion relates to factual
matters, we have assumed, without independent investigation, that representations of officers and directors of the Company and documents furnished to us by the Company are true and correct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also assumed, consistent with the ALG Opinion, that (i)&nbsp;the Company is incorporated and validly existing under the laws of the Republic of
Ireland; (ii)&nbsp;the Company has all requisite power and authority to execute and deliver, and to perform its obligations under the Purchase Agreement and the Warrants; (iii)&nbsp;the Purchase Agreement has been duly authorized, executed and
delivered by the Company under the laws of the Republic of Ireland and (iv)&nbsp;the Warrants have been duly authorized, executed and delivered by the Company under the laws of the Republic of Ireland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion below is qualified to the extent that it may be subject to or affected by (i)&nbsp;applicable bankruptcy, insolvency, reorganization,
receivership, moratorium, fraudulent conveyance or similar laws relating to or affecting the rights or remedies of creditors generally, (ii)&nbsp;duties and standards imposed on creditors and parties to contracts, including, without limitation,
requirements of materiality, good faith, reasonableness and fair dealing, (iii)&nbsp;general equitable principles, and (iv)&nbsp;applicable usury laws of jurisdictions other than the State of New York. Furthermore, we express no opinion as to the
availability of any equitable or specific remedy upon any breach of any of the agreements as to which we are opining herein, or any of the agreements, documents or obligations referred to therein, or to the successful assertion of any equitable
defenses, inasmuch as the availability of such remedies or the success of any equitable defenses may be subject to the discretion of a court. We also express no opinion herein as to any provision of any agreement (a)&nbsp;that may be deemed to or
construed to waive any right of the Company; (b)&nbsp;to the effect that rights and remedies are not exclusive, that every right or remedy is cumulative and may be exercised in addition to or with any other right or remedy and does not preclude
recourse to one or more other rights or remedies; (c)&nbsp;relating to the effect of invalidity or unenforceability of any provision of an agreement on the validity or enforceability of any other provision thereof; (d)&nbsp;requiring the payment of
penalties, consequential damages or liquidated damages; (e)&nbsp;which is in violation of public policy, including, without limitation, any provision relating to indemnification and contribution with respect to securities law matters; (f)
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g80934img52.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;22, 2020 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which provides that the terms of any agreement may not be waived or modified except in writing; (g)&nbsp;purporting to indemnify any person against his, her or its own negligence or misconduct;
or (h)&nbsp;relating to choice of law or consent to jurisdiction. We express no opinion herein as to the laws of any jurisdiction other than the state laws of the State of New York. We have not acted as counsel for the Company with respect to
matters of Irish law or other applicable foreign law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, we are of the opinion that when the Warrants have been
duly executed by the Company and are delivered and paid for in accordance with the terms and conditions of the Purchase Agreement and the Prospectus, the Warrants will constitute valid and binding obligations of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is
based upon currently existing statutes, rules, regulations and judicial decisions and is rendered as of the date hereof, and we disclaim any obligation to advise you of any change in any of the foregoing sources of law or subsequent developments in
law or changes in facts or circumstances that might affect any matters or opinions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion with
the Commission, in accordance with the requirements of Item&nbsp;601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act, as an exhibit to the Registration Statement and to the use of our name therein and in the
related Prospectus under the caption &#147;Legal Matters.&#148; In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations
of the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WILMER CUTLER PICKERING<BR>HALE AND DORR LLP</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian A. Johnson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Brian A. Johnson, a Partner</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d80934dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Iterum Therapeutics plc: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use of our report incorporated by reference herein and to the reference to our firm under the heading &#147;Experts&#148; in the prospectus.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our report dated March&nbsp;12, 2020 contains an explanatory paragraph that states that the Company has suffered recurring losses from operations and has
a net capital deficiency, which raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty. Also, our report
on the consolidated financial statements refers to a change to the method of accounting for leases as of January&nbsp;1, 2019 due to the adoption of ASC Topic 842,<I>&nbsp;Leases.</I> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ KPMG</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dublin, Ireland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">October&nbsp;22, 2020</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g80934001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80934001.jpg
M_]C_X  02D9)1@ ! 0$"60)9  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
MQ@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%%
M 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!
M\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+!
M LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#
MQP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-
M^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_ D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9 YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$ T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE
M3FY.MT\ 3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1 9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"
M](-7@[J$'82 A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M# P,# P,# P,#/_  !$( "X#- ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MT)]!^)<FM1:H]U:2R7D!L;+[5&8)%F5%W'*L&C?CD8P:C^!/Q^\7?%;]I?\
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M_$?3=;TO7]:'Q>^PGQE<W7B345N-<-D@2V)>.=/L^Q548MO*5@H!! Q7NM%
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M2R\*^!=0AU3PPA\0:C/>>&[F%2D<EG=RSO<0X1I$V+($:.:6-E9)9%;T:_\
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M;HUO)\47\96=E>W,%U?:=:?\(;%HR2.8VDB6Z^TI(I6&1E6-\AVY)]*_9/\
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>3:JLI:%0%7;;SV,:OU*1JGW8E ]0HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g80934g49n79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80934g49n79.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1784&AO=&]S:&]P(#,N,  X0DE-! 0
M    %;R^560X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!SDFZ0
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M6CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              '@   )8          $
M                 0             "6    '@
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   '@     4F=H=&QO;F<   )8
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   !X     %)G:'1L;VYG   "6     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      +F@
M  $   "*    '    :   "V    +?@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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MBQ3Z;[(+[LNTZDL[_P!0VMMNL_K.JK6!C=1N=5=8/=E9V4<?7DD%EUE?
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0'_P  1"  E +@# 1$  A$! Q$!_\0 'P   @(" P #
M        !PD&"@4( 00+  (#_\0 /!   @(# 0 ! @0$ @,1    ! 4#!@$"
M!P@)$1( $Q05"A8A(C%!%R-1&!DF*#(U-T9'6&%Q@:.QTO#_Q  = 0 !! ,!
M 0             $ P4&!P$""  )_\0 /Q$  @(" 0,"! 0#! 8+     0(#
M! 41!A(3(0 Q!Q0B014C46$R<8$(%D*1%R0E-%*A0U-55G*"HK'!U?#_V@ ,
M P$  A$#$0 _ +AGM/VO7O+*0%*I$ LO5[,%*8@KQD^VBU.KUDW&Q9+'B"2(
MK8'<J.8=:N'E'(;D#&:Z%"#ADD:5/\4_BE3^'="".&L,ER#(J[8_'DLL,42'
MI>]?=/K2LK@I%&A66U*&CC9$266*X_A%\([OQ,R-B6>T<5QO&,HR62 1IYI2
MO<6ACDD^B2TT>I)I7#15(6661)&>**5#%QZ/Z ]!0EW?J/535U*+,G@A-L[U
MBBHV2--LQS+ZG2T Y9#V4+&=86.E6K+H@#7:&6P$0?GX)EX^R&9^(G.(ILWR
M+D[8/ 22/&EG(7I\7AV<'ZZN+Q5&.6WDY(@567Y*A=E0:-N53]7KMS&X+X8\
M FBX]QGB0Y#R&*))9:V-QU?+YL1D;CN97+Y&2&GBHIRIDB6]DJ5>3S\G"1I?
M0FQ6N71X^PKJ#2633ZXS(JYV68%)GZ:YVW@F:65"=O#]V?IIL2L%ESKC/WPQ
M9_MS&S0XHIT_/<@\G@.T'',B\18;!Z&GR%>1E^X9X8V8';(I.O4J&2Y@0#%\
M.L='&PVBV.58V*95^PD6MB[40('N$GE4>0KL 6]?;^7>3X_[3+-_E_AS&+_/
M.,Y_Z_?[?_3'_CC\8^1XD??G65_KQJU_]OZ]^(\S/@_#W$-H_P#>RH?8^X_V
M%_S_ ']60/CB%3!^5*? @;%NUFM@NV8F!RC5(1)OM9F&9M-E^K)KK%K%)G;3
M3?!N_P";KC&_V1_7[,=R_!*.G%\.\2E#(2Y2J+.4*79ZKTI92<C8+AJ[SV&7
MMMN,$RGJ"A@%! ]?/KX]R7Y?B;FGR6-AQ-LU<2)*,%Q+\40&-K!&6TE>JK]Q
M=.0(5Z"Q4EB.HUFOGN](^FO('KBDTWS=[&]0IBNLT8GJ%HYQCHVTM6J15ANC
MNOUE30 EZ]>2H4%[(VT<20V9GD344/(I>(R-HM>LN#XO&97&6ILEBJ4B5)1!
M'8[<BR2@1"28RMW=,Z=R-@P5?#:(T!ZH/(2RQ2QK#-(K2 [78Z1M@%T- ^=,
M/<GQ]O)].[ZZCO7QZ_&AZ8ZW>?27?>S]AT\[:0%VGL'1=GPU>ZXZ0SU1-)SD
M ,!3'4PY;]< _P G6*9@WE'7I]2FAI(.")895[.<S]"K%1J5*LEY5$-:)EZJ
MP<.XF+.[2$01MU'8&RYT ?!S[KUY',CLPC_B=O/5K0UX\;8CP!Y.O!/NE'XL
M/B_]K^P.7A^@_4/MCV'QWD]O!A+Y-5J;VFZ0]#O*F7;[M+PQ,LC1TOKE/-UU
M^E;A(2'.+6)+E[!NG1Y4&V&4\FS. QMMZ.*P.%LSPLR6IYZ43Q1R Z:&,1]!
MDD0C4KLW2I'0 6ZBHU6.W+&))K,ZA@"JJY#%2=[;JZM [\ ?;R/<;AML)LWG
M'W-ZH\W<R]/>I.D4OD*7CZV1MU[MEBM[S%NL%:(M%EU%( U0K11 \N@5.T,"
MO2?]0K(_/(GS^7C3D#^UIF,KB^+_  RR6)GDX[9RN0Y:+)P+SX@6H*L>#6H+
M!J3(9PA>9H>X2JF9NE5+,S==?V3L%A,[E>>09S%T,W'2J<>-9<M3K7Q7:>7*
MB=H!9CD6,N$C[A5=N$79 7I+R?'OE-GWOA";IU_[MZ'3.+$[LD:G2L]*,$!R
MC4G_ +*/)*.U";32%9:+F^V\NI.D6\&T$>(=-XMI)(?\+^!7N7\)H9[/<UY]
M#=R4]]X?D.3VX8UJ067J0;CF%D,YDKS2]6P&$B@J54$F?%OXA8_A?/<CQWCO
M!OAW/C\77Q\<WXAQ2E/,]R>LMR?<L)JE5$=F&'IT2AB+*P9F]"KBW-.S4OY!
M47%+3U+H-HKU)9FW7<L^VV38)_50$,K^M&&@;M9Q]\$L)TZ]H#)^>+@W!@>^
MTX^/[XWQ+#<SQ'QOAXIDN4\ARF*Q4=G,AK66OO%=Q?R;M0:Q7DL-%(?FYZ\%
MA.DQF:&4*H4#U*.99O@N:^ <W,,7Q'C6'S&6EJX)DIX;'I-0R_SJ#(+6LI72
M:-/DJ]FS6;J$JPS1=;;8>M'_ .(G[UW?R!T7AUH\^^N?2-"LG<(;T?:N:I>B
MX$YO6D=#!H21*RJZ )8(:C(>L&K&1AK.S9"LC!6)D<0<^)LS_1'@..HY=+T5
M_&4[$=,0]NPT<@G+V'E/2[B3H=5$8 VH9 0 2#XX/R,DD/;:.5T+E@5##IT
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M%T(Y+5>66:9H6>2-"_:B[/5)TQL2LI+%6;Z4((\@A8\RS!Y)9I&"L%5=@*=
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M+C9?B%EGQ.5N9JB:V,$60OW)[UJ8BA )%>S9597$;]2(&&D50H.AZJ&>E?\
MCS?Q(5:Y[#C9S4Z/W[FE W"SG]1%BI^<4(5OZFKDQM]8M!B'=6Z+O)C&OV:X
M,VQG&TVVWW]:T!^#_#N>P05DLU9Y=Z_QY"45H#[^?RY(6V?8+L;^U'2?GY)5
M!VL;*"/T[8ZV_3[^#_3U=5]&^;N1>K^8F<<[G72K;SAF]K=@;UJ!Z[0#N"ZH
MX%?)Q6A"$]<88KT:!"DE+)"/TAFT$6"(]\::_2H:=VUC["6Z<K06(UE5)5"E
MD$T3PR%>H, QCD8!@.I2=J00"'AT612K@,IT2#['1##_ "(!]&6&%8A51#C0
M!J4R5?I".,-#"&O6K%PV-(H!X(=8X!0PQ8=8XH8M-(8((]=--==-<8P-]3M]
MV9C]SLLS'[D^Y)/N?<^MO8?L/7G4^=>O3=^]8^W^V23SD:=3Z@PNP'Y^V9)(
M4]@N=X.1 :YQ_A$M2S +AM-?[(QQ8M--<::XU_%,_P!N"D:?&_@_0127@DY)
M"5 (+S"IQL/X&SU23%B1KW/Z^NM/[&DP_%?B5,[A46GQYV=O94[^;\DC6@J*
M2"2 ![G0._0%\^4+?F'#^54*>+$)U:HU>!;1ZX^F/WV0"$M]OC&?ZXQ*Z(/E
MQC/USC[_ *9SG.,YS8?$L../\7X_A  &QF(H5)=  -/%7C%E_'C<D_<D.ONQ
M]<X<RS;<DY9R3/,Q89;-9&[%LDE:\UJ1JT8)\],5?M1KOV50/MZD&O+:-IT^
M3L>J33_2)+3L4+=_DLW/_!C5IJYP#JOR1E;K-^NTUVRPU$PPS!C])DG(OUBR
M:,)BQFFY$*B#,MC1B&O=<O<..6R;8K=OK[.A8)D[G;[OGIZ^CZ?0)SV7."7C
M1NR'!IE&S*X_IC[8R;UA3:UU]'>ZC741]LR=KQUB/K);U1M^:K9I[:^:OFWE
M1"UVU#12<$\XPSPP?N(:0N]M(+M<[%(O_-AT*E2A=&VV;1?GP9F@K.@LDT>!
M]=M;]XATX?AUW+.H)D^=MA2S*7$"_+PQD^Z]<D;!64; D##SKU#;NYKL4(/\
M)1=^#KJ(9CK^7N#^GV'L^7HWE;VV7[V^/2N]4]*/?0?EVHONC=>L:%/Q"L\F
MJM#O/$:E!+S(JUDT?)BQSNVL5J2:4T1\<-^W3UYW,J7D3;2EA06#(XA</FC#
M02IDIDKUH)'M267DAL3,;0C$NFC(BC(D=0W4'"L0&TS@T<QFAW(6B7K9E"!?
M*@=&V!T??0&OL2/;TPSVWZ2J_-? WIGT-1;>C?+D'%NC_P EVNLN0&Z8JZ%"
M,:/6=06ZT@@,G<:_E@K"/TT^^\1L$XN<ZD1[:ZLV(HO;S&.HR(R&:Y62174J
MPB9U>0]+ ?\ 0]3*#X8:^QWZ6FD"0R2;&E1B#[C>CK_GKU2,^+-S[,\H>4?9
M'R%>5*WR:RA4$VE<CO('0Z?:+-8 :A]D=IM]HIDB*X5D"""HS-Z$VMX38)O#
M,EWP[S(O%K9T#2X^4+B,IEL-@<E);A[RO8A>M-#'&9I#V88IED@E;<O:=(V1
MXPKL$8,6#(RU.]%!-8B",5(4JP)8JOEB"I &M[(*L= C?@$N$^#CE?EKY +5
M??=_HII9^Y^_*/TR)C>@>C-TLU,ILF^FN_)KYSWGZ),G &4B(56B"O9>[NQJ
MQ8Z<?)7@U&04I6(ES*?)8-(L%26.G@I8/]7["MWK /\ O4=JP[,SR=UF,@3H
M62.1.H$,1Z,I"*QNP_UV ?J)]E\[4HOV&AXV2=@ZT->MK?XF3M6_._C\5\N!
MGWT8]^['3:L9%IMG3[JO2-3.DM9MM\9QC.FE@K50%WCSG&)-3MOKC.NNVN6_
MX>4_F<^)R-K1JS3C>M=V3IKH/<:/3+(ZD>=IZ4R3]-5E!T9"%_I_$?Z> #[>
M_HX_P^/&->0_&-R)G/!' W[19+WV5O\ EXT^LFKYUFKUN7??7'UWVFI5/K$V
M<;9SF/:3:+']-,?@+G%SYOD=T GHJB*H@(T1VD!D]B=COO+H^-KHZ'MZWHIT
M58_U<=P_^;R/_3KT>/7&\74?<OQR>?X]]#@*C<^O>Q;ZMBVUDD7J^*\],H/,
MF1\6N<[0#$]2ZXLE7338UBG,0$ZPYWG&^D;=CMU\5F[GL9(JN+B)^[6YQ8F
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M*I!!K?L\G598G[;*S(#K[*!YUZSC4Z:P;Q^8S/\ T_A'G[_P['\_53^=?<>
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M77"U[.9?)(([V0M6(AK\IY"(CKR"8DZ4)!\@E2=^=[]:QP0Q>8XU4G[@;/\
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MDC25HX(5BF=FE41H>O8!]?K1>547F\,,%14F":"KHTR_=I8;):)U*.':+:%
MD*M+=T2CK\6XX^\:%1,$HTW''VU"QM!#G13'8FABH8X*,+1111+!"LEBS9[%
M=-".O UJ:9H:\8"B.O$R0HJJJ( J@)Y+,9'+S2SWYUEEGF:S8:.O5JBQ9<'K
MM6$J0P)/:?J8R69E>>1GD9Y&9W+2"LU&N4T5D%654"D9P_=VEII#O/+L=8+(
MPE:.VI$I,T\NY+ ^>4B;.=_LUSMB.+2.+32/5>I2JT4ECJ0) D]FS<E6,$"2
MU<G>S:G;9)+S3R/(YWK;: "@ #W+]S(212W;$EAX*E2C"TA!,52C!'5J5TT
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M5BG9;2(%V\!CXR-@];'L&;QZ[+@'T#%F<6!Z:R=L_P!"%%$"OC./GB7 Q1A
MZ#BQZ18MJI0JTNZ:T72]AUDL3222SV+#HBQ(]BS.\MB=DB18T,LC]$:JBZ4
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$5'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g80934img51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80934img51.jpg
M_]C_X  02D9)1@ ! 0$ R #&  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M# P,# P,# P,#/_  !$( "8 N0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M:][PG))+K=HW:1G53R<5Y1X"_;)^'/Q)\5+HNC^*K&>_F.R"*5);?SV]$:1
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M\T_L$>(M0^%WQC\3?#O5M.N/#[:L/[4L-/N&#-:$=$!!(8&+ R/^>8'&*O\
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M(9L'H.9 /J5 KU;X1?L)>"_A+XQAUY6UCQ!J]L0;6YU:Y6<V;#(#HH4 , 2
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#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g80934img52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80934img52.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M# P,# P,# P,#/_  !$( !\ B ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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4@S1L0"5)4D9&<<$C\**GHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
